Novel Compounds as Inhibitors of Cyclic GMP-AMP Synthase and Their Uses
By providing novel cGAS inhibitor compounds, the lack of effective treatments for cGAS-related diseases in existing technologies has been resolved, achieving both regulation of cGAS activity and therapeutic effects.
Patent Information
- Application Number
- CN202580028677.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-03-19
- Filing Date
- 2025-04-15
- Publication Date
- 2026-11-17
AI Technical Summary
There is currently no demand for novel compounds as cGAS inhibitors to treat diseases caused by inappropriate cGAS activity and undesirable type I interferon activity.
Compounds of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), and (IB-2), as well as their pharmaceutically acceptable salts or stereoisomers, are provided for the preparation of pharmaceutical compositions that modulate the activity of cGAS by administering these compounds, thereby treating related diseases.
These compounds can effectively regulate cGAS activity, potentially treating cGAS-related diseases and providing new therapeutic approaches.
Smart Images

Figure QLYQS_1 
Figure QLYQS_3 
Figure QLYQS_4
Abstract
Description
[0001] Cross-references
[0002] This patent application claims priority to the following international applications: International Application No. PCT / CN2024 / 087976, filed April 16, 2024; International Application No. PCT / CN2024 / 103981, filed July 5, 2024; International Application No. PCT / CN2024 / 120796, filed September 24, 2024; International Application No. PCT / CN2024 / 137781, filed December 9, 2024; International Application No. PCT / CN2025 / 077176, filed February 13, 2025; and International Application No. PCT / CN2025 / 083380, filed March 19, 2025; the entire contents of which are incorporated herein by reference.
[0003] This disclosure of the field
[0004] This disclosure relates to novel compounds or pharmaceutically acceptable salts thereof used as inhibitors of cyclic GMP-AMP synthase (cGAS). This disclosure further relates to pharmaceutical compositions comprising one or more such compounds or pharmaceutically acceptable salts thereof as active ingredients, and the use of such compounds or pharmaceutically acceptable salts thereof in the treatment of diseases or disorders.
[0005] background
[0006] Cyclic GMP-AMP synthase (cGAS) is a key innate immune sensor that recognizes cytoplasmic DNA to induce an immune response against invading pathogens. cGAS is traditionally thought to function as a nucleotide transferase that catalyzes the synthesis of cGAMP upon recognizing cytoplasmic DNA, leading to the activation of STING and the production of type I / III interferons to combat pathogens.
[0007] Abnormal accumulation of cytosolic DNA can induce type 1 interferon, while other cytokines can induce autoimmunity. There remains an unmet need for novel compounds as cGAS inhibitors to treat diseases caused by inappropriate cGAS activity and undesirable type 1 interferon activity.
[0008] Overview
[0009] In one aspect, this disclosure provides compounds of formula (I): Formula (I), Or a pharmaceutically acceptable salt or stereoisomer thereof, as disclosed herein.
[0010] In one aspect, this disclosure provides compounds of formula (I-1): Formula (I-1), Or a pharmaceutically acceptable salt or stereoisomer thereof, as disclosed herein.
[0011] In one aspect, this disclosure provides compounds of formula (I-2): Formula (I-2), Or a pharmaceutically acceptable salt or stereoisomer thereof, as disclosed herein.
[0012] In one aspect, this disclosure provides compounds of formula (IA): Formula (IA), Or a pharmaceutically acceptable salt or stereoisomer thereof, as disclosed herein.
[0013] In one aspect, this disclosure provides compounds of formula (IB): Formula (IB), Or a pharmaceutically acceptable salt or stereoisomer thereof, as disclosed herein.
[0014] This document also discloses pharmaceutical compositions comprising the compounds disclosed herein (e.g., compounds of formula (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2) or compounds listed in Table 1 or Table 2) or their pharmaceutically acceptable salts or stereoisomers, and pharmaceutically acceptable excipients.
[0015] This document also discloses a method for modulating (e.g., inhibiting) cGAS in an individual, the method comprising administering to the individual a compound disclosed herein (e.g., a compound of formula (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2) or a compound listed in Table 1 or Table 2) or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutical composition disclosed herein.
[0016] This document also discloses the use of the compounds disclosed herein (e.g., compounds of formula (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2) or the compounds listed in Table 1 or Table 2) or pharmaceutically acceptable salts or stereoisomers thereof or pharmaceutical compositions disclosed herein in the preparation of a medicament for regulating (e.g., inhibiting) cGAS in an individual.
[0017] This document also discloses the use of the compounds disclosed herein (e.g., formula (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2) or the compounds listed in Table 1 or Table 2) or pharmaceutically acceptable salts or stereoisomers thereof, or the pharmaceutical compositions disclosed herein, in the preparation of a medicament for treating or preventing a disease or disorder in an individual in need. In some embodiments, the disease or disorder is a cGAS-related disease or disorder.
[0018] By incorporating references
[0019] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication, patent or patent application is specifically and individually cited and incorporated herein by reference.
[0020] Detailed Explanation
[0021] definition
[0022] In the following description, certain specific details are set forth to provide a thorough understanding of various embodiments. However, those skilled in the art will understand that the invention can be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context requires otherwise, throughout the specification and the appended claims, the word “comprise” and its variations, such as “comprises” and “comprising”, should be interpreted in an open, inclusive sense, meaning “including but not limited to”. Furthermore, the headings provided herein are for convenience only and do not constitute an explanation of the scope or meaning of the claimed invention.
[0023] Throughout this specification, the phrases “some embodiments” or “one embodiment” mean that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Therefore, the phrases “some embodiments” or “one embodiment” appearing in various places throughout the specification do not necessarily all refer to the same embodiment. Furthermore, a particular feature, structure, or characteristic may be combined in any suitable manner in one or more embodiments. Additionally, as used in this specification and the appended claims, the singular form and “said” or “the” include plural referents unless expressly specified otherwise. It should also be noted that the term “or” is generally used to include the meaning of “and / or” unless expressly specified otherwise.
[0024] Unless otherwise stated, the following terms as used herein have the following meanings.
[0025] The definitions of specific functional groups and chemical terms are described in more detail below. For the purposes of this disclosure, chemical elements are identified according to the periodic table (CAS version) in the 75th edition of the *Handbook of Chemistry and Physics*, and specific functional groups are generally defined as described therein. Furthermore, the general principles of organic chemistry, as well as specific functional groups and reactivity, are described in *Organic Chemistry, Thomas Sorrell, 2nd ed., University Science Books, Sausalito, 2006; Smith and March March's *Advanced Organic Chemistry, 6th ed., John Wiley & Sons, Inc., New York, 2007; Larock, *Comprehensive Organic Transformations, 3rd ed., VCH Publishers, Inc., New York, 2018; Carruthers, *Some Modern Methods of Organic Synthesis, 4th ed., Cambridge University Press, Cambridge, 2004*; the entire contents of each of these are incorporated herein by reference.
[0026] Linking substituents are described in several locations within this disclosure. Where the structure explicitly requires a linking group, the Markush variable listed for that group is understood to be a linking group that can connect to two or more other groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl," then it should be understood that "alkyl" represents a linking alkylene group. For example, as required by the Markush structure, the term "alkyl" can be linked to one, two, or three other groups.
[0027] When the bond connecting a substituent is shown as a bond passing through two atoms in the connecting ring, such a substituent can bond to any atom in the ring. When substituents are listed without specifying which atom they bond to the rest of the compound in a given structural formula, such substituents can bond to any atom in the structural formula. Combinations of substituents and / or variables are permitted, provided that such combinations produce a stable compound.
[0028] When any variable (e.g., R) i When a group appears more than once in any component or structural formula of a compound, its definition for each occurrence is independent of its definition for each of its other occurrences. Therefore, for example, if a group shows 0-2 R... i If partially substituted, then the group can optionally be replaced by up to two R groups.i Partial replacement, and each occurrence of R i Independently selected from R i The definition of [the compound]. Furthermore, combinations of substituents and / or variables are permitted, provided that such combinations produce stable compounds.
[0029] As used in this article, the term "C" i -C j "C" represents a range of carbon atoms, where i and j are integers, and the range includes the endpoints (i.e., i and j) and every integer point in between, where j is greater than i. For example, C1-C6 represents a range of one to six carbon atoms, including one, two, three, four, five, and six carbon atoms. In some implementations, the term "C" is used to indicate the range of carbon atoms. 1-12 "" indicates 1 to 12 carbon atoms, particularly 1 to 10, particularly 1 to 8, particularly 1 to 6, particularly 1 to 5, particularly 1 to 4, particularly 1 to 3 or particularly 1 to 2 carbon atoms.
[0030] "Oxytochemical" refers to the compound oxygen (O).
[0031] "Cyano" refers to -CN.
[0032] "Amino," whether used as part of another term or independently, refers to the -NR group. a R b , where R a and R b The group is independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heterocyclic or other suitable organic groups, and each of these groups may optionally be substituted.
[0033] "Hydroxy" refers to -OH, whether used as part of another term or on its own.
[0034] "Alkyl", whether used as part of another term or independently, refers to a straight-chain or branched saturated hydrocarbon group having one to ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl, as well as longer alkyl groups, such as heptyl, octyl, etc. Whenever this term appears, numerical ranges such as "C1-C6 alkyl" or "C1-6 alkyl" indicate that the alkyl group can consist of 1, 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the use of the term "alkyl" where no numerical range is specified. In some embodiments, the alkyl group is C1- 10 Alkyl group. In some embodiments, the alkyl group is C1-6 alkyl. In some embodiments, the alkyl group is C1-5 alkyl. In some embodiments, the alkyl group is C1-4 alkyl. In some embodiments, the alkyl group is C1-3 alkyl. Unless specifically stated otherwise in the specification, the alkyl group may optionally be substituted, for example, by one or more of the following substituents: such as oxo, halogen, amino, cyano, nitro, hydroxy, haloalkyl, alkoxy, carboxyl, carboxyl ester, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the alkyl group is optionally substituted by one or more of the following substituents: such as oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl group is optionally substituted by one or more of the following substituents: such as halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl group is optionally substituted with a halogen.
[0035] "Alkenyl," whether used as part of another term or independently, refers to a straight-chain or branched hydrocarbon group having one or more carbon-carbon double bonds and having two to ten carbon atoms, more preferably two to six carbon atoms. The group may be in a cis or trans conformation at the double bond, or alternatively, an E or Z conformation, and should be understood to include both isomers. Examples include, but are not limited to, vinyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl, etc. Wherever it appears herein, numerical ranges such as "C2-C6 alkenyl" or "C2-6 alkenyl" mean that the alkenyl group may consist of 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term "alkenyl" where no numerical range is specified. Unless otherwise specifically stated in the specification, the alkenyl group may optionally be substituted, for example, by one or more of the following substituents: such as oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxyl ester, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the alkenyl group is optionally substituted by one or more of the following substituents: such as oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkenyl group is optionally substituted by one or more of the following substituents: such as halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl group is optionally substituted with a halogen.
[0036] "Alynyl", whether used as part of another term or independently, refers to a straight-chain or branched hydrocarbon group having one or more carbon-carbon triple bonds and having two to ten carbon atoms, more preferably two to six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, etc. Whenever it appears here, numerical ranges such as "C2-C6 alkynyl" or "C2-6 alkynyl" mean that the alkynyl group can consist of 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term "alkynyl" where no numerical range is specified. Unless specifically stated otherwise in the specification, the alkynyl group may optionally be substituted, for example, by one or more substituents such as oxo, halogen, amino, cyano, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylic ester, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the alkynyl group is optionally substituted with one or more substituents selected from the group consisting of oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl group is optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, -OH, or -OMe. In some embodiments, the alkynyl group is optionally substituted with a halogen.
[0037] "Alkoxy" whether used as part of another term or independently refers to the formula -OR a The group, wherein R a This is an alkyl group as defined herein. Whenever it appears here, numerical ranges such as “C1-C6 alkoxy” or “C1-6 alkoxy” indicate that the alkyl group can consist of 1, 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the use of the term “alkoxy” where no numerical range is specified. In some embodiments, the alkoxy group is C1- 10 Alkoxy group. In some embodiments, the alkoxy group is C1-6 alkoxy. In some embodiments, the alkoxy group is C1-5 alkoxy. In some embodiments, the alkoxy group is C1-4 alkoxy. In some embodiments, the alkyl group is C1-3 alkoxy. In some embodiments, the alkyl group is C1-2 alkoxy. In some embodiments, the alkyl group is methoxy. Unless specifically stated otherwise in the specification, the alkoxy group may optionally be substituted, for example, by oxo, halogen, amino, cyano, nitro, hydroxy, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the alkoxy group is optionally substituted by halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy group is optionally substituted by halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy group is optionally substituted by halogen.
[0038] "Aryl," whether used as part of another term or independently, refers to a group derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring. The aryl group can be a monocyclic or polycyclic (including, but not limited to, bicyclic, tricyclic, or tetracyclic) ring system. Polycyclic ring systems can include fused (e.g., fused aromatic ring with a cycloalkyl ring), bridged (e.g., fused aromatic ring with a bridged cycloalkyl ring), or spirocyclic (e.g., fused aromatic ring with a spiroalkyl ring) ring system. In some embodiments, the aryl group is 6- to 10-membered aryl. In some embodiments, the aryl group is 6-membered aryl (phenyl). The aryl group includes, but is not limited to, aryl groups derived from the following hydrocarbon ring systems: anthracene, naphthyl, phenanthrene, anthracene, azulene, benzene, phenanthrene, fluoranthene, fluorene, asymmetric indole, symmetric indole, indene, naphthalene, phenatene, phenanthrene, heptamethrin, pyrene, and triphenylene. Unless otherwise specifically stated in the specification, the aryl group may optionally be substituted, for example, by one or more of the following substituents: such as halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the aryl group is optionally substituted by one or more of the following substituents: such as halogen, methyl, ethyl, -CN, -COOH, -COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the aryl group is optionally substituted by one or more of the following substituents: such as halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl group is optionally substituted with a halogen.
[0039] "Cycloalkyl," whether used as part of another term or independently, refers to a partially or fully saturated monocyclic or polycyclic carbocyclic ring, which may include fused (e.g., fused with another cycloalkyl ring), spirocyclic, or bridged ring systems. In some embodiments, the cycloalkyl group is fully saturated. In some embodiments, the cycloalkyl group is partially saturated. Representative cycloalkyl groups include, but are not limited to, cycloalkyl groups having three to fifteen carbon atoms (C3-C4). 15 Fully saturated cycloalkyl or C3-C 15 Cycloalkenyl groups (C3-C4) with three to ten carbon atoms 10 Fully saturated cycloalkyl or C3-C 10The cycloalkyl group comprises, for example, cycloalkyl (C3-C8 fully saturated cycloalkyl or C3-C8 cycloalkyl), cycloalkyl (C3-C6 fully saturated cycloalkyl or C3-C6 cycloalkyl), cycloalkyl (C3-C5 fully saturated cycloalkyl or C3-C5 cycloalkyl), or cycloalkyl (C3-C4 fully saturated cycloalkyl or C3-C4 cycloalkyl) having three to five carbon atoms. In some embodiments, the cycloalkyl group is a 3- to 10-membered fully saturated cycloalkyl or a 3- to 10-membered cycloalkyl. In some embodiments, the cycloalkyl group is a 3- to 6-membered fully saturated cycloalkyl or a 3- to 6-membered cycloalkyl. In some embodiments, the cycloalkyl group is a 5- to 6-membered fully saturated cycloalkyl or a 5- to 6-membered cycloalkyl. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornel, decahydronaphthyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decahydronaphthyl, trans-decahydronaphthyl, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, as well as 7,7-dimethyl-bicyclo[2.2.1]heptyl. Partially saturated cycloalkyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless specifically stated otherwise in the specification, cycloalkyl groups may optionally be substituted, for example, by one or more substituents such as oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the cycloalkyl group is optionally substituted with one or more of the following substituents: such as oxo, halogen, methyl, ethyl, -CN, -COOH, -COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the cycloalkyl group is optionally substituted with one or more of the following substituents: such as oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl group is optionally substituted with a halogen.
[0040] "Halogen" or "halogen" refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine or chlorine. In some embodiments, the halogen is fluorine.
[0041] "Halogenated alkyl" refers to an alkyl group as defined above that is substituted with one or more halogen groups as defined above, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc.
[0042] "Heterocyclic group," whether used as part of another term or independently, refers to a 3- to 24-membered partially or fully saturated cyclic group comprising 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from nitrogen, oxygen, phosphorus, silicon, and sulfur. In some embodiments, the heterocyclic group is fully saturated. In some embodiments, the heterocyclic group is partially unsaturated. In some embodiments, the heterocyclic group comprises one to three heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic group comprises one to three heteroatoms selected from nitrogen and oxygen. In some embodiments, the heterocyclic group comprises one to three nitrogen atoms. In some embodiments, the heterocyclic group comprises one or two nitrogen atoms. In some embodiments, the heterocyclic group comprises one nitrogen atom. In some embodiments, the heterocyclic group comprises one nitrogen atom and one oxygen atom. Unless specifically stated otherwise in the specification, the heterocyclic group can be a monocyclic or polycyclic (including, but not limited to, bicyclic, tricyclic, or tetracyclic) ring system. Polycyclic ring systems can include fused (e.g., a heterocyclic ring fused with a cycloalkyl group or another heterocyclic ring), spirocyclic, or bridged ring systems. The nitrogen, carbon, or sulfur atom in the heterocyclic group may optionally be oxidized; the nitrogen atom may optionally be quaternized. Representative heterocyclic groups include, but are not limited to, heterocyclic groups having two to fifteen carbon atoms (C2-C4). 15 Heterocyclic groups), heterocyclic groups with two to ten carbon atoms (C2-C 10Heterocyclic groups, heterocyclic groups having two to eight carbon atoms (C2-C8 heterocyclic groups), heterocyclic groups having two to seven carbon atoms (C2-C7 heterocyclic groups), heterocyclic groups having two to six carbon atoms (C2-C6 heterocyclic groups), heterocyclic groups having two to five carbon atoms (C2-C5 heterocyclic groups), or heterocyclic groups having two to four carbon atoms (C2-C4 heterocyclic groups). Examples of such heterocyclic groups include, but are not limited to: acridinel, aziridine, oxaziridine, dioxopentyl, dihydrofuranyl, thiophene[1,3]dithiohexane, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, isothiazolyl, isoxazolyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperidinyl, 2-oxopiperidinyl, 2-oxopiperidinyl, 2-oxopiperidyl, oxazolyl, piperidinyl, piperazine, 4-piperidinone, pyridinyl The terms heterocyclic, pyrazolyl, quinoline, thiazolyl, tetrahydrofuranyl, trithiohexaneyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-m-dioxacyclopenten-4-yl, and 2-oxo-1,3-m-dioxacyclopenten-4-yl are also included. The term heterocyclic also includes all cyclic forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. In some embodiments, the heterocyclic group has 2 to 10 carbons in the ring. It should be understood that when referring to the number of carbon atoms in a heterocyclic group, the number of carbon atoms in the heterocyclic group is different from the total number of atoms constituting the heterocyclic group (including heteroatoms) (i.e., the skeletal atoms of the heterocyclic ring). In some embodiments, the heterocyclic group is a fully saturated heterocyclic group of 3 to 8 members. In some embodiments, the heterocyclic group is a fully saturated heterocyclic group of 3 to 7 members. In some embodiments, the heterocyclic group is a fully saturated heterocyclic group of 3 to 6 members. In some embodiments, the heterocyclic group is a fully saturated heterocyclic group of 4 to 6 members. In some embodiments, the heterocyclic group is a fully saturated heterocyclic group of 5 to 6 members. Unless specifically stated otherwise in the specification, the heterocyclic group may optionally be substituted as described below, for example, by one or more substituents such as oxo, halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the heterocyclic group is optionally substituted by one or more substituents selected from: such as oxo, halogen, methyl, ethyl, -CN, -COOH, -COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heterocyclic group is optionally substituted with one or more substituents selected from: halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocyclic group is optionally substituted with a halogen.
[0043] "Heteroaryl," whether used as part of another term or independently, refers to a 5- to 14-membered ring system group comprising one to thirteen carbon atoms, one to six heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl group comprises one to three heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl group comprises one to three heteroatoms selected from nitrogen and oxygen. In some embodiments, the heteroaryl group comprises one to three nitrogen atoms. In some embodiments, the heteroaryl group comprises one or two nitrogen atoms. In some embodiments, the heteroaryl group comprises one nitrogen atom. The heteroaryl group can be a monocyclic or polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) ring system. Polycyclic ring systems may include fused (e.g., fused heteroaryl ring with cycloalkyl, heterocyclic, or aryl rings, or fused aryl ring with heterocyclic rings), bridged (e.g., fused aryl or heteroaryl rings with bridged cycloalkyl or heterocyclic rings), or spirocyclic (e.g., fused aryl ring with spiroheterocyclic rings, or fused heteroaryl ring with spirocycloalkyl or spiroheterocyclic rings) ring systems. The nitrogen, carbon, or sulfur atom in the heteroaryl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. In some embodiments, the heteroaryl group is a 5- to 10-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5- to 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-membered heteroaryl group. Examples include, but are not limited to: aziridine, acridine, benzimidazolyl, benzothiazolyl, benzoindolyl, benzo-m-dioxacyclopentenyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxazolyl, 1,4-benzodioxacyclohexyl, benzonaphthuranyl, benzooxazolyl, benzo-m-dioxacyclopentenyl, benzodioxenyl, benzopyranyl, benzopyranoneyl, benzofuranyl, benzofuranoneyl, benzothiophene, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazole, cenyl, dibenzofuranyl, dibenzothiophene, furanyl, furanoneyl, furanyl (furyl), iso Thiazolyl, imidazolyl, indazole, indolyl, isoindolyl, dihydroindolyl, isodihydroindolyl, isoquinolinyl, indene, isoxazolyl, naphridinyl, oxadiazolyl, 2-oxoazapyridine, oxazolyl, ethylene oxide, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, 1-phenyl-1H-pyrroleyl, phenazinyl, phenothiazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purine, pyrroleyl, pyrazolyl, pyridinyl, pyridinyl 1-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxolinyl, quinolinyl, quininecycloyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl.Unless otherwise specifically stated in the specification, the heteroaryl group may optionally be substituted, for example, by one or more substituents such as halogen, amino, cyano, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocyclic, heteroaryl, etc. In some embodiments, the heteroaryl group is optionally substituted by one or more substituents selected from: such as halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heteroaryl group is optionally substituted by one or more substituents selected from: such as halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl group is optionally substituted by halogen.
[0044] As used herein, the term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, as well as any quaternized form of basic nitrogen (including N-oxides).
[0045] The terms “partially saturated” or “partially unsaturated” refer to a group containing at least one double or triple bond and are intended to cover a ring with multiple unsaturated sites, but not to include aromatic (i.e., completely unsaturated) parts.
[0046] As used herein, the terms "individual" or "patient" refer to both mammals and non-mammals. Mammals mean any member of the class Mammalia, including but not limited to: humans; non-human primates such as chimpanzees and other ape and monkey species; farm animals such as cattle, horses, sheep, goats, and pigs; domesticated animals such as rabbits, dogs, and cats; laboratory animals, including rodents such as rats, mice, and guinea pigs; and so on. Examples of non-mammals include, but are not limited to, birds. The terms "individual" or "patient" do not indicate a specific age or sex. In some embodiments, the individual or patient is a human.
[0047] When two atoms are directly connected by a single bond (e.g., a single, double, or triple bond), they are “adjacent” to each other. When two atoms are connected by one or more other atoms and two or more bonds (e.g., single, double, or triple bonds), they are not adjacent or “non-adjacent” to each other. For example, in hexane, carbon atom 1 and carbon atom 2 or carbon atom 1 and carbon atom 6 are “adjacent” atoms; while carbon atom 1 and carbon atom 3, carbon atom 1 and carbon atom 4, or carbon atom 1 and carbon atom 5 are “non-adjacent” atoms.
[0048]
[0049] Hexane with carbon atom numbering
[0050] The terms “optional” or “optionally” mean that the event or situation described below may or may not occur, and the description includes both the possibility that the event or situation occurs and the possibility that it does not occur. For example, “optionally substituted alkyl” means “alkyl” or “substituted alkyl” as defined above. Furthermore, the optionally substituted group can be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted to any degree between full and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.). Those skilled in the art will understand that for any group containing one or more substituents, such groups are not intended to introduce any substitution or substitution pattern that is sterically impractical and / or synthetically infeasible. Therefore, any described substituent should generally be understood to have a maximum molecular weight of about 1,000 Daltons, more typically up to about 500 Daltons.
[0051] When referring to optional substituents, the term "one or more" means that the target group is optionally substituted by one, two, three, four, or more substituents. In some embodiments, the target group is optionally substituted by one, two, three, or four substituents. In some embodiments, the target group is optionally substituted by one, two, or three substituents. In some embodiments, the target group is optionally substituted by one or two substituents. In some embodiments, the target group is optionally substituted by one substituent. In some embodiments, the target group is optionally substituted by two substituents.
[0052] "Effective dose" or "therapeutic effective dose" refers to the amount of a compound administered to an individual mammal, whether as a single dose or as part of a series of doses, that effectively produces the desired therapeutic effect.
[0053] As used herein, the term “treatment” includes reducing, weakening or improving at least one symptom of a disease or condition, preventing additional symptoms, suppressing a disease or condition (e.g., preventing the development of a disease or condition), alleviating a disease or condition, causing the remission of a disease or condition, relieving the condition caused by a disease or condition, or stopping the symptoms of a disease or condition.
[0054] compound
[0055] This article describes compounds that can be used as cGAS inhibitors and are useful in the treatment of diseases or disorders, or their pharmaceutically acceptable salts or stereoisomers.
[0056] In one aspect, this paper provides compounds of formula (I): Formula (I), Or its pharmaceutically acceptable salts or stereoisomers. in: Is it a single bond or a double bond? Ring A is a heterocyclic, aryl, or heteroaryl group; Ring B is a cycloalkyl, heterocyclic, aryl, or heteroaryl group; Ring C is a heterocyclic group; X 1 It is O, S, Se, N, NR 1a CR 1a or CR 1a R 1b ; X 2 It is C, CR 2 Or N; X 3 It is C, CR 3 Or N; X 4 It is CR 4 Or N; X 5 It is CR 5 Or N; X 6 It is CR 6 Or N; X 7 It is CR 7 Or N; X 8 It is C or N; X 9 It is C or N; X 10 It is NR 10a or CR 10a R 10b ; R 10a and R 10b Each is independently hydrogen or R X ; Or R 4 With R 10a Together they form a linking group L that connects ring A and ring C; Or R 4 With an R X Together they form a linking group L that connects ring A and ring C; L is each a key or optionally a key of one or more R. y Replacement of linear C 1-20 A divalent hydrocarbon chain, wherein one or more methylene units of the chain are optionally and independently converted by cycloalkyl, heterocyclic, or -C(R) groups. L )=C(R L )-、 -O-, -S-, -N(R)L )-, -C(=O)-, -OC(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2-, -N(R L )C(=O)-、-C(=O)N(R L )-、-N(R L )S(=O)2- or -S(=O)2N(R L - Substitution; R L Each is independently hydrogen, alkyl, or cycloalkyl; R y Each is independently a halogen, oxo, cyano, nitro, or -OR group. y1 -OC(=O)R y1 -OC(=O)OR y1 -OC(=O)N(R) y2 )2、-SR y1 -S(=O)R y1 -S(=O)2R y1 -S(=O)2N(R) y2 )2、-S(=O)(=NR y2 )R y1 -N(R) y2 )2、-NR y2 C(=O)N(R y2 )2、-NR y2 C(=O)R y1 -NR y2 C(=O)OR y1 -NR y2 S(=O)2R y1 -N=S(=O)(R y1 )2、-C(=O)R y1 -C(=O)OR y2 -C(=O)N(R) y2 2. Alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, or heterocyclic group, wherein the alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, or heterocyclic group is optionally represented by one or more R groups. y3 replace; R y1 Each is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocyclic, and each is optionally radicalized by one or more R groups. y3 replace; R y2Each of the following is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, or -alkyl-heterocyclic, optionally influenced by one or more R y3 replace; Or two R atoms on the same atom y2 Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. y3 Substituted heterocyclic groups; and R y3 Each of these can be independently a halogen, cyano, hydroxyl, oxo, -SF5, -SH, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)2NH2, -S(=O)2NH-alkyl, -S(=O)2N(alkyl)2, -S(=O)(=N-alkyl)(alkyl), -NH2, -NH-alkyl, -N(alkyl)2, -N=S(=O)(alkyl)2, -C(=O)-alkyl, -C(=O)OH, -C(=O)O-alkyl, -C(=O)NH2, -C(=O)NH-alkyl, -C(=O)N(alkyl)2, -P(=O)(alkyl)2, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, heteroalkyl, or cycloalkyl; L 1 For bonds, -C(=O)-, -S(=O)-, -S(=O)2- or -S(=NH)(=O)-; L 2 The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl groups. L 3 It is hydrogen, cyano, -OR a -N(R) b 2. Cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by one or more groups independently selected from the group consisting of: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl. R XEach of these groups is independently a halogen, hydroxyl, cyano, alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocyclic, -alkyl-aryl, or -alkyl-heteroaryl, wherein the alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocyclic, -alkyl-aryl, and -alkyl-heteroaryl groups are optionally substituted by one or more groups independently selected from: -OR a -SR a Halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; Or two Rs X Together with the atoms in between, they form cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. Or two Rs X Together with the same atom they are attached to, they form C (=O); Or two Rs X Together with the same atoms they are attached to, they form C=C(R) a R b ); R 1a R 1b R 2 and R 3 Each of the groups is independently hydrogen, halogen, hydroxyl, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. Or R 1a and R 1b Together with the same atom they are attached to, they form C (=O); Or R 1a and R 1b Together with the same atom to which they are attached, they form cycloalkyl or heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one or more groups independently selected from the following groups: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl; R 4 R 5 R 6 and R 7 Each is independently hydrogen, -ORa -SR a -SF5, -N(R) b )2、-N(R b )C(=O)R c -OC(=O)R c Halogen, hydroxyl, cyano, oxo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by one or more groups independently selected from the group consisting of: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl; R a R b and R c Each of the groups is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. n1, n2, and n3 are each independently 0 or 1; m is any integer from 0 to 8; and The condition is (1) When X 1 When it is O or S, then X 10 Is it optional to be R X The NH that is replaced or is replaced by one or two R X Replaced CH2; (2) When X 1 When it is N or NH, then X 2 Is it C or CH, X 4 It is CH, X 10 It is -C(CH3)-, and -L 2 -L 3 It is -CH2NH2, -CH2OH, or -CH2OCH3; and (3) The compound is not , , , , , .
[0057] In some implementations of formula (I), X 1 It is O, S, or Se, and X 2 It's C.
[0058] In some implementations of formula (I), X 10It is CR 10a R 10b And R 10a and R 10b At least one of them is R X .
[0059] In some embodiments, the compounds disclosed herein have formula (I-1): Formula (I-1), in: X 1 Is it O, S, or Se? R 11a R 11b R 12a R 12b R 13a R 13b R 14a and R 14b Each is independently hydrogen or R X ;and The condition is when X 1 It is O or S and R 10a When it is hydrogen, then R 10b It is R X .
[0060] In some implementations of formula (I), X 1 It is CR 1a R 1b And X 2 It is N.
[0061] In some embodiments, the compounds disclosed herein have formula (I-2): Formula (I-2), Where R 10a R 10b R 11a R 11b R 12a R 12b R 13a R 13b R 14a and R 14b Each is independently hydrogen or R X .
[0062] In some embodiments of equation (I), (I-1), or (I-2), (1) n1 is 0, n2 is 0, and n3 is 0; (2) n1 is 1, n2 is 0, and n3 is 0; (3) n1 is 0, n2 is 1, and n3 is 0; (4) n1 is 1, n2 is 1, and n3 is 0; (5) n1 is 0, n2 is 1, and n3 is 1; or (6) n1 is 1, n2 is 1, and n3 is 1. In some embodiments, n1 is 0, n2 is 1, and n3 is 0. In some embodiments, n1 is 0, n2 is 1, and n3 is 1. In some embodiments, n1 is 1, n2 is 1, and n3 is 0.
[0063] In some implementations of formula (I), R 4 With R 10a Together they form a linking group L that connects ring A and ring C.
[0064] In some implementations of equation (I), n1 is 0, and X 10 It is CR 10a R 10b .
[0065] In some embodiments, the compounds disclosed herein have formula (IA): Formula (IA).
[0066] In some embodiments, the compounds disclosed herein have formula (IA-1) or (IA-2): Formula (IA-1); Formula (IA-2).
[0067] In some implementations of formula (I), R 4 With an R X Together they form a linking group L that connects ring A and ring C.
[0068] In some implementations of equation (I), n1 is 1.
[0069] In some embodiments, the compounds disclosed herein have the formula (IB): Formula (IB).
[0070] In some embodiments, the compounds disclosed herein have the formula (IB-1) or (IB-2): Equation (IB-1), Equation (IB-2), In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), L is L 11 L 12 L 13 L 14 and L 15 Each is independently selected from bond, S, -C(=O)-, O, NH, -S(=O)2-, -S(=O)-, alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, cycloalkyl, or heterocyclic, wherein the alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, cycloalkyl, or heterocyclic group is optionally separated by one or more R y Replacement (e.g., two, or three, etc.). In some implementations, L 11 Connect to Q or Z 2 Or R X In some implementations, L 11 L 12 L 13 L 14 and L 15 At least one of them is not a key. In some implementations, L 11 L 12 L 13 L 14 and L 15 One of them is the key. In some implementations, L 11 L 12 L 13 L 14 and L 15 The two in are keys. In some implementations, L 11 L 12 L 13 L 14 and L 15 The three in it are keys. In some implementations, L 11 L 12 L 13 L 14 and L 15 The four in the text are keys. In some implementations, the connection base L... 1 With -L 11 -L 12 -、-L 11 -L 12 -L 13 -、-L 11 -L 12 -L 13 -L 14 -、-L 11 -L 12 -L13 -L 14 -L 15 -、-L 13 -L 14 -L 15 -or-L 11 -L 15 - structure. In some implementations, the connection base L 1 With -L 11 -L 12 - structure. In some implementations, L 11 L 12 L 13 L 14 and L 15 Each is independently selected from bond, S, -C(=O)-, O, NH, -S(=O)2-, -S(=O)-, C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkenyl groups, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkynyl group, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) heteroalkyl, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) heteroene group, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) heteroyne group, C 3-6 (e.g., C) 3-4 cycloalkyl (C3, C4, C5, or C6, etc.) or 3- to 6-membered (e.g., 3-, 4-, 5-, or 6-membered) heterocyclic groups, wherein the alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, cycloalkyl, or heterocyclic group is optionally surrounded by one or more (e.g., two or three, etc.) R y Replacement. In some implementations, L 11 L 12 L 13 L 14 and L 15 Each is independently selected from the following: bond, S, -C(=O)-, O, NH, -S(=O)2-, -S(=O)-, -CH2-, -CH2CH2-, -CH=CH-. or Among them, NH, -CH2-, -CH2CH2-, -CH=CH- or Optionally by one or more Ry replace.
[0071] In some embodiments of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), L is optionally a key or is bounded by one or more R. y Replacement of linear C 1-20 A divalent hydrocarbon chain, wherein one or more methylene units of the chain are optionally and independently C 3-6 (e.g., C) 3-4 Cycloalkyl groups (C3, C4, C5, or C6, etc.), 3- to 6-membered (e.g., 3-, 4-, 5-, or 6-membered) heterocyclic groups, -C(R L )=C(R L )-、 -O-, -S-, -N(R) L )-, -C(=O)-, -OC(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2-, -N(R L )C(=O)-、-C(=O)N(R L )-、-N(R L )S(=O)2- or -S(=O)2N(R L - Replacement. In some implementations, R L Each is independently hydrogen, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl or C 3-6 (e.g., C) 3-4 Cycloalkyl groups (C3, C4, C5 or C6, etc.)
[0072] In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), R y Each is independently a halogen, oxo, cyano, nitro, or -OR group. y1 -OC(=O)R y1 -OC(=O)OR y1 -OC(=O)N(R) y2 )2、-SR y1 -S(=O)R y1 -S(=O)2R y1 -S(=O)2N(R) y2 )2、-S(=O)(=NR y2 )R y1 -N(R) y2 )2、-NR y2 C(=O)N(R y2 )2、-NRy2 C(=O)R y1 -NR y2 C(=O)OR y1 -NR y2 S(=O)2R y1 -N=S(=O)(R y1 )2、-C(=O)R y1 -C(=O)OR y2 -C(=O)N(R) y2 2. C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkenyl groups, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkynyl group, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) heteroalkyl, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) heteroene group, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) heteroyne group, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) haloalkyl, hydroxyalkyl, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) aminoalkyl, C 3-6 (e.g., C) 3-4 cycloalkyl (C3, C4, C5, or C6, etc.) or 3- to 6-membered (e.g., 3-, 4-, 5-, or 6-membered) heterocyclic groups, wherein the alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, and heterocyclic groups are optionally surrounded by one or more R y3 Replacement. In some implementations, R y1 Each is independently hydrogen, C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) haloalkyl groups, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) hydroxyalkyl, C 1-6 (e.g., C)1-3 (C1, C2, C3, C4, C5 or C6, etc.) aminoalkyl, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) heteroalkyl, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkenyl groups, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkynyl group, C 3-6 (e.g., C) 3-4 cycloalkyl groups (C3, C4, C5, or C6, etc.) or 3- to 6-membered (e.g., 3-, 4-, 5-, or 6-membered) heterocyclic groups, each optionally surrounded by one or more R groups. y3 Replacement. In some implementations, R y2 Each is independently hydrogen, C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) haloalkyl groups, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) hydroxyalkyl, aminoalkyl, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) heteroalkyl, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkenyl groups, C 2-6 (e.g., C) 2-3 (C2, C3, C4, C5 or C6, etc.) alkynyl group, C 3-6 (e.g., C) 3-4 Cycloalkyl groups (C3, C4, C5, or C6, etc.), 3- to 6-membered (e.g., 3-, 4-, 5-, or 6-membered) heterocycloalkyl groups, C 6-12 For example, C 6-11 (or C6, etc.) aryl, 5- to 12-membered (e.g., 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 5- to 6-, 7- to 8- or 10- to 12-membered) heteroaryl, -C 1-6 (e.g., C) 1-3 Alkyl-C (C1, C2, C3, C4, C5, or C6, etc.) 3-6 (e.g., C) 3-4 (C3, C4, C5 or C6, etc.) cycloalkyl or -C 1-6 (e.g., C) 1-3(C1, C2, C3, C4, C5 or C6, etc.) alkyl-, 3- to 6-membered (e.g. 3-, 4-, 5- or 6-membered) heterocyclic groups, optionally surrounded by one or more R y3 Replacement. In some implementations, two R atoms on the same atom... y2 Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. y3 The substituted 3- to 6-membered (e.g., 3-, 4-, 5-, or 6-membered) heterocyclic group. In some embodiments, R y3 Each group independently represents a halogen, cyano, hydroxyl, oxo, -SF5, -SH, or -S(=O)-C group. 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.) and -S(=O)2-C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), -S(=O)2NH2, -S(=O)2NH-C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.) and -S(=O)2N(C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl) 2, -S (=O) (=NC) 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl group (C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl groups, -NH2, -NH-C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.) and -N(C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl) 2, -N=S(=O)(C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl group 2, -C (=O)-C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), -C(=O)OH, -C(=O)OC 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), -C(=O)NH2, -C(=O)NH-C 1-6 (e.g., C) 1-3Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.) and -C(=O)N(C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl) 2, -P (=O) (C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) alkyl group 2, C 1-6 (e.g., C) 1-3 Alkyl groups (C1, C2, C3, C4, C5, or C6, etc.), C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) alkoxy groups, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) haloalkyl groups, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) haloalkoxy groups, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) hydroxyalkyl, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5 or C6, etc.) aminoalkyl, C 1-6 (e.g., C) 1-3 (C1, C2, C3, C4, C5, or C6, etc.) heteroalkyl or C 3-6 (e.g., C) 3-4 Cycloalkyl groups (C3, C4, C5 or C6, etc.)
[0073] In some embodiments of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), L is -CH2CH2-#, -CH2CH2CH2-#, or -CH2 CH2CH2CH2-#, -CH2CH2O-#, -OCH2CH2-#, -CH2OCH2CH2-#, -NHCH2CH2-#, -CH2CH2NH-#, -NHCH2CH2CH2-#, -CH2CH2CH2O-#, -OCH2CH2CH2-#, -CH2CH2CH2CH2O-#, -OCH2CH2CH2CH2-#, -OCH2CH2O-#, -OCH2CH2CH2O-#, -CH=CHCH2O-#, -OCH2CH=CH-#, -CH2CH2CH2NH-# or -NHCH2CH2CH2-#, where the # end of L is connected to ring A or ring C.
[0074] In some embodiments of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), one or more R X Independently, it is halogen, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl group, C 3-12 Cycloalkyl, 3- to 12-membered heterocyclic, C 6-12 aryl or 5- to 12-membered heteroaryl, wherein the alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from: -OR a -SR a Halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl. In some embodiments, one or more R X Independently, it is cyano, C 1-6 alkyl( example like, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl groups, etc.), C 3-6 cycloalkyl ( For example, C 3-5 cycloalkyl or C 3-4 cycloalkyl, etc.), 5- to 6-membered heteroaryl or -C 1-6 Alkyl-C 6-8 Aryl (e.g.) , -C 1-6 Alkyl-C6 aryl, -C 1-5 Alkyl-C6 aryl, -C 1-4 Alkyl-C6 aryl, -C 1-3 alkyl-C6 aryl or -C 1-2 Alkyl-C6 aryl, such as -C6 alkyl-C6 aryl, -C5 alkyl-C6 aryl, -C4 alkyl-C6 aryl, -C3 alkyl-C6 aryl, -C2 alkyl-C6 aryl, or -C1 alkyl-C6 aryl), wherein the alkyl, cycloalkyl, heteroaryl, and -alkyl-aryl groups are optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl. In some embodiments, one or more R X Independently, it is cyano, C 1-6 alkyl( For example,(methyl, ethyl, n-propyl or isopropyl, etc.), C 3-6 cycloalkyl ( For example, Cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, etc.) or 5- to 6-membered heteroaryl ( For example, (Pyridyl, pyrimidinyl, or pyrazolyl, etc.) wherein the alkyl, cycloalkyl, and heteroaryl groups are optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 alkyl( For example, (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl ( For example, -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl ( For example, -CH2OH, etc.
[0075] In some embodiments of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), one or more R X Independently, they are cyano, -F, -Cl, -Br, -CH3, -CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CH2OH, -CH2OCH3, -CH2SCH3, -CH2CH2OH, -CH2C(CH3)2OH, -CH2CN, , , or .
[0076] In some embodiments of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), two R atoms connected to the same carbon atom X Together with the same carbon atom to which they are attached, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl. In some embodiments, two R atoms are attached to the same carbon atom.X Together with the same carbon atom they are attached to, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.). In some implementations, the two R... X Together with the same atoms they are attached to, they form C=C(R) a R b In some implementations, two Rs X Together with the same atom they are attached to, they form C=CH2, C=CF2, C=CCl2, or C=CFCH3. In some embodiments, the two R atoms... X Together with the same atom they are attached to, they form C (=O).
[0077] In some embodiments of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), the two R atoms connected to two adjacent carbon atoms X Together with the carbon atoms to which they are attached, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -ORa -SR a Or hydroxyalkyl. In some embodiments, the two R atoms are attached to two adjacent carbon atoms. X Together with the carbon atoms they are attached to, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0078] In some embodiments of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), the two R atoms connected to two non-adjacent carbon atoms... X Together with the atoms in between, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl. In some embodiments, the two R atoms are attached to two non-adjacent carbon atoms. X Together with the atoms in between, they form C 3-8 cycloalkyl (e.g.) ,C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0079] In some implementations of formula (I), (I-1), or (I-2), R 10a and R 10b Together with the same atom to which they are attached, they form cycloalkyl or heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R 10a and R 10b Together with the same atom they are attached to, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. ,3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.). In some implementations, R 10a and R 10b Together with the same atoms they are attached to, they form C=C(R) a R b In some implementations, R 10a and R 10b Together with the same atom they are attached to, they form C=CH2, C=CF2, C=CCl2, or C=CFCH3. In some embodiments, R 10a and R 10b Together with the same atom they are attached to, they form C (=O).
[0080] In some implementations of formula (I-1) or (I-2), R 11a and R 11b 、or R 12a and R 12b 、or R 13a and R 13b 、or R 14a and R 14b Together with the same atom to which they are attached, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
[0081] In some implementations of formula (I-1) or (I-2), R 11a and R11b Together with the same atom they are attached to, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a ( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.). In some implementations, R 11a and R 11b Together with the same atoms they are attached to, they form C=C(R) a R b In some implementations, R 11a and R 11b Together with the same atom they are attached to, they form C=CH2, C=CF2, C=CCl2, or C=CFCH3. In some embodiments, R 11a and R 11b Together with the same atom they are attached to, they form C (=O).
[0082] In some implementations of formula (I-1) or (I-2), R 12a and R 12b Together with the same atom they are attached to, they form C 3-8 cycloalkyl (e.g.) ,C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a ( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.). In some implementations, R 12a and R 12b Together with the same atoms they are attached to, they form C=C(R) a R b In some implementations, R 12a and R 12b Together with the same atom they are attached to, they form C=CH2, C=CF2, C=CCl2, or C=CFCH3. In some embodiments, R 12a and R 12b Together with the same atom they are attached to, they form C (=O).
[0083] In some implementations of formula (I-1) or (I-2), R 13a and R 13b Together with the same atom they are attached to, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a ( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.). In some implementations, R 13a and R 13b Together with the same atoms they are attached to, they form C=C(R) a R b In some implementations, R 13a and R 13b Together with the same atom they are attached to, they form C=CH2, C=CF2, C=CCl2, or C=CFCH3. In some embodiments, R 13a and R 13b Together with the same atom they are attached to, they form C (=O).
[0084] In some implementations of formula (I-1) or (I-2), R 14a and R 14b Together with the same atom they are attached to, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. ,3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a ( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.). In some implementations, R 14a and R 14b Together with the same atoms they are attached to, they form C=C(R) a R b In some implementations, R 14a and R 14b Together with the same atom they are attached to, they form C=CH2, C=CF2, C=CCl2, or C=CFCH3. In some embodiments, R 14a and R 14b Together with the same atom they are attached to, they form C (=O).
[0085] In some implementations of formula (I-1) or (I-2), R 11a and R 12a 、or R 12a and R 14a 、or R 10a and R 13a Together with the atoms they are attached to, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
[0086] In some implementations of formula (I-1) or (I-2), R 11a and R 12aTogether with the atoms they are connected to and interposed with, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0087] In some implementations of formula (I-1) or (I-2), R 12a and R 14a Together with the atoms they are connected to and interposed with, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) ,(methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0088] In some implementations of formula (I-1) or (I-2), R 10a and R 13a Together with the atoms they are connected to and interposed with, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C 3-4 cycloalkyl groups, etc.) or 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 3-to-7-membered heterocyclic group, 3-to-6-membered heterocyclic group, 3-to-5-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0089] In some implementations of formula (I-1) or (I-2), R 10a and R 11a 、or R 10a and R 12a 、or R 10a and R 14a 、or R 13a and R 14a 、or R 13a and R 12a 、or R 13a and R 11a 、or R 11a and R 14a Together with the atoms in between, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
[0090] In some implementations of formula (I-1) or (I-2), R 10a and R 11a Together with atoms in between, they form 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 7-membered heterocyclic group, 8-membered heterocyclic group, 4-to-8-membered heterocyclic group, 4-to-7-membered heterocyclic group, 5-to-8-membered heterocyclic group, 5-to-7-membered heterocyclic group, 6-to-7-membered heterocyclic group, 6-to-8-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0091] In some implementations of formula (I-1) or (I-2), R 10a and R12a Together with atoms in between, they form 4- to 8-membered heterocyclic groups (e.g. , 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 7-membered heterocyclic group, 8-membered heterocyclic group, 4-to-8-membered heterocyclic group, 4-to-7-membered heterocyclic group, 5-to-8-membered heterocyclic group, 5-to-7-membered heterocyclic group, 6-to-7-membered heterocyclic group, 6-to-8-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0092] In some implementations of formula (I-1) or (I-2), R 10a and R 14a Together with atoms in between, they form 4- to 8-membered heterocyclic groups (e.g. , 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 7-membered heterocyclic group, 8-membered heterocyclic group, 4-to-8-membered heterocyclic group, 4-to-7-membered heterocyclic group, 5-to-8-membered heterocyclic group, 5-to-7-membered heterocyclic group, 6-to-7-membered heterocyclic group, 6-to-8-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a(For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0093] In some implementations of formula (I-1) or (I-2), R 13a and R 14a Together with atoms in between, they form 5- to 8-membered heterocyclic groups (e.g. , 5-membered heterocyclic group, 6-membered heterocyclic group, 7-membered heterocyclic group, 8-membered heterocyclic group, 5-to-8-membered heterocyclic group, 5-to-7-membered heterocyclic group, 5-to-6-membered heterocyclic group, 6-to-7-membered heterocyclic group, 6-to-8-membered heterocyclic group, 7-to-8-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0094] In some implementations of formula (I-1) or formula (I-2), R 13a and R 12a Together with atoms in between, they form 5- to 8-membered heterocyclic groups (e.g. , 5-membered heterocyclic group, 6-membered heterocyclic group, 7-membered heterocyclic group, 8-membered heterocyclic group, 5-to-8-membered heterocyclic group, 5-to-7-membered heterocyclic group, 5-to-6-membered heterocyclic group, 6-to-7-membered heterocyclic group, 6-to-8-membered heterocyclic group, 7-to-8-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) ,Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0095] In some implementations of formula (I-1) or (I-2), R 13a and R 11a Together with atoms in between, they form 3- to 8-membered heterocyclic groups (e.g. , 3-membered heterocyclic group, 4-membered heterocyclic group, 5-membered heterocyclic group, 6-membered heterocyclic group, 7-membered heterocyclic group, 8-membered heterocyclic group, 4-to-8-membered heterocyclic group, 4-to-7-membered heterocyclic group, 5-to-8-membered heterocyclic group, 5-to-7-membered heterocyclic group, 6-to-7-membered heterocyclic group, 6-to-8-membered heterocyclic group, etc.), each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0096] In some implementations of formula (I-1) or (I-2), R 11a and R 14a Together with the atoms in between, they form C 3-8 cycloalkyl (e.g.) , C8 cycloalkyl, C7 cycloalkyl, C6 cycloalkyl, C5 cycloalkyl, C4 cycloalkyl, C3 cycloalkyl, C 3-7 cycloalkyl, C 3-6 cycloalkyl, C 3-5 cycloalkyl or C3-4 Cycloalkyl groups, etc., each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, C 1-6 Alkyl (e.g.) , (methyl, ethyl, n-propyl or isopropyl, etc.), C 2-6 alkenyl (e.g.) , Acetylene group, etc.), C 2-6 alkynyl (e.g.) , Vinyl, etc.), C 1-6 Halogenated alkyl groups (e.g.) , -CHF2, -CF3 or -CH2CF3, etc.), -OR a (For example , -OCH3 or -OCH2CH3, etc.), -SR a( For example , -SCH3 or -SCH2CH3, etc.) or C 1-6 Hydroxyalkyl (e.g.) , -CH2OH, etc.
[0097] In some implementations of formula (I), (I-1), or (I-2), R 10a It is hydrogen, and R 10b It is an alkyl group. In some embodiments, R 10a It is hydrogen, and R 10b It is C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl group. In some embodiments, R 10a It is hydrogen, and R 10b It is a C6 alkyl, C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, or C1 alkyl. In some embodiments, R 10a It is hydrogen, and R 10b It is -CH3 or -CH2CH3. In some implementations, R 10a It is hydrogen, and R 10b It is -CH3.
[0098] In some implementations of formulas (I), (IA), (IA-1), or (IA-2), R 10b It is hydrogen or alkyl. In some embodiments, R 10b Is it hydrogen or C? 1-6 Alkyl group. In some embodiments, R 10b It is hydrogen, C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl, C 1-2Alkyl, C6 alkyl, C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, or C1 alkyl. In some embodiments, R 10b It is hydrogen, -CH3 or -CH2CH3.
[0099] In some embodiments of equation (I), equation (I-1), or equation (I-2), ring C is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ,in Indicates with L 1 The connection point.
[0100] In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), ring C is , , , , , , , , , , , , , , , , , , , , or ,in Indicates with L 1 The connection point is indicated by #, which represents the connection point with L.
[0101] In some embodiments of formula (I), (I-1), or (I-2), X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 In some implementations, X 4 It is N, X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 In some implementations, X 4 It is CR 4 X 5 It is N, X 6 It is CR 6 And X 7 It is CR 7 .
[0102] In some implementations of formula (I), (I-1), or (I-2), R 4 R 5 R 6 and R 7 Each is independently hydrogen, -OR a -SR a -N(R) b )2、-N(R b )C(=O)R c , cyano, C 1-6 Alkyl (e.g.) , C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl), C 2-6 alkenyl (e.g.) , C 2-5 Alkenyl, C 2-4 alkenyl or C 2-3 alkenyl), C 2-6 alkynyl (e.g.) , C2-5 alkynyl group, C 2-4 alkynyl or C 2-3 The alkyl group (alkynyl), halogen, or 5- to 6-membered heteroaryl group is optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c Each is independently hydrogen or alkyl, optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c One or more of them are C independently 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c One or more of them are independently C6 alkyl, C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, or C1 alkyl, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c One or more of them are hydrogen.
[0103] In some implementations of formula (I), (I-1), or (I-2), R 4 R 5 R 6 and R 7 Each of these can be independently represented by hydrogen, cyano, -F, -Cl, -Br, -CH2CH3, -CH3, -OH, -OCH3, -SCH3, -OCH2CN, -OCH2CH3, -OCHF2, -OCH2F, -SCHF2, -CH2CH2CN, -CH2CN, -CHF2, or -CH=CH2. , , , or In some embodiments, hydrogen is D. In some embodiments, CH3 is CD3. In some embodiments, OCH3 is OCD3.
[0104] In some embodiments of formula (I), (I-1), or (I-2), X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is an independent halogen, and R 4 and R 5 Each is hydrogen. In some implementations, X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, or Br, and R 4 and R 5 Each is hydrogen. In some implementations, X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is either halogen or hydrogen, R 4 It is hydrogen, and R 5 Is it halogen or -OR a In some implementations, X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 It is F, Cl or Br, R 7 It is hydrogen, F, Cl or Br, R 4 It is hydrogen, and R 5 It is OCH3 or OCH2CH3. In some implementations, X 4 It is CR4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl or Br, R 4 It is hydrogen, and R 5 It is OCH3 or OCH2CH3. In some embodiments, OCH3 is OCD3. In some embodiments, X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl or Br, R 4 It is hydrogen, and R 5 It is OCD3. In some implementations, X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 5 R 6 and R 7 Each is independently F, Cl, or Br, and R 4 It is hydrogen. In some implementations, X 4 It is CR 4 X 5 It is N, X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently either halogen or hydrogen, and R 4 and R 5 Each is hydrogen. In some implementations, X 4 It is CR 4 X 5 It is N, X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, Br, or hydrogen, and R4 and R 5 Each is hydrogen. In some implementations, X 4 It is CR 4 X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, or Br, and R 4 and R 5 Each is hydrogen, F, Cl, or Br.
[0105] In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 In some implementations, X 5 It is N, X 6 It is CR 6 And X 7 It is CR 7 .
[0106] In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), R 5 R 6 and R 7 Each is independently hydrogen, -OR a -SR a -N(R) b )2、-N(R b )C(=O)R c , cyano, C 1-6 Alkyl (e.g.) , C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl), C 2-6 alkenyl (e.g.) , C 2-5 Alkenyl, C 2-4 alkenyl or C 2-3 alkenyl), C 2-6 alkynyl (e.g.) , C 2-5 alkynyl group, C 2-4alkynyl or C 2-3 The alkyl group (alkynyl), halogen, or 5- to 6-membered heteroaryl group is optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c Each is independently hydrogen or alkyl, optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c One or more of them are C independently 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c One or more of them are independently C6 alkyl, C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, or C1 alkyl, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a R b and R c One or more of them are hydrogen.
[0107] In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), R 5 R 6 and R 7 Each of these can be independently represented by hydrogen, cyano, -F, -Cl, -Br, -CH2CH3, -CH3, -OH, -OCH3, -SCH3, -OCH2CH3, -OCH2CN, -OCHF2, -OCH2F, -SCHF2, -CH2CH2CN, -CH2CN, -CHF2, or -CH=CH2. , , , or In some implementations, -OCH3 is -OCD3.
[0108] In some implementations of formulas (I), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is an independent halogen, and R 5 It is hydrogen. In some implementations, X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, or Br, and R 5 It is hydrogen. In some implementations, X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, or Br, and R 5 Yes - OR a In some implementations, X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, or Br, and R 5 It is -OCH3. In some implementations, -OCH3 is -OCD3. In some implementations, X 5 It is CR 5 X 6 It is CR 6 And X 7 It is CR 7 R 5 R 6 and R 7 Each is independently F, Cl, or Br. In some implementations, X 5 It is N, X 6 It is CR 6 And X 7 It is CR 7R 6 and R 7 Each is independently either halogen or hydrogen, and R 4 and R 5 Each is hydrogen. In some implementations, X 5 It is N, X 6 It is CR 6 And X 7 It is CR 7 R 6 and R 7 Each is independently F, Cl, Br, or hydrogen, and R 4 and R 5 Each is hydrogen.
[0109] In some implementations of formulas (I), (I-1), (IA), (IA-1), (IB), or (IB-1), X 1 It is O, S, Se, N, NH, CR 1a or CR 1a R 1b In some implementations, X 1 It is O, S, or Se. In some implementations, X 1 It is O or S. In some implementations, X 1 It is O. In some implementations, X 1 It is S. In some implementations, X 1 It is Se. In some implementations, X 1 It is N. In some implementations, X 1 Yes -NR 1a - In some implementations, X 1 It is -NH-. In some implementations, X 1 Yes -CR 1a -
[0110] In some implementations of formula (I), X 1 It is CR 1a R 1b .
[0111] In some implementations of formulas (I), (I-2), (IA), (IA-2), (IB), or (IB-2), R 1a It is hydrogen, and R 1b It is hydrogen or alkyl, or R 1a and R 1b Together with the same atom they are attached to, they form C (=O). In some implementations, R 1a It is hydrogen, and R 1b Is it hydrogen or C? 1-6 Alkyl, C 1-5 Alkyl, C1-4 Alkyl, C 1-3 Alkyl or C 1-2 Alkyl group. In some embodiments, R 1a It is hydrogen, and R 1b It is hydrogen or a C6 alkyl, C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, or C1 alkyl. In some embodiments, R 1a It is hydrogen, and R 1b It is hydrogen or methyl. In some embodiments, R 1a and R 1b Together with the same atom they are attached to, they form C (=O).
[0112] In some implementations of formula (I), (IA), or (IB), R 2 and R 3 Each is hydrogen.
[0113] In some implementations of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), L 1 For key or -C (=O)-. In some implementations, L 1 As a key. In some implementations, L 1 It is -C(=O)-. In some implementations, L 1 It is -S(=O)-. In some implementations, L 1 It is -S(=O)2-. In some implementations, L 1 It is -S(=NH)(=O)-.
[0114] In some implementations of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), L 2 For key, C 1-6 Alkyl (e.g.) , C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2 alkyl) or 5- to 6-membered heteroaryl (e.g. , (Pyrimidinyl or pyridinyl, etc.). In some embodiments, L 2 As a key. In some implementations, L 2 It is C 1-6 Alkyl (e.g.) , C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2alkyl) or 5- to 6-membered heteroaryl (e.g. , (such as pyrimidinyl or pyridinyl), wherein the C 1-6 The alkyl and heteroaryl groups are optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, L 2 For bonds, -CH2-, -CH2-CH2-, -CH(CH3)-, -CH(OH)-, -CH(OH)CH2-, , or In some implementations, -CH2- is -CD2-. In some implementations, L 2 It is -CD2-.
[0115] In some implementations of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), L 3 It is hydrogen, cyano, -OR a -N(R) b )2 or 5- to 6-membered heterocyclic group, optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, L 3 Yes - OR a -N(R) b )2, or 5- to 6-membered heterocyclic groups (e.g. , Piperazinyl, piperidinyl, or pyrrolidinyl (e.g., piperazine, piperidinyl, or pyrrolidinyl), optionally substituted with one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. In some embodiments, R a and R b Each is independently hydrogen or alkyl. In some embodiments, R a and R b Each is independently hydrogen or C 1-6 Alkyl group, wherein the alkyl group is optionally substituted by one or more groups independently selected from: halogen or C 1-6 Alkoxy (e.g.) , -OCH3 or -OCH2CH3). In some implementations, R a and R b Each is independently hydrogen or C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl or C 1-2Alkyl group. In some embodiments, R a and R b Each is independently hydrogen or a C6 alkyl, C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, or C1 alkyl. In some embodiments, L 3 It is -CN, -OH, -OCH3, -OCH2CH2OH, -OCH2CH2OCH3, -NH2, -NHCH3, -NHCH2CH3, -N(CH3)2, or In some implementations, -CH3 is -CD3. In some implementations, L 3 It is -CD3. In some implementations, L 3 It is hydrogen. In some implementations, L 3 Yes - CN.
[0116] In some implementations of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), -L 1 -L 2 -L 3 It is hydrogen. , , , , , , , , , , , , , , or In some implementation schemes, yes In some implementation schemes, yes .
[0117] In some implementations of formulas (I), (I-1), (I-2), (IA), (IA-1), (IA-2), (IB), (IB-1), or (IB-2), -L 1 -L 2 -L 3 yes or .
[0118] This article also provides the compounds listed in Table 1 or Table 2, or their pharmaceutically acceptable salts or stereoisomers.
[0119] Table 1 Exemplary Compounds
[0120] Table 2 Exemplary Compounds
[0121] Other forms of the compounds disclosed herein
[0122] Isomers / stereoisomers
[0123] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, E (entgegen), and Z (zusammen) isomers and corresponding mixtures thereof. In some embodiments, the compounds described herein have one or more chiral centers, and each center exists in an R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms and corresponding mixtures thereof. In other embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomeric compounds produced by a single preparation step, combination, or interconversion can be used in the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compounds with an optically active resolving agent to form a pair of diastereomeric compounds, separating the diastereomeric compounds, and recovering the optically pure enantiomer. In some embodiments, a dissociable complex is preferred. In some embodiments, diastereomers possess different physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.) that can be utilized for separation. In some embodiments, diastereomers are separated by chiral chromatography, or preferably by separation / resolution techniques based on solubility differences. In some embodiments, the optically pure enantiomers, along with the resolving agent, are then recovered by any practical method that does not lead to racemization.
[0124] tautomer
[0125] In some cases, compounds exist as tautomers. The compounds described herein include all possible tautomers within the structures described herein. Tautomers are compounds that can interconvert through the migration of hydrogen atoms, accompanied by the exchange of single bonds and adjacent double bonds. In the bond arrangements where tautomerization is possible, a chemical equilibrium of tautomers will exist. All tautomer forms of the compounds disclosed herein are considered. The exact proportions of tautomers depend on several factors, including temperature, solvent, and pH.
[0126] Unless otherwise stated, in this disclosure, the solid wedge line ( ) and virtual wedge line ( The bond, represented by a solid line, is used to indicate the absolute configuration of the chiral center. ) and dashed lines ( The bond, represented by ) is used to indicate the relative configuration of the chiral center, and is indicated by wavy lines ( The key indicated by ) is used to indicate (1) solid wedge line ( ) or virtual wedge line ( ), or (2) a solid line( ) or a dashed line( ).
[0127] Isotopic forms
[0128] Unless otherwise stated, the compounds described herein may exhibit their natural isotopic abundance, or one or more atoms may be artificially enriched with a specific isotope that has the same atomic number but an atomic mass or mass number different from the atomic mass or mass number that predominantly exists in nature. All isotopic variants of the compounds of the present disclosure, whether radioactive or not, are included within the scope of the present disclosure. For example, hydrogen has three naturally occurring isotopes, denoted as 1 H (protium), 2 H (deuterium) and 3 H (tritium). Protium is the most abundant hydrogen isotope in nature. Enrichment with deuterium may provide some therapeutic advantages, such as increased in vivo half-life and / or exposure, or may provide a compound that can be used to study in vivo drug elimination and metabolic pathways.
[0129] For example, the compounds described herein may be artificially enriched at one or more specific isotopes. In some embodiments, the compounds described herein may be artificially enriched at one or more isotopes that are not predominantly found in nature. In some embodiments, the compounds described herein may be artificially enriched at one or more isotopes selected from deuterium( 2 H), tritium( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). In some embodiments, the compounds described herein are enriched at an isotope selected from 2 H, 11 C, 13 C, 14 C, 15 C, 12 N, 13 N, 15 N, 16 N, 16 O, 17 O, 14 F, 15 F, 16 F, 17 F, 18 F, 33 S, 34 S, 35 S, 36 S, 35 Cl, 37 Cl, 79 Br, 81 Br,131 I and 125 The enriched isotopes are artificially enriched on one or more isotopes of I. In some embodiments, the abundance of the enriched isotopes is independently, in molar terms, at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
[0130] In some embodiments, the compound is deuterated at at least one position. In some embodiments, some or all of the compounds disclosed herein are used. 1 H atoms are 2 H atom substitution.
[0131] Methods for synthesizing deuterium-containing compounds are known in the art and include, by way of non-limiting example only, the steps described in U.S. Patent Nos. 5,846,514 and 6,334,997, and the following synthetic methods. For example, the synthesis of deuterium-substituted compounds can be carried out using various methods described in the following literature: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In: Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled Compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.
[0132] Deuteration starting materials are readily available, and the synthetic methods described herein can provide the synthesis of deuterium-containing compounds. A wide range of deuterium-containing reagents and structural units are commercially available from chemical suppliers such as Aldrich Chemical Co.
[0133] Pharmaceutically acceptable salts
[0134] In some embodiments, the compounds described herein are present as pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.
[0135] In some embodiments, the compounds described herein have acidic or basic groups and thus react with several inorganic or organic bases, as well as any of inorganic and organic acids, to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by reacting the purified compound in its free form alone with a suitable acid or base and isolating the resulting salt.
[0136] Examples of pharmaceutically acceptable salts include those prepared by reacting the compounds described herein with inorganic acids, organic acids, or inorganic bases. Such salts include acetates, acrylates, adipates, alginates, aspartates, benzoates, benzenesulfonates, hydrogen sulfates, bisulfites, bromides, butyrates, butyn-1,4-dicitates, camphorates, camphorsulfonates, hexanoates, octanoates, chlorobenzoates, chlorides, citrates, cyclopentanepropionates, decanoates, digluconates, dihydrogen phosphates, dinitrobenzoates, dodecyl sulfates, ethanesulfonates, formates, fumarates, glucono-heptanoates, glycerophosphates, glycolates, hemisulfates, heptanates, hexyn-1,6-dicitates, hydroxybenzoates, and γ-hydroxybutyric acid. Salts, hydrochlorides, hydrobromides, hydroiodates, 2-hydroxyethanesulfonates, iodides, isobutyrates, lactates, maleates, malonates, methanesulfonates, mandelates, metaphosphates, methanesulfonates, methoxybenzoates, methylbenzoates, monohydrogen phosphates, 1-naphthalenesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, dihydroxynaphthalates, pectates, persulfates, 3-phenylpropionates, phosphates, picrates, pentanoates, propionates, pyrosulfates, pyrophosphates, propynates, phthalates, phenylacetates, phenylbutyrates, propionate salts, salicylates, succinates, sulfates, sulfites, succinates, octanoates, sebacic acid salts, sulfonates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates, and xylenesulfonates.
[0137] Furthermore, the compounds described herein can be prepared as pharmaceutically acceptable salts by reacting the free base form of the compounds with pharmaceutically acceptable inorganic or organic acids, including but not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, etc.; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-( 4-Hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-en-1-carboxylic acid, glucoheponic acid, 4,4'-methylenebis-(3-hydroxy-2-en-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and mucoconic acid. In some embodiments, other acids, such as oxalic acid, although not pharmaceutically acceptable on their own, are used to prepare salts as intermediates useful in obtaining the compounds disclosed herein and their pharmaceutically acceptable acid addition salts.
[0138] In some embodiments, the compounds described herein containing free acid groups react with suitable bases, such as hydroxides, carbonates, bicarbonates, and sulfates of pharmaceutically acceptable metal cations, with ammonia, or with pharmaceutically acceptable primary, secondary, tertiary, or quaternary ammonium organic amines. Representative salts include alkali metal or alkaline earth metal salts, such as lithium, sodium, potassium, calcium, and magnesium salts, as well as aluminum salts. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, and N2SO4. + (C 1-4 Alkyl)4, etc.
[0139] Representative organic amines that can be used to form base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, etc. It should be understood that the compounds described herein also include quaternization of any basic nitrogen-containing groups they contain. In some embodiments, such quaternization yields water-soluble, oil-soluble, or dispersible products.
[0140] Treatment
[0141] This document discloses a method for regulating cyclic GMP-AMP synthase (cGAS) in individuals in need, the method comprising administering to the individual a therapeutically effective amount of the compound disclosed herein, or a pharmaceutically acceptable salt thereof.
[0142] This document discloses a method for inhibiting cGAS in individuals in need, the method comprising administering to the individual a therapeutically effective amount of the disclosed compound, or a pharmaceutically acceptable salt thereof.
[0143] This document discloses methods for treating a disease or disorder in an individual in need, the methods comprising administering to the individual a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein. In some embodiments, the disease or disorder is a cGAS-related disease or disorder.
[0144] In some implementations, the disease or disorder is inflammation, autoimmune disease, cancer, infection, central nervous system disease or disorder, metabolic disease, cardiovascular disease, respiratory disease, kidney disease, liver disease, eye disease, skin disease, lymphatic disease, rheumatic disease, mental illness, graft-versus-host disease, abnormal pain, or cGAS-related disease in individuals who have been identified as carrying cGAS germline or somatic non-silent mutations.
[0145] In some implementations, the disease or disorder is a central nervous system disease or disorder (e.g., Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, or multiple sclerosis); a kidney disease (e.g., acute kidney disease, chronic kidney disease, or rare kidney disease); a skin disease (e.g., psoriasis, hidradenitis suppurativa (HS), or atopic dermatitis); a rheumatic disease (e.g., dermatomyositis, Still's disease, or juvenile idiopathic arthritis); or a cold pyridine-associated autoinflammatory syndrome (e.g., familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal multisystem inflammatory disease).
[0146] This document also discloses the use of the disclosed compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of a medicament for regulating cGAS in individuals in need.
[0147] This document also discloses the use of the disclosed compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of a medicament for inhibiting cGAS in individuals in need.
[0148] This document also discloses the use of the disclosed compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the preparation of a medicament for treating a disease or disorder in an individual in need. In some embodiments, the disease or disorder is a cGAS-related disease or disorder.
[0149] In some implementations, the disease or disorder is inflammation, autoimmune disease, cancer, infection, central nervous system disease or disorder, metabolic disease, cardiovascular disease, respiratory disease, kidney disease, liver disease, eye disease, skin disease, lymphatic disease, rheumatic disease, mental illness, graft-versus-host disease, abnormal pain, or cGAS-related disease in individuals who have been identified as carrying cGAS germline or somatic non-silent mutations.
[0150] In some implementations, the disease or disorder is a central nervous system disease or disorder (e.g., Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, or multiple sclerosis); a kidney disease (e.g., acute kidney disease, chronic kidney disease, or rare kidney disease); a skin disease (e.g., psoriasis, hidradenitis suppurativa (HS), or atopic dermatitis); a rheumatic disease (e.g., dermatomyositis, Still's disease, or juvenile idiopathic arthritis); or a cold pyridine-associated autoinflammatory syndrome (e.g., familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal multisystem inflammatory disease).
[0151] Dosage
[0152] In some embodiments, compositions comprising the compounds described herein are administered for treatment. In some therapeutic applications, the composition is administered to a patient already suffering from the disease or condition in an amount sufficient to cure or at least partially suppress at least one symptom of the disease or condition. The effective amount for this purpose depends on the severity and course of the disease or condition, previous treatment, the patient's health status, weight, response to the drug, and the judgment of the attending physician. The therapeutically effective amount may optionally be determined by methods including, but not limited to, dose escalation and / or dose range searching in clinical trials.
[0153] In some implementations, when a patient’s condition does not improve, the physician may decide, at his discretion, to administer the compound for an extended period of time, including throughout the patient’s life, to improve or otherwise control or limit the symptoms of the patient’s disease or condition.
[0154] Application route
[0155] Suitable routes of administration include, but are not limited to: oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, ear, nasal, and local application. Furthermore, to name just a few examples, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection.
[0156] Pharmaceutical Compositions / Formulations
[0157] The compounds described herein are administered, alone or in combination with pharmaceutically acceptable carriers, excipients, or diluents, to individuals in need, in accordance with standard pharmaceutical practices. In some embodiments, the compounds described herein are administered to animals.
[0158] On the other hand, this document provides pharmaceutical compositions comprising the compounds described herein, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable excipients that facilitate the processing of the active compound into a pharmaceutically usable formulation. A suitable formulation depends on the chosen route of administration. A summary of the pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), the disclosure of which is incorporated herein by reference.
[0159] Example
[0160] For illustrative purposes, the following examples are included. The examples provided herein describe the compounds disclosed herein and the synthesis of intermediates for the preparation of said compounds. However, it should be understood that these examples do not limit the scope of this disclosure, but are merely intended to suggest methods for practicing the present disclosure. Those skilled in the art will recognize that the described chemical reactions can be readily adapted to prepare many other compounds of this disclosure, and alternative methods for preparing the compounds of this disclosure are considered within the scope of this disclosure. For example, the synthesis of compounds not illustrated in this disclosure can be successfully carried out with modifications readily apparent to those skilled in the art, such as by appropriately protecting interfering groups, by utilizing other suitable reagents and structural units known in the art besides those described, and / or by conventional modifications to the reaction conditions. Furthermore, those skilled in the art will also understand that individual steps described herein or in separate batches of the compounds can be combined. Alternatively, other reactions disclosed herein or known in the art will be recognized as suitable for the preparation of other compounds of this disclosure. Therefore, the following description is not intended to limit the scope of this disclosure, but is specifically illustrated by the appended claims.
[0161] Example 1: Synthesis of an exemplary compound
[0162] Example 1.1
[0163] NaOH (670 mg, 16.75 mmol) was added to a solution of 2,3-dichlorothiophenol (1000 mg, 5.58 mmol) and chloroacetic acid (581 mg, 6.14 mmol) in water (20 mL) at 25°C. The resulting mixture was stirred at 100°C under nitrogen for 16 hours to obtain a yellow solution. The reaction mixture was cooled to room temperature. The resulting mixture was quenched with ice water (20 mL) and extracted with EA (30 mL × 3). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compounds 1-2 (1.3 g, 98% yield). 1 H NMR (400MHz, CD3OD) δ 7.30 (m, 2H), 7.25 (m, 1H), 3.82 (s, 2H).
[0164] Phosphorus trichloride (3475 mg, 25.3 mmol) was added to a solution of compounds 1-2 (5.0 g, 21.2 mmol) in chlorobenzene (50 mL) at 25°C under nitrogen. The mixture was stirred at 100°C under nitrogen for 2 hours. The reaction mixture was cooled to room temperature, and aluminum chloride (3094 mg, 23.2 mmol) was added at 25°C under nitrogen. The mixture was stirred at 25°C under nitrogen for 16 hours. The resulting mixture was quenched with ice water (10 mL) and extracted with EA (50 mL × 3). The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compounds 1-3 (3.7 g, 80% yield). 1 H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.2 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 3.82 (s, 2H).
[0165] To a solution of compounds 1-3 (4.0 g, 18.26 mmol) in MeOH (30 mL), NaBH4 (1.036 g, 27.4 mmol) was added, and the mixture was stirred at 0°C for 2 hours to obtain a yellow solution. The reaction mixture was quenched with water (50 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (50 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compounds 1-4 (3.86 g, 96% yield). 1 H NMR (400 MHz, CDCl3) δ 7.69 -7.62 (m, 1H), 7.50 (d, J = 5.4 Hz, 1H), 7.47 - 7.42 (m, 1H), 7.33 (t, J = 4.4Hz, 1H).
[0166] To a stirred solution of compounds 1-4 (1.86 g, 8.41 mmol) in acetic acid (20 mL), boron trifluoride diethyl ether (5.33 mL, 42.1 mmol) was added. The resulting suspension was stirred at 120°C for 15 min. The reaction mixture was cooled and quenched with ice water (20 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compounds 1-5 (1.63 g, 95% yield). 1 H NMR (400 MHz, CDCl3) δ7.69 - 7.62 (m, 1H), 7.50 (d, J = 5.4 Hz, 1H), 7.47 - 7.42 (m, 1H), 7.33 (t, J = 4.3 Hz, 1H).
[0167] Add to a solution of compound 1-5 (1.46 g, 7.19 mmol) in THF (10 ml) at -78°C Uncle Ding lithium base (11.6 mL, 15.1 mmol) was added to the reaction mixture and stirred at -78°C for 2 hours to obtain a yellow solution. Ethylene oxide (4.79 mL, 14.38 mmol) was added to the reaction mixture and stirred at -78°C for 2 hours to obtain a yellow solution. The reaction mixture was quenched with water (20 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compounds 1-6 (900 mg, 50.7% yield). 1 H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.4 Hz, 1H), 7.43 - 7.35 (m, 1H), 7.09 (d, J = 14.8 Hz, 1H), 3.97 (q, J = 6.0 Hz, 2H), 3.16 (td, J = 6.1, 0.9 Hz, 2H), 1.64 - 1.55(m, 1H).
[0168] Methanesulfonyl chloride (834 mg, 7.28 mmol) and TEA (1.52 mL, 10.93 mmol) were added to a solution of compounds 1-6 (900 mg, 3.64 mmol) in DCM (10 mL) at 25°C under nitrogen. The mixture was stirred at 25°C under nitrogen for 16 hours. The reaction mixture was quenched with ice water (20 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compounds 1-7 (1.10 g, 93% yield). 1 H NMR (400 MHz, CDCl3) δ 7.62 - 7.50 (m, 1H), 7.49 - 7.38 (m, 1H),7.13 (d, J = 16.8 Hz, 1H), 4.56 - 4.45 (m, 2H), 3.39 - 3.31 (m, 2H), 2.98 (d, J = 9.0 Hz, 3H), 1.45 - 1.35 (m, 1H).
[0169] Sodium azide (660 mg, 10.15 mmol) was added to a solution of compounds 1-7 (1.1 g, 3.38 mmol) in DMF (5 mL) at 25°C under nitrogen. The mixture was stirred at 70°C under nitrogen for 16 hours. The reaction mixture was cooled, quenched with ice water (50 mL), and stirred for 20 minutes. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compounds 1-8 (820 mg, 89% yield). 1 H NMR (400MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 1H), 7.40 (dd, J = 8.3, 4.0 Hz, 1H), 7.11(s, 1H), 3.71 - 3.60 (m, 2H), 3.17 (td, J = 6.8, 0.8 Hz, 2H).
[0170] Pd / C (50 mg, 10% wt., 55% H2O) was added to a solution of compounds 1-8 (890 mg, 3.27 mmol) in THF (10 mL). The reaction mixture was repeatedly evacuated and purged with hydrogen. The reaction mixture was stirred at 40°C under hydrogen for 16 hours. The reaction mixture was extracted with EA (30 mL × 3), washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compounds 1-9 (600 mg, 74.5% yield). LCMS: 246.0 [M+H] + .
[0171] Acetyl chloride (63.8 mg, 0.81 mmol) was added to a solution of compounds 1-9 (100 mg, 0.41 mmol) in DCM (5 mL), and the mixture was stirred for 30 min. TEA (0.17 mL, 1.22 mmol) was added to the resulting suspension, and the mixture was stirred at 25°C for 2 h. The reaction mixture was quenched with ice water (20 mL) and stirred for 20 min. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compounds 1-10 (90 mg, 77% yield). LCMS: 288.0 [M+H] + .
[0172] To a solution of compound 1-10 (180 mg, 0.625 mmol) in acetonitrile (5 mL), phosphoryl chloride (0.116 mL, 1.25 mmol) was added. The reaction mixture was stirred at 80°C for 2 hours to obtain a yellow solution. The reaction mixture was cooled to room temperature, quenched with ice water (20 mL), and stirred for 20 minutes. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compound 1-11 (160 mg, 95% yield). LCMS: 270.0 [M+H] + .
[0173] NaBH4 (44.8 mg, 1.18 mmol) was added to a solution of compound 1-11 (160 mg, 0.59 mmol) in MeOH (5 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with ice water (20 mL) and stirred for 20 minutes. The resulting mixture was extracted with DCM (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 1-12 (65 mg, 40.3% yield). LCMS: 272.0 [M+H] + .
[0174] EDCI (169 mg, 0.88 mmol), HOBt (67.5 mg, 0.44 mmol), and DIPEA (0.26 mL, 1.47 mmol) were added to a solution of 2-hydroxyacetic acid (33.5 mg, 0.44 mmol) in DMF (5 mL), and the mixture was stirred for 30 minutes. Then, compounds 1-12 (80 mg, 0.29 mmol, in DMF) were added. The mixture was stirred at 25°C for 1 hour. The reaction mixture was quenched with ice water (20 mL) and stirred for 20 minutes. The resulting mixture was extracted with DCM (30 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 1 (60 mg, 63% yield). LCMS: 330.0 [M+H] + .
[0175] Compound 1 (60 mg) was sent for chiral separation to obtain two enantiomers.
[0176] Compound 1A (peak 1, 14.9 mg, t) R = 3.101 min), LCMS: 330.0 [M+H] + , 1 H NMR (400 MHz, DMSO-) d 6) δ 7.82 (t, J = 8.2 Hz, 1H), 7.64 (dd, J = 17.8, 8.2 Hz, 1H), 5.55 (dt, J= 189.0, 6.6 Hz, 1H), 4.81 - 4.63 (m, 1H), 4.28 - 4.15 (m,2H), 4.04 - 3.43 (m, 1H), 3.19 - 2.84 (m, 2H), 1.47 (dd, J = 32.4, 6.6 Hz, 3H).
[0177] Compound 1B (peak 2, 19.5 mg, t) R = 4.809 min), LCMS: 330.0 [M+H] + , 1 H NMR (400 MHz, DMSO-) d 6) δ 7.83 (t, J = 7.8 Hz, 1H), 7.65 (dd, J = 18.0, 7.8 Hz, 1H), 5.56 (dt, J = 188.4, 6.2 Hz, 1H), 4.86 - 4.65 (m, 1H), 4.36 - 4.13 (m,2H), 4.07 - 3.43 (m, 1H), 3.19 - 2.82 (m, 2H), 1.48 (dd, J = 32.2, 6.6 Hz, 3H).
[0178] Chiral analysis method: Column: Regis WhelkO1 (R, R), 4.6 mm ID × 150 mm, 5 µm; Mobile phase: 45% methanol (0.1% NH3H2O) in supercritical CO2; Temperature: 35°C; Flow rate: 1.0 mL / min; Detection wavelength: 254 nm. Chiral preparation method: Column: Regis WhelkO1 (R, R), 40 mm ID × 250 mm, 10 µm; Mobile phase: 45% methanol (0.1% NH3H2O) in supercritical CO2; Temperature: 35°C; Flow rate: 120.0 mL / min; Detection wavelength: 254 nm.
[0179] Example 1.3
[0180] To a solution of compounds 1-12 (45.0 mg, 0.165 mmol) in DMF (0.5 mL), 5-methoxypyrimidine-2-carboxylic acid (30.0 mg, 0.195 mmol), DIPEA (0.102 mL, 0.584 mmol), and HATU (89.0 mg, 0.234 mmol) were added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched by adding ice water (10 mL) and extracted with EA (30 mL × 3). The combined organic phases were washed with water (10 mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 3 (4.7 mg, 5.9% yield).
[0181] LCMS: 408.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.64 (d, J = 12.4 Hz, 2H), 7.78 (dd, J = 96.1, 8.6 Hz, 1H), 7.57 (dd, J = 29.6, 8.6 Hz, 1H), 5.87(q, J = 6.4 Hz, 1H), 4.86 - 4.76 (m, 1H), 3.97 (d, J = 3.6 Hz, 3H), 3.62 -3.55 (m, 1H), 3.07 - 2.86 (m, 2H), 1.55 (dd, J = 17.0, 6.8 Hz, 3H).
[0182] Example 1.4:
[0183] EDCI (141 mg, 0.74 mmol) was added to a solution of N-Boc-glycine (97 mg, 0.55 mmol) in DMF (5 mL), and the mixture was stirred for 30 minutes. Then, compound 1-12 (100 mg, 0.367 mmol) was added. The reaction mixture was stirred at room temperature under nitrogen for 5 hours. The reaction mixture was quenched by adding ice water (10 mL) and extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 4-1 (130 mg, 66.8% yield). LCMS: 451.0 [M+Na] + .
[0184] To a solution of compound 4-1 (130 mg, 0.30 mmol) in dioxane (3 mL), HCl / dioxane (3 mL, 4.0 M) was added, and the mixture was stirred for 30 minutes. The reaction mixture was concentrated under reduced pressure to obtain a crude residue. The residue was purified by preparative HPLC to give compound 4 (29.8 mg, 27.8% yield).
[0185] LCMS: 329.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.86 - 7.82 (m, 1H), 7.68 - 7.62 (m, 1H), 5.77 - 5.28 (m, 1H), 4.81 - 3.98 (m, 1H), 3.48 - 3.44(m, 2H), 3.20 - 2.66 (m, 4H), 1.51 - 1.42 (m, 3H).
[0186] Example 1.5
[0187] To a solution of compound 5-1 (5.0 g, 30.7 mmol) in DMF (50 mL), bromoacetaldehyde dimethyl acetal (5.0 mL, 46.0 mmol) and Cs₂CO₃ (20.0 g, 61.4 mmol) were added at room temperature. The mixture was stirred at 80°C for 16 hours. The reaction mixture was quenched with ice water (200 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (50 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 5-2 (7.3 g, 95% yield). 1 HNMR (400 MHz, CD3Cl) δ 7.17 - 7.03 (m, 2H), 6.84 (dd, J = 8.0, 1.6 Hz, 1H), 4.74 (t, J = 5.2 Hz, 1H), 4.05 (d, J = 5.2 Hz, 2H), 3.50 (s, 6H).
[0188] Polyphosphoric acid (7.28 mL, 29.1 mmol) was added to a solution of compound 5-2 (7.3 g, 29.1 mmol) in DCE (80 mL) at room temperature. The mixture was stirred at 90°C for 3 hours. The reaction mixture was quenched with ice water (200 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (50 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 5-3 (3.7 g, 68.1% yield). 1 H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 2.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H).
[0189] Add to a solution of compound 5-3 (3.2 g, 17.1 mmol) in THF (50 mL) at -78°C under nitrogen atmosphere. tert-butyllithium(27.6 mL, 35.9 mmol). The reaction mixture was stirred at -78°C for 1 hour, and then added at -78°C. 1, 2,3-oxathiazolidin-3-carboxylic acid tert-butyl ester 2,2-Dioxide (7.64 g, 34.2 mmol). The mixture was stirred at -78°C for 2 hours and then slowly cooled to room temperature overnight. The reaction mixture was quenched with saturated NH4Cl aqueous solution (200 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (80 mL × 3). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 5-4 (4.7 g, 83% yield). LCMS: 352.3 [M+Na] + .
[0190] Compound 5-4 (4.2 g, 12.72 mmol) was dissolved in dioxane (10 mL) and 4 M HCl / dioxane (10 mL), and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to give compound 5-5 (crude product) as a red solid. LCMS: 230.4 [M+H] + .
[0191] The synthesis method was similar to that in Example 1.4, using the same starting materials, to obtain compound 5 (13.2 mg, 34.8% yield). LCMS: 313.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.09 (s, 3H), 7.67 (dd, J = 40.0, 8.4 Hz, 1H), 7.54 (dd, J = 15.2, 8.4 Hz, 1H), 5.52 (dt, J = 182.4,6.4 Hz, 1H), 4.84 - 3.45 (m, 4H), 3.11 - 2.82 (m, 2H), 1.49 (dd, J = 35.8, 6.6 Hz, 3H).
[0192] Example 1.6
[0193] The synthesis method was similar to that in Example 1.5, using the same starting materials, to obtain compound 6 (2 mg, 3.2% yield). LCMS: 357.2 [M+H] + , 1 H NMR (400 MHz, CD3OD) δ 8.52 (s, 1H), 7.56 (dd, J = 8.0, 3.1 Hz, 1H), 7.42 (dd, J = 8.0, 2.0 Hz, 1H), 5.83 - 5.07 (m, 1H), 4.17 - 3.54(m, 4H), 3.11 - 2.77 (m, 2H), 1.57 (dd, J = 37.6, 6.6 Hz, 3H).
[0194] Example 1.7
[0195] The synthesis method is similar to that of compounds 1-5, using the corresponding starting materials to obtain compounds 7-5 (1.0 g, 77% yield). 1 H NMR (400 MHz, CDCl3) δ 7.61 - 7.54 (m, 2H), 7.48 (d, J = 5.4 Hz, 1H), 7.34(d, J = 5.4 Hz, 1H).
[0196] The synthetic method was similar to that for compound 5, using the same starting materials to give compound 7 (2.1 mg, 5.3% yield). LCMS: 373.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.34 (s, 1H), 7.82 - 7.76 (m, 1H), 7.75 (d, J = 0.8 Hz, 1H), 5.60 (dt, J = 182.2, 6.3 Hz, 1H), 4.82 - 3.95(m, 2H), 3.52 (d, J = 11.2 Hz, 2H), 3.23 - 2.78 (m, 3H), 1.49 (dd, J = 32.0, 6.4 Hz, 3H).
[0197] Example 1.8
[0198] The synthetic method was similar to that for compounds 5-9, using the same starting materials to obtain compound 8 (160 mg). LCMS: 358.0 [M+H] + .
[0199] Compound 8 (160 mg) was separated by chiral SFC to give compound 8A (peak 3, 53.4 mg, t). R = 1.968 min), compound 8B (peak 4, 48.0 mg, t R = 2.332 min), compound 8C (peak 1, 1.9 mg, t R = 1.315min) and compound 8D (peak 2, t R = 1.623 min). Chiral analysis method: Column: Daicel ChiralPakIJ, 4.6 mm ID × 150 mm, 5 μm, mobile phase 30% methanol (0.1% NH3H2O) in supercritical CO2, temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 254 nm. Chiral preparation method: Column: Daicel ChiralPakIJ, 40 mm ID × 250 mm, 10 μm, mobile phase 20% methanol in supercritical CO2, temperature: 35°C, flow rate: 120.0 mL / min, detection wavelength: 254 nm.
[0200] Compound 8A, LCMS: 358.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.84 (d, J =8.6 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 5.64 - 4.49 (m, 2H), 4.40 - 4.21 (m,2H), 3.34 (s, 3H), 3.19 (dd, J = 17.2, 4.0 Hz, 1H), 2.97 - 2.86 (m, 1H), 1.60(dd, J = 28.8, 6.6 Hz, 3H), 1.29 (dd, J = 24.4, 6.6 Hz, 3H).
[0201] Compound 8B, LCMS: 358.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.84 (d, J =8.6 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 5.64 - 4.49 (m, 2H), 4.40 - 4.21 (m,2H), 3.34 (s, 3H), 3.19 (dd, J = 17.2, 4.0 Hz, 1H), 2.97 - 2.86 (m, 1H), 1.60(dd, J = 28.8, 6.6 Hz, 3H), 1.29 (dd, J = 24.4, 6.6 Hz, 3H).
[0202] Compound 8C, LCMS: 358.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.84 (d, J =8.6 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 5.64 - 4.51 (m, 2H), 4.43 - 4.15 (m,2H), 3.34 (s, 3H), 3.19 (dd, J = 17.9, 5.0 Hz, 1H), 2.96 - 2.85 (m, 1H), 1.60(dd, J = 29.0, 6.8 Hz, 3H), 1.29 (dd, J = 24.4, 6.8 Hz, 3H).
[0203] Example 1.9
[0204] The synthesis method was similar to that in Example 1.1, using the same starting materials to obtain compound 9 (27.0 mg). LCMS: 344.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.81 (m, 1H), 7.64 (m, 1H), 5.80 -5.16 (m, 1H), 4.68 - 4.04 (m, 1H), 4.32 - 4.13 (m, 2H), 3.58 - 3.45 (m,1H),3.33 - 3.30 (m,3H), 3.19 - 2.84 (m,2H), 1.47 (m,3H).
[0205] Compound 9 (27.0 mg) was separated by chiral SFC to give compound 9A (peak 1, 12.2 mg, t). R =2.328 min) and compound 9B (peak 2, 9.9 mg, t R = 4.072 min). Chiral analysis method: Column: RegisWhelkO1 (R,R), 4.6 mm ID × 150 mm, 5 μm, mobile phase: 45% methanol (0.1% NH3H2O) in supercritical CO2, temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 254 nm. Chiral preparation method: Column: Regis WhelkO1 (R,R), 40 mm ID × 250 mm, 10 μm, mobile phase: 45% methanol (0.1% NH3H2O) in supercritical CO2, temperature: 35°C, flow rate: 120.0 mL / min, detection wavelength: 254 nm.
[0206] Compound 9A, LCMS: 344.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.81 (m, 1H),7.64 (m, 1H), 5.80 - 5.16 (m, 1H), 4.68 - 4.04 (m, 1H), 4.32 - 4.13 (m, 2H),3.58 - 3.45 (m,1H),3.33 - 3.30 (m,3H), 3.19 - 2.84 (m,2H), 1.47 (m,3H).
[0207] Compound 9B, LCMS: 344.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.81 (m, 1H), 7.64 (m, 1H), 5.48 (m, 1H), 4.68 - 4.04 (m, 1H), 4.30 - 4.15 (m, 2H), 3.52 (m, 1H), 3.31 (s, 3H), 3.15 - 2.76 (m, 2H), 1.48 (m, 3H).
[0208] Example 1.10
[0209] Add ( ) to a solution of compound 1-12 (80.0 mg, 0.294 mmol) in DMF (2 mL) S 2,2-Dimethyl-1,3-dioxolane-4-carboxylic acid (43.0 mg, 0.294 mmol), DIPEA (0.15 mL, 0.88 mmol), and HATU (145.0 mg, 0.382 mmol) were added. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched by adding ice water (20 mL) and extracted with EA (30 mL × 3). The combined organic phases were washed with water (20 mL) and brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 10-2 (100 mg, 85.0% yield).
[0210] A mixture of compound 10-2 (80 mg, 0.20 mmol) and acetic acid (2.5 mL) was stirred at 80°C for 1 hour to obtain a colorless solution. This mixture was poured into a saturated aqueous solution of NaHCO3 (20 mL) and extracted with EA (30 mL × 3). The combined organic phases were washed with water (20 mL) and brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give compound 10 (51.5 mg, 71.5% yield).
[0211] LCMS: 360.3 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.84 - 7.78 (m, 1H),7.71 - 7.58 (m, 1H), 5.81 - 5.48 (m, 1H), 5.31 - 4.99 (m, 1H), 4.80 - 4.67(m, 1H), 4.66 - 4.28 (m, 2H), 3.66 - 3.40 (m, 3H), 3.09 - 2.79 (m, 2H), 1.58- 1.38 (m, 3H).
[0212] Example 1.11
[0213] HATU (1.30 g, 3.41 mmol) and DIEA (1.49 mL, 8.53 mmol) were added to a solution of compounds 1-9 (700 mg, 2.84 mmol) and 2,2-difluoroacetic acid (410 mg, 4.27 mmol) in DMF (10 mL) at 25°C. The mixture was stirred at 25°C for 16 hours. The reaction mixture was quenched with ice water (20 mL) and extracted with DCM (30 mL × 3). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 11-2 (370 mg, 32.1% yield). LCMS: 324.0 [M+H] + .
[0214] Phosphoryl chloride (1.04 mL, 11.1 mmol) was added to a solution of compound 11-2 (360 mg, 1.11 mmol) in acetonitrile (10 mL). The reaction mixture was stirred at 100°C for 16 hours. The reaction mixture was cooled to room temperature, quenched with water (20 mL), and stirred for 20 minutes. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 11-3 (100 mg, 29.4% yield). LCMS: 306.2 [M+H] + .
[0215] To a solution of compound 11-3 (90 mg, 0.29 mmol) in MeOH (5 mL), NaBH3CN (74 mg, 1.18 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with ice water (20 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 11-4 (60 mg, 66.2% yield). LCMS: 308.2 [M+H] + .
[0216] 2-Chloro-2-oxoethyl acetate (34 mg, 0.243 mmol) was added to a solution of compound 11-4 (50 mg, 0.162 mmol) and TEA (0.1 mL) in DCM (1 mL) at 0°C. The mixture was stirred at 0°C for 2 hours. The reaction mixture was quenched with ice water (10 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 11-5 (50 mg, 91.0% yield). LCMS: 430.0 [M+H] + .
[0217] K₂CO₃ (30 mg, 0.202 mmol) was added to a solution of compound 11-5 (55 mg, 0.135 mmol) in MeOH (1 mL) at 25°C, and the mixture was stirred at 25°C for 30 min. The reaction mixture was quenched with water (10 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by preparative HPLC to give compound 11 (18.1 mg, 36.7% yield).
[0218] LCMS: 366.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.99 - 7.89 (m, 1H), 7.73 - 7.62 (m, 1H), 6.71 - 6.27 (m, 1H), 6.15 - 5.59 (m, 1H), 5.03 - 4.73(m, 1H), 4.30 (d, J = 6.0 Hz, 2H), 4.25 - 4.06 (m, 1H), 3.70 - 3.58 (m, 1H), 3.21 - 2.96 (m, 2H).
[0219] Compound 11 (200 mg) was separated by chiral SFC to obtain compound 11A (peak 1, 80 mg, t). R = 3.700 min) and compound 11B (peak 2, 80 mg, t R = 5.501 min). Chiral analysis method: Column: Daicel ChiralPak IH, 4.6 mm ID × 150 mm, 5 μm, mobile phase: 50% ethanol (0.1% TFA) in n-hexane, temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 235 nm. Chiral preparation method: Column: Daicel ChiralPak IH, 40 mm ID × 250 mm, 10 μm, mobile phase: 30% methanol (0.1% TFA) in n-hexane, room temperature, flow rate: 80.0 mL / min, detection wavelength: 235 nm.
[0220] Compound 11A, LCMS: 366.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.99 - 7.89(m, 1H), 7.73 - 7.61 (m, 1H), 6.71 - 6.28 (m, 1H), 6.18 - 5.51 (m, 1H), 5.13- 4.73 (m, 1H), 4.37 - 4.26 (m, 2H), 4.24 - 4.05 (m, 1H), 3.72 - 3.54 (m,1H), 3.26 - 3.03 (m, 2H).
[0221] Compound 11B, LCMS: 366.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.98 - 7.91(m, 1H), 7.74 - 7.62 (m, 1H), 6.76 - 6.22 (m, 1H), 6.17 - 5.53 (m, 1H), 5.08- 4.72 (m, 1H), 4.37 - 4.27 (m, 2H), 4.24 - 4.06 (m, 1H), 3.70 - 3.57 (m,1H), 3.27 - 3.00 (m, 2H).
[0222] Example 1.12
[0223] The synthesis method was similar to that in Example 1.1, using the corresponding starting materials to obtain compound 12-5 (1.30 g). 1 H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 5.2 Hz, 1H), 7.40 -7.30 (m, 2H).
[0224] The synthesis method was similar to that in Example 1.5, using the same starting materials to obtain compound 12 (26.2 mg). LCMS: 313.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.76 - 7.65 (m, 1H), 7.64 - 7.51 (m,1H), 5.76, 5.29 (q, J = 6.4 Hz, 1H), 4.74, 4.04 (dd, J = 13.0, 5.4 Hz, 1H), 3.56 - 3.48 (m, 1H), 3.47 - 3.40 (m, 2H), 3.15 - 2.77 (m, 4H), 1.56 - 1.35 (m, 3H).
[0225] Example 1.13
[0226] The synthesis method was similar to that in Example 1.1, using the same starting materials to obtain compound 13 (70.3 mg). LCMS: 314.3 [M+H] + , 1 H NMR (400 MHz, DMSO-d 6) δ 7.75 - 7.65 (m, 1H), 7.64 - 7.53 (m,1H), 5.73, 5.24 (q, J = 6.6 Hz, 1H), 4.85 - 4.67, 4.10 - 3.93 (m, 1H), 4.31 -4.14 (m, 2H), 3.56 - 3.45, 3.23 - 2.81 (m, 3H), 1.56 - 1.41 (m, 3H).
[0227] Example 1.14
[0228] The synthesis method was similar to that of Example 1.9, using the same starting materials to obtain compound 14 (15.5 mg). LCMS: 314.3 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.73 - 7.65 (m, 1H), 7.63 - 7.53 (m,1H), 5.79 - 5.18 (m, 1H), 4.30 - 4.16 (m, 2H), 4.76 - 4.61, 4.11 - 3.98 (m,1H), 3.31 - 3.29 (m, 3H), 3.59 - 3.43, 3.20 - 2.75 (m, 3H), 1.56 - 1.40 (m, 3H).
[0229] Example 1.15
[0230] Add to a solution of compound 1-5 (3.6 g, 17.73 mmol) in THF (60 mL) at -78°C under nitrogen atmosphere. n-ButylLithium (27.6 mL, 35.9 mmol). The reaction mixture was stirred at -78°C for 1 hour, and then DMF (2.75 mL, 35.5 mmol) was added at -78°C. The mixture was stirred at -78°C for another 2 hours. The reaction mixture was quenched with saturated NH4Cl aqueous solution (200 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (100 mL × 3). The combined organic phases were washed with water (100 mL) and brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 15-2 (3.2 g, 78% yield). 1 H NMR (400 MHz, DMSO-) d 6) δ 10.08 (s, 1H), 8.44 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H).
[0231] To a solution of compound 15-2 (3.5 g, 15.15 mmol) in THF / MeOH (volume / volume = 1 / 1, 70 mL), NaBH4 (0.573 g, 15.15 mmol) was added, and the mixture was stirred at 25°C for 1 hour. The mixture was quenched with ice water (10 mL). The resulting mixture was extracted with EA (100 mL × 3). The combined organic phases were washed with water (100 mL) and brine (100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 15-3 (2.5 g, 70.8% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 7.79 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.38 (t, J = 1.2 Hz, 1H), 5.83 (t, J = 5.6 Hz, 1H), 4.77 (dd, J = 5.6, 1.2 Hz, 2H).
[0232] Phosphorus tribromide (2.023 mL, 21.45 mmol) was added to a solution of compound 15-3 (2.5 g, 10.72 mmol) in DCM (50 mL) at 0°C, and the mixture was stirred at 0°C for 30 minutes. The mixture was quenched with ice water. The mixture was then quenched with ice water (10 mL). The resulting mixture was extracted with DCM (100 mL × 3). The combined organic phases were washed with water (100 mL) and brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 15-4 (2.3 g, 72.5% yield). 1 H NMR (400 MHz, DMSO- d 6) δ7.86 (d, J = 8.4 Hz, 1H), 7.67 (s, 1H), 7.65 (d, J = 8.4 Hz, 1H), 5.13 (s, 2H).
[0233] Potassium cyanide (0.76 g, 11.66 mmol), potassium hydroxide (0.11 g, 1.94 mmol), and tetrabutylammonium hydrogen sulfate (0.66 g, 1.94 mmol) were added to a solution of compound 15-4 (2.3 g, 7.77 mmol) in CHCl3 / H2O (v / v = 1:1, 50 mL). The reaction mixture was stirred at 60°C for 30 min. The mixture was quenched with ice water (20 mL). The resulting mixture was extracted with DCM (60 mL × 3). The combined organic phases were washed with water (60 mL) and brine (60 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 15-5 (1.1 g, 58.5% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 7.82 (d, J = 8.4Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.41 (s, 1H), 4.13 (d, J = 14.8 Hz, 1H), 3.98 (d, J = 14.8 Hz, 1H).
[0234] Sodium hydride (248 mg, 6.20 mmol, 60% wt) was added to a solution of compound 15-5 (600 mg, 2.48 mmol) in THF (12 mL) at 0°C. The reaction mixture was stirred at 0°C for 30 min. Then, 1,2-dibromoethane (0.534 mL, 6.20 mmol) was added, and the reaction mixture was stirred at 25°C under nitrogen for 1 h. The mixture was quenched with ice water (20 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 15-6 (220 mg, 33.1% yield). 1 H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.33 (s, 1H), 1.87 (q, J = 5.4 Hz, 2H), 1.57 (dd, J = 4.4, 3.6 Hz, 2H).
[0235] A solution of the borane-tetrahydrofuran complex in THF (1.60 mL, 1.0 M) was added dropwise to a solution of compound 15-6 (215 mg, 0.802 mmol) in THF (4 mL) for 30 minutes at 0°C. The reaction was then heated to 50°C and stirred under nitrogen for 1 hour. The mixture was quenched with methanol (2 mL). The solvent was removed under vacuum to give compound 15-7 (210 mg, 96% yield) as a colorless oil, which could be used in the next step without further purification. LCMS: 272.0 [M+H] + .
[0236] The synthesis method was similar to that in Example 1.4, using the same starting materials to obtain compound 15 (3.2 mg). LCMS: 355.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 8.07 (s, 2H), 7.86 - 7.80 (m, 1H), 7.72 - 7.64 (m, 1H), 5.87 - 5.33 (m, 1H), 4.26 - 4.09 (m, 1H), 4.00 - 3.87 (m, 2H), 3.74 - 3.04 (m, 1H), 1.55 (dd, J = 32.4, 6.4 Hz, 3H), 1.47 - 1.33 (m,1H), 1.29 - 1.06 (m, 2H), 0.95 - 0.85 (m, 1H).
[0237] Example 1.16
[0238] The synthesis method was similar to that of Example 1.8, using the same starting materials to obtain compound 16 (37.5 mg). LCMS: 297.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.94 - 8.89 (m, 1H), 8.21 (s, 1H), 5.85 - 5.29 (m, 1H), 4.75 - 4.19 (m, 2H), 4.19 - 3.97 (m, 1H), 3.27 - 2.76 (m, 4H), 1.56 - 1.46(m, 3H).
[0239] Example 1.17
[0240] Ethyl glyoxylate (1.29 g, 6.34 mmol, 50% wt in toluene) and TFA (2.00 mL, 26.0 mmol) were added to a solution of compounds 1-9 (1.20 g, 4.88 mmol) in toluene (60 mL) at 25°C. The reaction mixture was stirred at 110°C for 18 hours to give a red solution. The resulting solution was concentrated to give a residue, which was diluted with EA (50 mL). The organic phase was washed with saturated aqueous solution of NaHCO3 (30 mL) and brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 17-2 (940 mg, 58.4% yield). 1 H NMR (400 MHz, DMSO- d6) δ 7.68 (d, J = 8.6 Hz, 1H), 7.61 (d, J =8.6 Hz, 1H), 4.84 (s, 1H), 4.14 - 4.04 (m, 2H), 3.22 - 3.06 (m, 3H), 2.89 -2.76 (m, 2H), 1.15 (t, J = 7.0 Hz, 3H).
[0241] 2-Chloro-2-oxoethyl acetate (50 mg, 0.363 mmol) was added to a solution of compound 17-2 (100 mg, 0.30 mmol) and TEA (0.1 mL) in THF (2 mL) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was quenched with ice water (10 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 17-3 (100 mg, 77% yield). LCMS: 430.2 [M+H] + .
[0242] LiCl (47.3 mg, 1.12 mmol) and NaBH4 (42.2 mg, 1.12 mmol) were added to a solution of compound 17-3 (80.0 mg, 0.186 mmol) in THF (3.0 mL) at 25°C, followed by the addition of EtOH (6.0 mL). The solution was stirred at 25°C for 18 hours to obtain a white mixture. This solution was poured into water (20 mL), and the aqueous phase was extracted with EA (30 mL × 2). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by preparative HPLC to give compound 17 (38.8 mg, 60.3% yield). LCMS: 346.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.92 - 7.80 (m,1H), 7.72 - 7.58 (m, 1H), 5.79 - 5.21 (m, 1H), 5.17 - 4.92 (m, 1H), 4.74 (dd, J= 13.3, 5.6 Hz, 1H), 4.70 - 4.48 (m, 1H), 4.38 - 4.20 (m, 2H), 4.01 - 3.65(m, 3H), 3.27 - 3.02 (m, 1H), 2.98 - 2.88 (m, 1H).
[0243] Example 1.18
[0244] Bromine (25.7 mL, 499 mmol) was added dropwise to a solution of 2,3-dichloronitrobenzene (63.9 g, 333 mmol) and silver sulfate (51.9 g, 166 mmol) in sulfuric acid (800 mL) at 0°C. The reaction mixture was stirred at 50°C for 18 hours to obtain a black solution. The resulting mixture was poured into ice water (2 L). The resulting mixture was extracted with DCM (1 L × 2). The combined organic phases were washed with saturated aqueous sodium bicarbonate solution and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compound 18-2 (49.2 g, 54.6% yield). 1 HNMR (400 MHz, DMSO- d 6) δ 8.39 (d, J = 2.2 Hz, 1H), 8.35 (d, J = 2.2 Hz, 1H).
[0245] A solution of vinyl magnesium bromide (364 mL, 1 M, in THF) was added to a solution of compound 18-2 (49.3 g, 182 mmol) in THF (500 mL) at -40°C. The reaction mixture was then stirred at -40°C for 2 hours to obtain a red solution. The reaction mixture was poured into a saturated aqueous solution of NH4Cl (2 L). The resulting mixture was extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compound 18-3 (11.8 g, 24.5% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 12.06 (brs, 1H), 7.58 (t, J = 2.8 Hz, 1H), 7.48 (s, 1H), 6.50 (dd, J=2.8, 2.0 Hz, 1H).
[0246] NaH (15.8 g, 396 mmol, 60% mineral oil dispersion) was added in portions to a solution of compound 18-3 (50.0 g, 189 mmol) in THF / DMF (volume / volume = 5 / 1, 1200 mL) at 0°C. The reaction mixture was stirred at 0°C for 30 minutes. Then, in portions, NaH was added to the mixture at 0°C. p-Toluenesulfonyl chloride (54.0 g, 283 mmol). The reaction mixture was heated to 20°C and stirred for 4 hours. The reaction mixture was quenched with saturated NH4Cl aqueous solution (1000 mL) and stirred for 20 minutes. The resulting mixture was extracted with EA (1000 mL × 3). The combined organic phases were washed with brine (1000 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was ground with MeOH (200 mL) to give compound 18-4 (70 g, 88% yield). LCMS: 442.0 [M+Na] + .
[0247] The synthesis method was similar to that in Example 1.8, using the same starting materials to obtain compound 18-10 (650 mg). LCMS: 574.2 [M+Na] + .
[0248] Triphenylphosphine (619 mg, 2.36 mmol) was added to a solution of compound 18-10 (650 mg, 1.18 mmol) in THF / MeOH (volume / volume = 1 / 1, 10 mL) at 20°C. Water (1 mL) was then added dropwise to the reaction mixture. The mixture was stirred at 60°C under nitrogen for 16 hours. The mixture was concentrated to give a crude residue. The residue was purified by silica gel chromatography to give compound 18-11 (450 mg, 72.7% yield). LCMS: 526.2 [M+H] + .
[0249] TEA (0.60 mL, 4.28 mmol) and di-tert-butyl dicarbonate (374 mg, 1.71 mmol) were added to a solution of compound 18-11 (450 mg, 0.86 mmol) in MeOH (5 mL) at 20°C. The reaction mixture was then stirred at 20°C under nitrogen for 16 hours. The mixture was concentrated to give a crude residue. The residue was purified by silica gel chromatography to give compound 18-12 (500 mg, 93% yield). LCMS: 648.2 [M+Na]+ .
[0250] Cs₂CO₃ (219 mg, 0.67 mmol), XPhos (45.7 mg, 0.10 mmol), and Pd₂(dba)₃ (43.9 mg, 0.05 mmol) were added to a solution of compound 18-12 (300 mg, 0.48 mmol) in toluene (10 mL) at 20°C. The reaction mixture was then stirred at 100°C under nitrogen for 16 hours. The reaction mixture was quenched with ice water (20 mL). The resulting mixture was extracted with EA (30 mL × 3). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 18-13 (50 mg, 19.1% yield). LCMS: 544.2 [M+H] + .
[0251] Boron tribromide (0.37 mL, 1 M, in DCM) was added dropwise to a solution of compound 18-13 (40 mg, 0.073 mmol) in DCM (5 mL) at -70°C. The reaction mixture was stirred at -70°C under nitrogen for 1 hour. The mixture was then slowly cooled to room temperature and stirred under nitrogen for 14 hours. Methanol (1 mL) was then added dropwise to the mixture at -70°C and stirred for 10 minutes. The mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 18 (10.7 mg, 41.1% yield). LCMS: 354.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ11.25 - 11.13 (m, 1H), 6.58 - 6.49 (m, 1H), 5.65 - 5.00 (m, 2H), 4.72 - 4.55(m, 1H), 4.28 - 3.81 (m, 3H), 3.27 - 2.95 (m, 3H), 2.93-2.66 (m, 2H), 2.02- 1.56 (m, 4H).
[0252] Example 1.19
[0253] K₂CO₃ (8.79 g, 63.6 mmol) was added to a solution of 4-chloro-2-fluoro-5-methoxybenzaldehyde (3.98 g, 21.2 mmol) and methyl 2-mercaptoacetate (2.48 g, 23.3 mmol) in DMF (60 mL) at room temperature. The reaction mixture was stirred at 60°C for 16 hours. The mixture was then poured into ice water (200 mL) and stirred for 5 minutes. The mixture was filtered, and the filter cake was dried to give compound 19-2 (4.0 g, 73.5% yield). 1 H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.84 (s, 1H), 7.30 (s, 1H), 3.97 (s, 3H), 3.94 (s, 3H).
[0254] Lithium hydroxide (746 mg, 31.2 mmol) was added to a mixture of compound 19-2 (4.0 g, 15.6 mmol) in MeOH / H₂O (volume / volume = 10 / 1, 44 mL) at room temperature. The reaction mixture was stirred at 60°C for 16 hours. The reaction mixture was poured into ice water (200 mL) and acidified to pH 4 using an aqueous HCl solution (2N). The reaction mixture was filtered, and the filter cake was dried to give compound 19-3 (3.6 g, 95% yield). 1 H NMR (400 MHz, DMSO- d 6) δ8.20 (s, 1H), 8.02 (s, 1H), 7.69 (s, 1H), 3.91 (s, 3H).
[0255] Copper (1.13 g, 17.7 mmol) was added to a mixture of compound 19-3 (4.3 g, 17.7 mmol) in diphenyl ether (50 mL) at room temperature. The reaction mixture was stirred at 210 °C for half an hour. Dimethylacetamide (10 mL) was added to the reaction mixture at 210 °C, and the mixture was stirred at 210 °C for another 2 hours. The reaction mixture was purified by silica gel chromatography to give compound 19-4 (1.0 g, 28.4% yield). 1 H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 0.4Hz, 1H), 7.44 (d, J = 5.6 Hz, 1H), 7.30 (s, 1H), 7.24 (dd, J= 5.6, 0.8 Hz, 1H), 3.96 (s, 3H).
[0256] The synthetic method was similar to that for compounds 5-9, using the same starting materials to obtain compound 19 (25.5 mg). LCMS: 326.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.05 (s, 1H), 7.44 - 7.36 (m, 1H), 5.79 - 5.14 (m, 1H), 4.77 - 4.61 (m, 1H), 4.35 - 4.12 (m, 2H), 4.02 - 3.90 (m, 4H), 3.55 - 3.44 (m, 1H), 3.23 - 2.96 (m, 1H), 2.92 - 2.77 (m, 1H), 1.55- 1.42 (m, 3H).
[0257] Compound 19 (65 mg) was isolated by chiral SFC to give compound 19A (peak 1, 23.8 mg, t). R =2.710 min) and compound 19B (peak 2, 21.7 mg, t) R = 5.381 min). Chiral analysis method: Column: Daicel ChiralPak IH, 3.0 mm ID × 100 mm, 3 μm, mobile phase A: supercritical CO2, mobile phase B: MeOH (+0.1% DEA in MeOH), A / B: 80 / 20; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: Daicel ChiralPak IH, 30 mm ID × 250 mm, 10 μm, mobile phase A: supercritical CO2, mobile phase B: MeOH (+0.1% 7.0 mol / L ammonia in MeOH), A / B: 55 / 45, room temperature, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0258] Compound 19A, LCMS: 326.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 8.05 (s,1H), 7.44 - 7.37 (m, 1H), 5.80 - 5.15 (m, 1H), 4.78 - 4.62 (m, 1H), 4.35 -4.13 (m, 2H), 4.03 - 3.91 (m, 4H), 3.56 - 3.43 (m, 1H), 3.24 - 2.95 (m, 1H), 2.94 - 2.75 (m, 1H), 1.49 (dd, J = 29.6, 6.4 Hz, 3H).
[0259] Compound 19B, LCMS: 326.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.05 (s,1H), 7.44 - 7.36 (m, 1H), 5.81 - 5.13 (m, 1H), 4.81 - 4.62 (m, 1H), 4.32 -4.10 (m, 2H), 4.04 - 3.89 (m, 4H), 3.56 - 3.42 (m, 1H), 3.23 - 2.94 (m, 1H), 2.94 - 2.79 (m, 1H), 1.49 (dd, J = 29.6, 6.4 Hz, 3H).
[0260] Example 1.20
[0261] 2-Bromoacetic acid (523 mg, 3.8 mmol) in THF (3 mL) was added dropwise to a suspension of sodium hydride (410 mg, 10.3 mmol) in THF (10 mL) at 0°C under a nitrogen atmosphere. After addition, the reaction mixture was stirred at room temperature for 30 minutes, and then 2-((tetrahydro-2-dimethylaminopropionate) in DMF (3 mL) was added dropwise to the mixture. H -pyran-2-yl)oxy)ethane-1-ol (500 mg, 3.4 mmol). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into ice water (20 mL) and acidified to pH 4 with aqueous HCl solution (1 N). The mixture was extracted with EA. The combined organic phases were washed with saturated aqueous sodium bicarbonate solution and brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give compound 20-2 (500 mg, crude product), which required no further purification.
[0262] The synthesis method was similar to that in Example 1.4, using the same starting materials to obtain compound 20 (10.5 mg). LCMS: 370.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.05 (s, 1H), 7.40 - 7.36 (m, 1H), 5.78 - 5.27 (m, 1H), 4.75 - 4.63 (m, 1H), 4.37 - 4.19 (m, 2H), 4.14 - 4.03(m, 1H), 3.98 - 3.92 (m, 3H), 3.58 - 3.45 (m, 5H), 3.20 - 3.00 (m, 1H), 2.93- 2.83 (m, 1H), 1.57 - 1.41 (m, 3H).
[0263] Example 1.21
[0264] A solution of lithium diisopropylamino (61.5 mL, 2.0 M, in THF) was added dropwise to a solution of 5-bromo-1,2-dichloro-3-fluorobenzene (20.0 g, 82.6 mmol) in THF (300 mL) at -70°C. The reaction mixture was then stirred at -70°C for another 30 minutes. DMF (9.52 mL, 123 mmol) was then slowly added to the mixture at -70°C. The reaction mixture was stirred at -70°C under a nitrogen atmosphere for 2 hours. The reaction mixture was poured into a saturated ammonium chloride solution and extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 21-2 (18.0 g, 81% yield). 1 H NMR (400 MHz, CDCl3) δ 10.26 (d, J = 1.2 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H).
[0265] K₂CO₃ (27.4 g, 199 mmol) was added to a solution of compound 21-2 (18.0 g, 66.2 mmol) and methyl 2-mercaptoacetate (7.73 g, 72.8 mmol) in DMF (300 mL) at room temperature. The reaction mixture was stirred at 60°C for 16 hours. The mixture was then poured into ice water and stirred for 10 minutes. The mixture was filtered, and the filter cake was dried to give compound 21-3 (20 g, 89% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 8.11 (s, 1H), 8.01 (s, 1H), 3.93 (s, 3H).
[0266] Lithium hydroxide (0.85 g, 35.3 mmol) was added to a mixture of compound 21-3 (6.0 g, 17.65 mmol) in MeOH / H₂O (volume / volume = 10 / 1, 15 mL) at room temperature. The reaction mixture was stirred at 60°C for 16 hours. The reaction mixture was then poured into ice water (200 mL) and the pH was adjusted to 4 with 2 M HCl aqueous solution. The reaction mixture was filtered, and the filter cake was dried to give compound 21-4 (5.5 g, 96% yield). 1 H NMR (400 MHz, DMSO- d 6) δ14.05 (s, 1H), 8.03 (s, 1H), 7.91 (s, 1H).
[0267] Copper (1.99 g, 31.3 mmol) was added to a mixture of compound 21-4 (5.1 g, 15.6 mmol) in quinoline (50 mL) at room temperature. The reaction mixture was stirred at 200°C for 2 hours. The residue was purified by silica gel chromatography to give compound 21-5 (3.2 g, 72.5% yield). 1 H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.56 (d, J = 5.6 Hz, 1H), 7.45 (d, J = 5.6 Hz, 1H).
[0268] The synthetic method was similar to that for compounds 5-8, using the same starting materials to obtain compounds 21-6 (200 mg). LCMS: 352.0 [M+H] + .
[0269] Triethylamine (0.16 mL, 1.14 mmol) and di-tert-butyl dicarbonate (186 mg, 0.85 mmol) were added to a solution of compound 21-6 (200 mg, 0.57 mmol) in DCM (5 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into ice water and extracted with DCM. The combined organic phases were washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 21-7 (200 mg, 78% yield). 1 H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 6.24 - 6.01 (m, 1H), 4.51 - 4.21 (m, 1H), 3.45 - 3.22 (m, 1H), 3.09 - 2.93(m, 1H), 2.92 - 2.77 (m, 1H), 1.55 - 1.47 (m, 12H).
[0270] Sodium tert-butoxide (63.9 mg, 0.67 mmol) was added to a solution of compound 21-7 (100 mg, 0.22 mmol) in dioxane / H₂O (volume / volume = 5 / 1, 1.0 mL) at room temperature. t- BuBrettPhos-Pd-G3 (10.5 mg, 0.011 mmol). The mixture was then stirred at 105°C under nitrogen atmosphere for 16 hours. The resulting solution was concentrated and purified by silica gel chromatography to give compound 21-8 (40 mg, 23.2% yield). LCMS: 410.2 [M+Na] + .
[0271] K₂CO₃ (42.7 mg, 0.31 mmol) and iodomethane (29.2 mg, 0.21 mmol) were added to a solution of compound 21-8 (40 mg, 0.10 mmol) in DMF (2 mL) at room temperature. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction mixture was poured into ice water and extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 21-9 (20 mg, 48.3% yield). LCMS: 424.2 [M+Na] + .
[0272] HCl (2 mL, 4 M, in dioxane) was added to a solution of compound 21-9 (30 mg, 0.08 mmol) in dioxane (2 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated under reduced pressure to give compound 21-10 (30 mg, crude product). LCMS: 302.0 [M+H] + .
[0273] To a solution of compound 21-10 (30 mg, 0.10 mmol) and 2-hydroxyacetic acid (15.1 mg, 0.20 mmol) in DMF (2 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (38.1 mg, 0.20 mmol), hydroxybenzotriazole (26.8 mg, 0.20 mmol), and triethylamine (0.042 mL, 0.30 mmol) were added. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction mixture was diluted with ice water and extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 21 (6.5 mg, 18.2% yield). LCMS: 360.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.21 (s, 1H), 5.98 - 5.27 (m, 1H), 4.68 - 4.59 (m,1H), 4.27 - 4.13 (m, 2H), 4.02 - 3.97 (m, 3H), 3.96 - 3.88 (m, 1H), 3.55 -3.45 (m, 1H), 3.25 - 2.77 (m, 3H), 1.52 - 1.37 (m, 3H).
[0274] Example 1.22
[0275] Cuprous iodide (I) (169 mg, 0.89 mmol), bis(triphenylphosphine)palladium dichloride (II) (312 mg, 0.45 mmol), and triethylamine (1.86 mL, 13.34 mmol) were added to a solution of compound 18-5 (2.5 g, 4.45 mmol) and pentan-4-yn-1-ol (561 mg, 6.67 mmol) in acetonitrile (50 mL) at room temperature. The reaction mixture was then stirred at 70°C under a nitrogen atmosphere for 16 hours. The reaction mixture was filtered and concentrated to give a crude product. The crude product was purified by silica gel chromatography to give compound 22-2 (2.2 g, 88% yield). LCMS: 509.2 [M-C4H8+H] + .
[0276] Platinum oxide (IV) (200 mg, 0.88 mmol) was added to a solution of compound 22-2 (2.2 g, 3.89 mmol) in THF (20 mL) at room temperature, and the reaction mixture was then stirred at 50°C under a hydrogen atmosphere for 16 hours. The reaction mixture was filtered, and the filtrate was concentrated to give compound 22-3 (2.2 g, 99% yield). LCMS: 591.2 [M+Na] + .
[0277] Tetrabutylammonium fluoride (1.84 g, 7.02 mmol) was added to a solution of compound 22-3 (2.0 g, 3.51 mmol) in THF (30 mL) at room temperature. The reaction mixture was then stirred at 60°C under a nitrogen atmosphere for 16 hours. The reaction mixture was quenched with ice water and extracted with EA. The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 22-4 (850 mg, 58% yield). LCMS: 437.4 [M+Na] + .
[0278] To a solution of compound 22-4 (1.0 g, 2.41 mmol) in DCM (30 mL), Dys-Martin oxidant (1.53 g, 3.61 mmol) was added at room temperature, and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with a saturated aqueous sodium bicarbonate solution and extracted with DCM. The combined organic phases were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 22-5 (600 mg, 60% yield). LCMS: 435.2 [M+Na] +.
[0279] TFA (5 mL) was added to a solution of compound 22-5 (500 mg, 1.21 mmol) in DCM (5 mL) at room temperature, and the reaction mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction mixture was concentrated to give a crude residue. The residue was purified by silica gel chromatography to give compound 22-6 (250 mg, 70% yield). LCMS: 295.2 [M+H] + .
[0280] To a solution of compound 22-6 (100 mg, 0.34 mmol) and 2-hydroxyacetic acid (51.5 mg, 0.68 mmol) in DMF (5 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (130 mg, 0.68 mmol), hydroxybenzotriazole (92 mg, 0.68 mmol), and triethylamine (0.14 mL, 1.02 mmol) were added. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction mixture was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 22 (57.9 mg, 48.4% yield). LCMS: 353.2 [M+H] + . 1 HNMR (400 MHz, DMSO- d 6) δ 11.43 - 11.38 (m, 1H), 6.92 (s, 1H), 6.08 - 5.36 (m,1H), 4.72 - 4.55 (m, 1H), 4.44 - 4.13 (m, 2H), 3.94 - 3.79 (m, 1H), 3.30 -2.65 (m, 5H), 2.11 - 1.84 (m, 2H), 1.79 - 1.52 (m, 3H), 1.31 - 1.10 (m, 1H).
[0281] Example 1.23
[0282] The synthetic method was similar to that of compound 22-6, using the same starting materials to obtain compound 23-1 (500 mg). LCMS: 297.0, 299.0 [M+H] + .
[0283] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 23 (75.3 mg). LCMS: 355.0, 357.0 [M+H] + .
[0284] Compound 23 (70.0 mg) was separated by chiral SFC to give compound 23A (peak 1, 12.8 mg, t). R =3.336 min) and compound 23B (peak 2, 18.2 mg, t R = 4.678 min). Chiral analysis method: Column: Daicel ChiralPak AS-H, 4.6 mm ID × 150 mm, 5 μm, mobile phase A: n-hexane (0.1% DEA), mobile phase B: EtOH (0.1% DEA); A: B = 60: 40, temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: Daicel ChiralPak AS, 40 mm ID × 250 mm, 10 μm, mobile phase A: n-hexane, mobile phase B: EtOH (0.1% NH3H2O); A: B = 60: 40, temperature: 25°C, flow rate: 80.0 mL / min, detection wavelength: 214 nm.
[0285] Compound 23A, LCMS: 355.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 11.58 -11.54 (m, 1H), 6.83 (s, 1H), 5.67 - 5.13 (m, 1H), 4.71 - 4.65 (m, 1H), 4.51 -4.37 (m, 1H), 4.27 - 4.14 (m, 2H), 3.99 - 3.75 (m, 2H), 3.09 - 2.67 (m, 3H), 2.23 - 1.83 (m, 2H), 1.77 - 1.70 (m, 2H).
[0286] Compound 23B, LCMS: 355.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 11.58 -11.54 (m, 1H), 6.83 (s, 1H), 5.67 - 5.13 (m, 1H), 4.71 - 4.65 (m, 1H), 4.51 -4.39 (m, 1H), 4.28 - 4.14 (m, 2H), 3.98 - 3.75 (m, 2H), 3.12 - 2.64 (m, 3H), 2.23 - 1.80 (m, 2H), 1.77 - 1.68 (m, 2H).
[0287] Example 1.24
[0288] Boron tribromide (4.67 mL, 1 M, in DCM) was added dropwise to a solution of compound 19-9 (250 mg, 0.93 mmol) in DCM (5 mL) at -70°C under a nitrogen atmosphere. The reaction mixture was slowly warmed to room temperature and stirred under a nitrogen atmosphere for 16 hours. The reaction mixture was quenched by adding methanol (10 mL) dropwise at -70°C. The reaction mixture was concentrated under reduced pressure to give the crude product compound 24-2 (250 mg, crude). LCMS: 254.0 [M+H] + .
[0289] Di-tert-butyl dicarbonate (323 mg, 1.48 mmol) and triethylamine (0.41 mL, 2.96 mmol) were added to a mixture of compound 24-2 (250 mg, 0.98 mmol) in DCM (10 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 24-3 (150 mg, 43.0% yield). LCMS: 298.0 [M-C4H8+H] + .
[0290] Diethyl (bromodifluoromethyl)phosphonate (272 mg, 1.02 mmol) and potassium fluoride (89 mg, 1.53 mmol) were added to a solution of compound 24-3 (180 mg, 0.51 mmol) in acetonitrile (10 mL) at room temperature. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction mixture was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 24-4 (80 mg, 38.9% yield). LCMS: 426.2 [M+H] + .
[0291] The synthesis method was similar to that of compound 21, using the same starting materials to obtain compound 24 (40.5 mg). LCMS: 362.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.27 (s, 1H), 7.76 (s, 1H), 7.63 -7.12 (m, 1H), 5.78 - 5.16 (m, 1H), 4.80 - 4.63 (m, 1H), 4.30 - 4.14 (m, 2H), 4.03 - 3.93 (m, 1H), 3.57 - 3.43 (m, 1H), 3.23 - 2.96 (m, 1H), 2.96 - 2.79 (m, 1H), 1.52 -1.42 (m, 3H).
[0292] Example 1.25
[0293] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 25 (100 mg). LCMS: 362.2 [M+H] + .
[0294] Compound 25 (100 mg) was isolated by chiral SFC to give compound 25A (peak 1, 38.1 mg, t). R =1.752 min) and compound 25B (peak 2, 35.0 mg, t R= 2.928 min). Chiral analysis method: Column: Daicel ChiralPak AS, 3.0 mm ID × 100 mm, 3 μm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 85 / 15; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 254 nm. Chiral preparation method: Column: Daicel ChiralPak AS, 30 mm ID × 250 mm, 10 μm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 55 / 45, room temperature, flow rate: 60.0 mL / min, detection wavelength: 254 nm.
[0295] Compound 25A, LCMS: 362.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.09 (s,1H), 7.64 - 7.57 (m, 1H), 6.74 - 6.35 (m, 1H), 6.18 - 5.58 (m, 1H), 4.95 -4.88 (m, 1H), 4.36 - 4.20 (m, 2H), 4.84 - 4.78, 4.13 - 4.03 (m, 1H), 3.95 (s, 3H), 3.69 - 3.60, 3.28 - 3.23 (m, 1H), 3.15 - 2.87 (m, 2H).
[0296] Compound 25B, LCMS: 362.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.09 (s,1H), 7.67 - 7.56 (m, 1H), 6.74 - 6.34 (m, 1H), 6.21 - 5.51 (m, 1H), 4.96 -4.85 (m, 1H), 4.35 - 4.21 (m, 2H), 4.85 - 4.76, 4.12 - 4.04 (m, 1H), 3.95 (s, 3H), 3.70 - 3.59, 3.29 - 3.21 (m, 1H), 3.16 - 2.87 (m, 2H).
[0297] Example 1.26
[0298] Add dropwise to a solution of 2-chloro-4-fluoroanisole (23 g, 143 mmol) in THF (300 mL) at -70°C. just Butyl Lithium (68.8 mL, 2.5 M, in hexane) was added, and the reaction mixture was stirred at -70°C under a nitrogen atmosphere for half an hour. A solution of hexachloroethane (33.9 g, 143 mmol) in THF (200 mL) was added dropwise to the mixture over 30 minutes at -70°C. The reaction mixture was then stirred at -70°C under a nitrogen atmosphere for another hour. The reaction mixture was poured into a saturated ammonium chloride solution and extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 26-2 (25.0 g, 89% yield). 1 H NMR (400 MHz, CDCl3) δ 7.05 (dd, J = 9.2, 8.4 Hz, 1H), 6.80 (dd, J =9.2, 4.4 Hz, 1H), 3.89 (s, 3H).
[0299] A solution of lithium diisopropylamino (96 mL, 2.0 M, in THF) was added dropwise to a solution of compound 26-2 (25.0 g, 128 mmol) in THF (400 mL) at -70°C. The reaction mixture was then stirred at -70°C for another 30 minutes. DMF (14.9 mL, 192 mmol) was then slowly added to the mixture at -70°C. The reaction mixture was stirred at -70°C under a nitrogen atmosphere for 2 hours. The reaction mixture was poured into a saturated ammonium chloride solution and extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 26.3 (25.0 g, 87% yield). 1 H NMR (400 MHz, CDCl3) δ 10.32(s, 1H), 7.28 (d, J = 5.6 Hz, 1H), 3.95 (s, 3H).
[0300] The synthesis method was similar to that of compound 19, using the same starting materials to obtain compound 26 (250 mg). LCMS: 360.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.49 - 7.45 (m, 1H), 5.83 - 5.19 (m,1H), 4.80 - 4.64 (m, 1H), 4.31 - 4.17 (m, 2H), 4.02 - 3.99 (m, 3H), 3.99 -3.92 (m, 1H), 3.56 - 3.43 (m, 1H), 3.23 - 2.98 (m, 1H), 2.96 - 2.80 (m, 1H),1.49 (dd, J = 30.0, 6.4 Hz, 3H).
[0301] Compound 26 (230 mg) was isolated by chiral SFC to give compound 26A (peak 1, 100.7 mg, t). R =2.341 min) and compound 26B (peak 2, 96.7 mg, t) R = 4.134 min). Chiral analysis method: Column: Daicel ChiralPak IH, 3.0 mm ID × 100 mm, 3 μm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 80 / 20; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: Daicel ChiralPak IH, 30 mm ID × 250 mm, 10 μm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 55 / 45, room temperature, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0302] Compound 26A, LCMS: 360.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.49 - 7.45(m, 1H), 5.82 - 5.17 (m, 1H), 4.81 - 4.64 (m, 1H), 4.32 - 4.15 (m, 2H), 4.02- 3.99 (m, 3H), 3.99 - 3.92 (m, 1H), 3.55 - 3.43 (m, 1H), 3.23 - 2.97 (m,1H), 2.98 - 2.78 (m, 1H), 1.49 (dd, J = 30.0, 6.4 Hz, 3H).
[0303] Compound 26B, LCMS: 360.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.49 - 7.43(m, 1H), 5.85 - 5.16 (m, 1H), 4.80 - 4.64 (m, 1H), 4.34 - 4.16 (m, 2H), 4.02- 3.99 (m, 3H), 3.99 - 3.94 (m, 1H), 3.59 - 3.43 (m, 1H), 3.24 - 2.98 (m,1H), 2.97 - 2.79 (m, 1H), 1.49 (dd, J = 29.6, 6.8 Hz, 3H).
[0304] Example 1.27
[0305] 2-Chloropropanedialdehyde (4.21 g, 39.7 mmol) was added to a solution of thiophene-3-amine (10.0 g, 101.0 mmol) in acetic acid (100.0 mL) at room temperature. The solution was then stirred at 100°C for 2 hours to give a yellow solution. The resulting solution was poured into water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 27-2 (5.3 g, 31.2% yield). LCMS: 170.2 [M+H] + .
[0306] Add to a solution of compound 27-2 (5.3 g, 31.4 mmol) in DCM (50.0 mL) at room temperature m-chloro peroxybenzoic acid(8.1 g, 46.9 mmol). The resulting suspension was stirred at room temperature for 18 hours to obtain a yellow mixture. The reaction mixture was poured into water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compound 27-3 (5.0 g, 86.4% yield). LCMS: 186.2 [M+H] + .
[0307] A mixture of compound 27-3 (5.0 g, 27.1 mmol) and acetic anhydride (50 mL) was stirred at 140°C for 4 hours to obtain a black mixture. This solution was poured into ice water, and the aqueous phase was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to obtain a crude residue. The residue was purified by silica gel chromatography to give compound 27-4 (4.35 g, crude). 1 H NMR (400 MHz, DMSO- d 6) δ 8.91 (d, J = 0.4 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 7.54 - 7.53 (m, 1H), 2.41 (s, 3H).
[0308] Sodium hydroxide (1.52 g, 38.0 mmol) in water (25 mL) was added to a solution of compound 27-4 (4.35 g, 19.0 mmol) in MeOH (50 mL) at room temperature. The reaction mixture was stirred at room temperature for 16 hours. The solution was poured into ice water, and the aqueous phase was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 27-5. (2.8 g, 78.9% yield). LCMS: 186.2 [M+H] + .
[0309] A mixture of compound 27-5 (2.8 g, 15.0 mmol) in phosphoryl chloride (10 mL) was stirred at 100°C for 24 hours. The solution was poured into water, and the aqueous phase was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give compound 27-6 (2.02 g, crude). LCMS: 204.2 [M+H] + .
[0310] Sodium methoxide (1.34 g, 24.8 mmol) was added to a solution of compound 27-6 (2.02 g, 9.9 mmol) in DMF (20 mL) at room temperature. The reaction mixture was stirred at 100°C for 1 hour. The solution was poured into water, and the aqueous phase was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 27-7. (1.42 g, 71.7% yield).
[0311] The synthetic method was similar to that for compounds 5-8, using the same starting materials to obtain compound 27-8 (72 mg). LCMS: 269.2 [M+H] + .
[0312] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 27 (26 mg). LCMS: 327.2 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8.55 (s, 1H), 5.64 (d, J = 6.8 Hz, 1H), 4.22 (d, J = 2.8 Hz,2H), 4.04 (s, 3H), 3.50 - 3.43 (m,2H), 3.06 - 2.90 (m,2H), 1.52 (d, J = 6.8 Hz, 3H).
[0313] Example 1.28
[0314] K₂CO₃ (18.06 g, 131 mmol) was added to a solution of 4-chloro-2,3-difluoro-5-methoxybenzaldehyde (9.00 g, 43.6 mmol) and methyl 2-mercaptoacetate (5.09 g, 47.9 mmol) in DMF (200 mL) at room temperature. The reaction mixture was stirred at 60°C under a nitrogen atmosphere for 16 hours. The reaction mixture was then poured into ice water and stirred for 5 minutes. The reaction mixture was filtered, and the filter cake was dried to give compound 28-2 (11.0 g, 92% yield). 1 H NMR (400MHz, CDCl3) δ 7.97 (d, J = 3.2 Hz, 1H), 7.14 (d, J= 0.8 Hz, 1H), 3.98 (s, 3H), 3.95 (s, 3H).
[0315] Lithium hydroxide (872 mg, 36.4 mmol) was added to a mixture of compound 28-2 (5.0 g, 18.2 mmol) in MeOH / H₂O (volume / volume = 10 / 1, 110 mL) at room temperature. The reaction mixture was stirred at 60°C for 3 hours. The reaction mixture was poured into ice water (400 mL) and acidified to pH 4 using an aqueous HCl solution (2N). The reaction mixture was filtered, and the filter cake was dried to give compound 28-3 (4.6 g, 97% yield). 1 H NMR (400 MHz, DMSO- d 6) δ8.09 (d, J = 3.6 Hz, 1H), 7.61 (d, J = 0.4 Hz, 1H), 3.95 (s, 3H).
[0316] Compound 28-3 (5.20 g, 20.0 mmol) was subjected to treatment at room temperature. N , N Cuprous(I) chloride (7.90 g, 80.0 mmol) was added to a mixture of dimethylformamide (200 mL). The reaction mixture was stirred at 120 °C for 72 hours. The reaction mixture was cooled to room temperature and quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 28-4 (3.99 g, 93% yield). 1 H NMR (400 MHz, CDCl3) δ 7.47 (dd, J = 5.2,0.4 Hz, 1H), 7.29 - 7.26 (m, 1H), 7.12 (d, J = 0.8 Hz, 1H), 3.97 (s, 3H).
[0317] A solution of lithium diisopropylamino (3.46 mL, 2.0 M, in THF) was added dropwise to a solution of compound 28-4 (1.00 g, 4.62 mmol) in THF (20 mL) at -70°C under a nitrogen atmosphere. The reaction mixture was stirred at -70°C for half an hour, and then added at -70°C. 1,2,3-oxathiazolidin-3-carboxylic acid tert-butyl ester2,2-Dioxide (1.55 g, 6.92 mmol). The mixture was stirred at -70°C for 2 hours and then slowly cooled to room temperature overnight. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl and stirred for 20 minutes. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 28-5 (1.40 g, 84% yield). LCMS: 382.2 [M+Na] + .
[0318] Compound 28-5 (1.40 g, 3.89 mmol) was dissolved in dioxane (10 mL) and 4 M HCl / dioxane (10 mL), and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to give compound 28-6 (1.20 g, HCl salt, crude product). LCMS: 260.0 [M+H] + .
[0319] Triethylamine (1.93 mL, 13.86 mmol) and acetic anhydride (0.65 mL, 6.93 mmol) were added to a solution of compound 28-6 (1.20 g, 4.62 mmol) in DCM (30 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with ice water (20 mL) and stirred for 20 minutes. The resulting mixture was extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 28-7 (1.20 g, 86% yield). LCMS: 302.0 [M+H] + .
[0320] Phosphoryl chloride (1.85 mL, 19.9 mmol) was added to a solution of compound 28-7 (1.20 g, 3.98 mmol) in acetonitrile (50 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at 100°C for 2 hours. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous sodium bicarbonate solution, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give compound 28-8 (1.10 mg, 97% yield). LCMS: 284.0 [M+H] + .
[0321] NaBH4 (147 mg, 1.18 mmol) was added fractionally to a solution of compound 28-8 (1.10 g, 3.88 mmol) in MeOH (20 mL) at room temperature. The reaction mixture was stirred at room temperature for half an hour. The reaction mixture was quenched with ice water and DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 28-9 (1.00 g, 90% yield). LCMS: 286.0 [M+H] + .
[0322] EDCI (268 mg, 1.40 mmol), HOBt (189 mg, 1.40 mmol), and triethylamine (0.29 mL, 2.10 mmol) were added to a solution of compound 28-9 (200 mg, 0.70 mmol) and 2-hydroxyacetic acid (80 mg, 1.05 mmol) in DMF (5 mL) at room temperature. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 28 (130 mg, 65.2% yield). LCMS: 344.0 [M+H] + .
[0323] Compound 28 (130 mg) was separated by chiral SFC to give compound 28A (peak 1, 57.4 mg, t). R =1.743 min) and compound 28B (peak 2, 58.2 mg, t R = 3.159 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 80 / 20; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 55 / 45, room temperature, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0324] Compound 28A, LCMS: 344.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.37 - 7.31(m, 1H), 5.82 - 5.18 (m, 1H), 4.80 - 4.64 (m, 1H), 4.32 - 4.16 (m, 2H), 4.04- 3.96 (m, 4H), 3.56 - 3.44 (m, 1H), 3.24 - 3.00 (m, 1H), 2.97 - 2.80 (m,1H), 1.49 (dd, J = 30.0, 6.4 Hz, 3H).
[0325] Compound 28B, LCMS: 344.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.38 - 7.28(m, 1H), 5.83 - 5.18 (m, 1H), 4.81 - 4.64 (m, 1H), 4.34 - 4.13 (m, 2H), 4.06- 3.94 (m, 4H), 3.56 - 3.44 (m, 1H), 3.24 - 2.99 (m, 1H), 2.98 - 2.77 (m,1H), 1.49 (dd, J = 30.0, 6.8 Hz, 3H).
[0326] Example 1.29
[0327] Sodium hydroxide (2.26 g, 56.6 mmol) was added to a solution of methyl fluoroacetate (5.0 g, 47.1 mmol) in ethanol (60 mL) and water (6.6 mL) at 25°C. The solution was stirred at 25°C for 18 hours. The resulting solution was concentrated to give compound 29-2 (6.0 g, crude). 1 H NMR (400 MHz, DMSO- d 6) δ 4.37 (s, 1H), 4.25 (s, 1H).
[0328] Compound 29-2 (406 mg, 4.05 mmol), DIPEA (2.0 mL, 11.5 mmol), EDCI (777 mg, 4.05 mmol), and HOBt (621 mg, 4.05 mmol) were added to a solution of compound 19-6 (700 mg, 2.90 mmol) in DMF (10 mL) at 25°C. The solution was stirred at 60°C for 18 hours. The reaction was quenched with ice water and extracted with EA. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 29-3 (396 mg, 45% yield). LCMS: 302.0 [M+H] + . 1 H NMR (400MHz, CD3Cl) δ 7.74 (s, 1H), 7.18 (s, 1H), 6.99 (d, J = 0.4 Hz, 1H), 6.48 (s,1H), 4.80 (d, J = 47.2 Hz, 2H), 3.94 (s, 3H), 3.69 (q, J = 6.4 Hz, 2H), 3.14(t, J = 6.6 Hz, 2H).
[0329] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 29 (90 mg). LCMS: 344.2 [M+H] + .
[0330] Compound 29 (90 mg) was isolated by chiral SFC to obtain compound 29A (peak 1, 38.7 mg, t). R =1.440 min) and compound 29B (peak 2, 35.2 mg, t R= 2.757 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 80 / 20; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 50 / 50, room temperature, flow rate: 170.0 mL / min, detection wavelength: 214 nm.
[0331] Compound 29A, LCMS: 344.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.07 (s,1H), 7.61 - 7.56 (m, 1H), 6.12 - 5.47 (m, 1H), 4.99 - 4.64, 4.09 - 4.01 (m,4H), 4.35 - 4.20 (m, 2H), 4.00 - 3.93 (m, 3H), 3.69 - 3.57, 3.30 - 3.22 (m, 1H), 3.12 - 2.83 (m, 2H).
[0332] Compound 29B, LCMS: 344.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.07 (s,1H), 7.61 - 7.56 (m, 1H), 6.12 - 5.47 (m, 1H), 4.99 - 4.64, 4.09 - 4.01 (m,4H), 4.35 - 4.20 (m, 2H), 4.00 - 3.93 (m, 3H), 3.69 - 3.57, 3.30 - 3.22 (m, 1H), 3.12 - 2.83 (m, 2H).
[0333] Example 1.30
[0334] Iodomethacin was added to a solution of compound 24-3 (100 mg, 0.28 mmol) in DMF (5 mL) at room temperature. d3 (61.4 mg, 0.42 mmol) and K₂CO₃ (117 mg, 0.85 mmol). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to give compound 30-2 (100 mg, crude). LCMS: 393.2 [M+H] + .
[0335] The synthesis method was similar to that of compound 1, using the same starting materials to obtain compound 30 (75.0 mg). LCMS: 329.2 [M+H] + .
[0336] Compound 30 (75.0 mg) was separated by chiral SFC to give compound 30A (peak 1, 24.6 mg, t). R =1.210 min) and compound 30B (peak 2, 23.0 mg, t) R = 2.547 min). Chiral analysis method: Column: DAICELCHIRALPAK® IA, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: isopropanol (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 60 / 40; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IA, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: isopropanol (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 55 / 45, room temperature, flow rate: 140.0 mL / min, detection wavelength: 214 nm.
[0337] Compound 30A, LCMS: 329.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 8.04 (s,1H), 7.43 - 7.36 (m, 1H), 5.81 - 5.13 (m, 1H), 4.80 - 4.61 (m, 1H), 4.36 -4.15 (m, 2H), 3.97 (dd, J = 14.0, 5.2 Hz, 1H), 3.56 - 3.42 (m, 1H), 3.22 -2.94 (m, 1H), 2.93 - 2.77 (m, 1H), 1.49 (dd, J = 29.6, 6.4 Hz, 3H).
[0338] Compound 30B, LCMS: 329.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.05 (s,1H), 7.44 - 7.36 (m, 1H), 5.78 - 5.14 (m, 1H), 4.78 - 4.62 (m, 1H), 4.34 -4.15 (m, 2H), 3.97 (dd, J = 14.0, 5.2 Hz, 1H), 3.58 - 3.44 (m, 1H), 3.24 -2.95 (m, 1H), 2.92 - 2.78 (m, 1H), 1.49 (dd, J = 29.6, 6.4 Hz, 3H).
[0339] Example 1.31
[0340] EDCI (76.0 mg, 0.39 mmol), HOBT (53.3 mg, 0.39 mmol), and triethylamine (0.082 mL, 0.59 mmol) were added to a solution of compound 24-2 (50 mg, 0.20 mmol) and 2-hydroxyacetic acid (22.5 mg, 0.30 mmol) in DMF (5 mL) at room temperature. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by preparative HPLC to give compound 31 (33.8 mg, 55.0% yield). LCMS: 334.0 [M+H] + ,1 H NMR (400 MHz, DMSO- d 6) δ 10.26 - 10.11 (m, 1H),7.96 (s, 1H), 7.27 - 7.15 (m, 1H), 5.62 - 5.04 (m, 1H), 4.78 - 4.62 (m, 1H),4.34 - 4.15 (m, 2H), 4.02 - 3.91 (m, 1H), 3.54 - 3.42 (m, 1H), 3.23 - 2.93 (m, 1H), 2.90 - 2.76 (m, 1H), 1.45 (dd, J = 40.8, 6.8 Hz, 3H).
[0341] Example 1.32
[0342] Ethyl iodine (52.9 mg, 0.34 mmol) and K₂CO₃ (94.0 mg, 0.68 mmol) were added to a solution of compound 24-3 (80 mg, 0.23 mmol) in DMF (5 mL) at room temperature. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to give compound 32-2 (80 mg, crude). LCMS: 404.2 [M+H] + .
[0343] The synthesis method was similar to that of compound 1, using the same starting materials to obtain compound 32 (38.0 mg). LCMS: 329.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.04 (s, 1H), 7.45 - 7.35 (m, 1H), 5.77 - 5.13 (m, 1H), 4.78 - 4.62 (m, 1H), 4.32 - 4.16 (m, 4H), 4.01 - 3.92(m, 1H), 3.56 - 3.43 (m, 1H), 3.23 - 2.96 (m, 1H), 2.91 - 2.78 (m, 1H), 1.53- 1.36 (m, 6H).
[0344] Example 1.33
[0345] To a solution of compound 24-3 (60 mg, 0.17 mmol) in DMF (5 mL), fluoroiodomethane (54.2 mg, 0.34 mmol) and K₂CO₃ (70.3 mg, 0.51 mmol) were added at room temperature. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to give compound 33-2 (60 mg, crude). LCMS: 408.2 [M+Na] + .
[0346] The synthesis method was similar to that of compound 1, using the same starting materials to obtain compound 33 (24.8 mg). LCMS: 344.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.17 (s, 1H), 7.68 - 7.63 (m, 1H), 6.17 - 5.93 (m, 2H), 5.77 - 5.17 (m, 1H), 4.79 - 4.65 (m, 1H), 4.32 - 4.16(m, 2H), 3.98 (dd, J = 14.0, 5.2 Hz, 1H), 3.55 - 3.44 (m, 1H), 3.25 - 2.97(m, 1H), 2.95 - 2.77 (m, 1H), 1.47 (dd, J = 32.0, 6.4 Hz, 3H).
[0347] Example 1.34
[0348] The synthetic method was similar to that of compound 4, using the same starting materials to obtain compound 34 (34.8 mg). LCMS: 343.4 [M+H] + . 1 H NMR (400 MHz, DMSO- d6) δ 8.32 (s, 1H), 7.50 - 7.24 (m, 1H), 5.91 - 5.23 (m, 1H), 4.80 - 3.96 (m, 1H), 3.96 (s, 3H), 3.89 - 3.59 (m, 2H), 3.56 - 2.71 (m, 3H), 1.61 - 1.37 (m, 3H).
[0349] Example 1.35
[0350] To a solution of compound 28-9 (50.0 mg, 0.18 mmol) in DMF (2 mL), 5-methoxypyrimidine-2-carboxylic acid (32.4 mg, 0.21 mmol), HATU (100 mg, 0.26 mmol), and DIPEA (45.2 mg, 0.35 mmol) were added at 25°C. The reaction mixture was stirred at 25°C for 16 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by preparative HPLC to give compound 35 (44.4 mg, 60.0% yield). LCMS: 422.4 [M+H] + . 1 H NMR (400 MHz, DMSO-) d 6) δ 8.66 (s, 2H), 7.42 (s, 1H), 5.94 (d, J = 6.8 Hz, 1H), 4.04 (s, 3H), 3.98 (s, 3H), 3.66 - 3.51 (m, 2H), 3.03 - 2.49(m, 2H), 1.59 (d, J = 6.8 Hz, 3H).
[0351] Example 1.36
[0352] Add to a solution of ethyl 5-bromo-1H-imidazolium-2-carboxylate (1.0 g, 4.6 mmol) in THF (10 mL) and water (2 mL) at 25°C t-BuXPhos Pd G3 (1.8 g, 2.3 mmol) and zinc cyanide (1.6 g, 13.8 mmol). The reaction mixture was then purged with nitrogen and stirred in a sealed tube at 100°C for 16 hours. The reaction mixture was cooled to room temperature, quenched with ice water, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by silica gel chromatography to give compound 36-2 (75.0 mg, 10.0% yield). LCMS: 166.2 [M+H] + .
[0353] Sodium hydroxide (33.6 mg, 0.84 mmol) was added to a solution of compound 36-2 (70.0 mg, 0.42 mmol) in THF (2 mL) and water (0.4 mL) at 25°C. The reaction mixture was stirred in a sealed tube at 25°C for 16 hours. The reaction was quenched with aqueous HCl (2 mL, 1 M), ice water, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by silica gel chromatography to give compound 36-3 (43.0 mg, 87.0% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 8.66 (s, 2H).
[0354] Compound 36-3 (43.0 mg, 0.32 mmol), HATU (120 mg, 0.32 mmol), and DIPEA (90.0 mg, 0.42 mmol) were added to a solution of compound 28-9 (60.0 mg, 0.21 mmol) in DMF (2 mL) at 25°C. The reaction mixture was stirred at 25°C for 16 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by preparative HPLC to give compound 36 (38.8 mg, 45.7% yield). LCMS: 405.2 [M+H] + . 1 H NMR (400MHz, DMSO- d6) δ 13.94 (s, 1H), 8.30 (s, 1H), 7.60 - 6.94 (m, 1H), 6.58 - 5.85 (m, 1H), 5.60 - 4.71 (m, 1H), 4.08 - 3.95 (m, 3H), 3.73 - 3.39 (m, 1H), 3.21- 2.94 (m, 2H), 1.77 - 1.51 (m, 3H).
[0355] Example 1.37
[0356] The synthesis method was similar to that of compound 19, using the same starting materials to obtain compound 37. LCMS: 374.0, 376.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.45 (s, 1H), 8.09 (s, 1H), 5.78 - 5.18 (m,1H), 4.79 - 4.60 (m, 1H), 4.31 - 4.15 (m, 2H), 4.03 - 3.93 (m, 1H), 3.55 -3.44 (m, 1H), 3.23 - 2.97 (m, 1H), 2.95 - 2.77 (m, 1H), 1.45 (dd, J = 26.8, 6.4 Hz, 3H).
[0357] Example 1.38
[0358] The synthesis method was similar to that of compound 19, using the same starting materials to obtain compound 38. LCMS: 370.0, 372.0 [M+H] + .
[0359] Compound 38 (110 mg) was separated by chiral SFC to give compound 38A (peak 1, 50.3 mg, t). R =1.442 min) and compound 38B (peak 2, 47.3 mg, t) R= 2.634 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA ammonia in MeOH solution), A / B: 70 / 30; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 50 / 50, room temperature, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0360] Compound 38A, LCMS: 370.0, 372.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.19(s, 1H), 7.41 - 7.32 (m, 1H), 5.80 - 5.14 (m, 1H), 4.78 - 4.61 (m, 1H), 4.34- 4.12 (m, 2H), 4.02 - 3.91 (m, 4H), 3.56 - 3.44 (m, 1H), 3.23 - 2.94 (m,1H), 2.91 - 2.78 (m, 1H), 1.49 (dd, J = 29.6, 6.4 Hz, 3H).
[0361] Compound 38B, LCMS: 370.0, 372.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.19(s, 1H), 7.40 - 7.33 (m, 1H), 5.80 - 5.15 (m, 1H), 4.78 - 4.62 (m, 1H), 4.35- 4.14 (m, 2H), 4.03 - 3.91 (m, 4H), 3.55 - 3.43 (m, 1H), 3.24 - 2.95 (m,1H), 2.92 - 2.77 (m, 1H), 1.49 (dd, J= 29.6, 6.8 Hz, 3H).
[0362] Example 1.39
[0363] A solution of lithium diisopropylamino (18.5 mL, 2.0 M, in THF) was slowly added to a solution of 1,2,3-trifluoro-4-methoxybenzene (4.0 g, 24.7 mmol) in THF (80 mL) at -70°C. The reaction mixture was stirred at -70°C for half an hour. Then, DMF (2.87 mL, 37.0 mmol) was slowly added to the mixture at -70°C. The reaction mixture was stirred again at -70°C under a nitrogen atmosphere for 2 hours. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl and extracted with EA. The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 39-2 (4.3 g, 92% yield). 1 H NMR (400 MHz, CD3Cl) δ 10.29(s, 1H), 7.21 (ddd, J = 8.0, 5.6, 2.4 Hz, 1H), 3.94 (s, 3H).
[0364] NaOH (0.59 g, 14.7 mmol) was added to a mixture of compound 39-2 (2.80 g, 14.7 mmol) and rhodanine (1.96 g, 14.7 mmol) in ethanol (50 mL) at room temperature. The reaction mixture was then stirred at 85°C under a nitrogen atmosphere for 16 hours. The reaction mixture was concentrated to remove ethanol, diluted with water, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give compound 39-3 (4.5 g, crude). LCMS: 306.0 [M+H] + .
[0365] Compound 39-3 (4.5 g, 14.7 mmol) was added to a solution of NaOH (4.13 g, 103.0 mmol) in water (20 mL) at room temperature. The reaction mixture was stirred at 95°C under a nitrogen atmosphere for 16 hours. The reaction mixture was cooled to 0°C and the pH was adjusted to 4 with 4 M HCl aqueous solution. The reaction mixture was filtered, and the filter cake was collected and dried to give compound 39-4 (3.5 g, crude product). LCMS: 245.0 [M+H] + .
[0366] The synthesis method was similar to that of compound 19, using the same starting materials to obtain compound 39 (10.7 mg). LCMS: 328.2 [M+H] + .
[0367] Example 1.40
[0368] The synthesis method was similar to that of compound 30, using the same starting materials to obtain compound 40 (100 mg). LCMS: 347.4 [M+H] + .
[0369] Compound 40 (100.0 mg) was separated by chiral SFC to give compound 40A (peak 1, 29.8 mg, t). R =1.704 min) and compound 40B (peak 2, 31.5 mg, t) R = 3.084 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 80 / 20; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 55 / 45, room temperature, flow rate: 60.0 mL / min, detection wavelength: 214 nm.
[0370] Compound 40A, LCMS: 347.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.37 - 7.30(m, 1H), 5.81 - 5.18 (m, 1H), 4.81 - 4.65 (m, 1H), 4.31 - 4.14 (m, 2H), 4.00(dd, J= 14.0, 5.2 Hz, 1H), 3.58 - 3.44 (m, 1H), 3.24 - 2.98 (m, 1H), 2.98 -2.81 (m, 1H), 1.49 (dd, J = 30.4, 6.4 Hz, 3H).
[0371] Compound 40B, LCMS: 347.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.37 - 7.31(m, 1H), 5.81 - 5.18 (m, 1H), 4.80 - 4.66 (m, 1H), 4.33 - 4.16 (m, 2H), 4.00(dd, J = 14.0, 5.2 Hz, 1H), 3.54 - 3.43 (m, 1H), 3.23 - 2.98 (m, 1H), 2.97 -2.79 (m, 1H), 1.49 (dd, J = 30.0, 6.4 Hz, 3H).
[0372] Example 1.41
[0373] The synthesis method was similar to that of compound 34, using the same starting materials to obtain compound 41 (60.2 mg). LCMS: 373.4 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.27 (s, 1H), 7.59 - 7.35 (m, 1H), 5.98 - 5.20 (m, 1H), 4.83 - 3.94 (m, 1H), 3.94 (s, 3H), 3.72 - 3.66 (m, 1H), 3.55 - 3.48 (m, 1H), 3.19 - 2.76 (m, 3H), 2.41 - 2.30 (m, 3H), 1.59 - 1.36 (m, 3H).
[0374] Example 1.42
[0375] Sodium tert-butoxide (3.53 g, 36.7 mmol) was added to a solution of compound 18-5 (7.50 g, 13.3 mmol) in dioxane / H₂O (volume / volume = 4 / 1, 100 mL) at room temperature. t -BuBrettPhos-Pd-G3 (633 mg, 0.67 mmol). The mixture was then stirred at 65°C under nitrogen atmosphere for 3 hours. The reaction mixture was cooled to room temperature, quenched with ice water, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 42-2 (6.3 g, 95% yield). LCMS: 399.0 [M+H-Boc] + .
[0376] A mixture of compound 42-2 (4.30 g, 8.61 mmol) and hydrogen chloride solution (60 mL, 4.0 M, in dioxane) was stirred at 30°C for 4 hours. The reaction mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 42-3 (2.00 g, 95% yield). LCMS: 245.0 [M+H] + .
[0377] To a solution of compound 42-3 (2.00 g, 8.16 mmol) in DMF (30 mL), 3-(benzyloxy)propionic acid (2.94 mg, 16.3 mmol), DIPEA (5.7 mL, 32.6 mmol), and HATU (6.21 g, 16.3 mmol) were added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by adding ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 42-4 (4.00 g, 86% yield). LCMS: 569.2 [M+H] + .
[0378] Lithium hydroxide monohydrate (589 mg, 14.1 mmol) was added to a mixture of compound 42-4 (4.00 g, 7.02 mmol) in THF / MeOH (volume / volume = 4 / 1, 125 mL) at room temperature. The reaction mixture was stirred at 40°C for 18 hours. The mixture was poured into ice water and acidified to pH 4 with aqueous HCl (2 M). The mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 42-5 (1.50 g, 52% yield). LCMS: 407.0 [M+H] + .
[0379] The synthetic method was similar to that for compounds 1-12, using the same starting materials to obtain compounds 42-7 (1.20 g). LCMS: 391.2 [M+H] + .
[0380] Di-tert-butyl dicarbonate (1.00 mL, 4.60 mmol) and triethylamine (0.86 mL, 6.13 mmol) were added to a mixture of compound 42-7 (1.20 g, 3.07 mmol) in THF (20 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 42-8 (800 mg, 53% yield). LCMS: 391.2 [M+H-Boc] + .
[0381] Pd / C (100 mg, 10% wt., 55% H2O) and Pd(OH)2 (100 mg, 10% wt., 55% H2O) were added to a solution of compound 42-8 (800 mg, 1.62 mmol) in MeOH (16 mL). The reaction mixture was repeatedly evacuated and purged with hydrogen. The reaction mixture was stirred at 60°C under hydrogen for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to obtain a crude residue. The residue was ground with DCM (5 mL). The solid was collected by filtration to give compound 42-9 (420 mg, 64% yield). LCMS: 345.0, 347.0 [M+H-C4H8] + .
[0382] Triphenylphosphine (131 mg, 0.50 mmol) and diisopropyl azodicarbonate (0.09 mL, 0.50 mmol) were added to a solution of compound 42-9 (100 mg, 0.25 mmol) in dioxane (5 mL) at 25°C. The solution was stirred at 100°C under a nitrogen atmosphere for 18 hours. The reaction mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 42-10 (70 mg, 73% yield). LCMS: 383.0, 385.0 [M+H] + .
[0383] Trimethylsilyl chloride (32.3 mg, 0.30 mmol) was added to a solution of compound 42-10 (76 mg, 0.20 mmol) in 2,2,2-trifluoroethanol (5 mL) at 25°C. The solution was stirred at 25°C for 18 hours. The reaction mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by reversed-phase chromatography to give compound 42-11 (52 mg, 93% yield). LCMS: 283.0 [M+H] + .
[0384] Triethylamine (32 mg, 0.32 mmol) and 2-methoxyacetyl chloride (25 mg, 0.24 mmol) were added to a solution of compound 42-11 (45 mg, 0.16 mmol) in THF (1 mL) at 25°C. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 42. LCMS: 355.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 11.60 (s, 1H), 6.65 (s,1H), 4.91 - 4.75 (m, 1H), 4.69 - 4.60 (m, 1H), 4.20 (s, 2H), 4.13 - 4.01 (m,2H), 3.33 (s, 3H). 2.98 (s, 1H), 2.82 - 2.75 (m, 2H), 2.67 - 2.61 (m, 1H), 1.85-1.73 (m, 1H).
[0385] Example 1.43
[0386] 3,4-Dihydropyran (25.4 mL, 277 mmol) was added to a solution of but-3-en-1-ol (10 g, 139 mmol) and p-toluenesulfonic acid pyridinium salt (3.49 g, 13.9 mmol) in DCM (200 mL). The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere. The mixture was filtered and concentrated to give compound 43-2 (18 g, 83% yield). 1 HNMR (400 MHz, CD3Cl) δ 5.86 - 5.81 (m, 1H), 5.12 - 5.02 (m, 2H), 4.61 - 4.59(m, 1H), 3.87 - 3.76 (m, 2H), 3.52 - 3.43 (m, 2H), 2.39 - 2.34 (m, 2H), 1.72- 1.51 (m, 6H).
[0387] Ozone was bubbled into a solution of compound 43-2 (20 g, 128 mmol) in DCM (100 mL) at -78°C. The reaction mixture was stirred for 1 hour, and dimethyl sulfide (9.47 mL, 128 mmol) was added. The reaction mixture was then slowly heated to 25°C and stirred at 25°C for another 2 hours. The solution was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-3 (15 g, 74% yield). 1 H NMR (400 MHz, CD3Cl) δ 9.82 (s, 1H), 4.64 - 4.62 (m, 1H), 4.12 - 4.07 (m, 1H), 3.87 - 3.82 (m, H), 3.79 - 3.73 (m, 1H), 3.35 - 3.31 (m, 1H), 2.72 - 2.68 (m,2H), 1.79 - 1.50 (m, 6H).
[0388] A solution of lithium diisopropylamino (54 mL, 2.0 M, in THF) was added dropwise to a solution of compound 1-5 (11.0 g, 54.2 mmol) in THF (200 mL) at -78°C. The reaction mixture was stirred at -78°C for 1 hour. Then, compound 43-3 (8.57 g, 54.2 mmol) was slowly added to the mixture at -78°C. The reaction mixture was slowly warmed to 25°C and stirred for 1 hour. The reaction mixture was poured into a cold, saturated ammonium chloride solution and extracted with EA. The combined organic phases were washed with water (500 mL) and brine (500 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-4 (25.0 g, 87% yield). 1 H NMR (400MHz, CDCl3) δ 7.51 (dd, J = 8.4, 0.8 Hz, 1H), 7.39 (dd, J = 8.4, 1.2 Hz, 1H),7.17 (s, 1H), 5.31 - 5.16 (m, 2H), 4.60 (dd, J = 4.4, 2.4 Hz, 1H), 3.95 -3.81 (m, 2H), 3.73 - 3.62 (m, 2H), 2.22 - 2.15 (m, 2H), 1.89 - 1.60 (m, 6H).
[0389] To a solution of compound 43-4 (15.0 g, 41.5 mmol) in DCM (300 mL), Dysmart oxidant (26.4 g, 62.3 mmol) was added at room temperature, and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with an aqueous sodium thiosulfate solution and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-5 (14.5 g, 97% yield). LCMS: 381.0, 383.0 [M+Na] + .
[0390] Add dropwise to a solution of (methoxymethyl)triphenylphosphonium chloride (8.02 g, 23.4 mmol) in THF (200 mL) at -78°C. n-ButylLithium (9.4 mL, 2.5 M, in hexane). The reaction mixture was stirred at -78°C for 1 hour. Then, compound 43-5 (7.00 g, 19.5 mmol) was added, and the mixture was stirred at 25°C for 2 hours. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl and extracted with EA. The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-6 (4.40 g, 58% yield). LCMS: 409.0, 411.0 [M+Na] + .
[0391] To a solution of compound 43-6 (1.20 g, 3.1 mmol) in THF / water (v / v = 1 / 1, 20 mL), an aqueous HCl solution (3.9 mL, 8 M) was added, and the mixture was stirred at 25°C for 12 hours. The reaction mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-7 (800 mg, 89% yield). LCMS: 271.0, 273.0 [M-OH] + .
[0392] To a solution of compound 43-6 (1.20 g, 3.1 mmol) in THF / water (v / v = 1 / 1, 20 mL), an aqueous HCl solution (3.9 mL, 8 M) was added, and the mixture was stirred at 25°C for 12 hours. The reaction mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-7 (800 mg, 89% yield). LCMS: 271.0, 273.0 [M-OH] + .
[0393] Acetic acid (16.6 mg, 0.28 mmol) and 4-methoxybenzylamine (0.72 mL, 5.53 mmol) were added to a solution of compound 43-7 (800 mg, 2.77 mmol) in methanol (16 mL). The reaction mixture was stirred at 25°C for 1 hour. Sodium cyanoborohydride (348 mg, 5.53 mmol) was then added, and the mixture was stirred at 25°C for another 3 hours. The reaction mixture was quenched with a saturated aqueous sodium bicarbonate solution and extracted with EA. The combined organic phases were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-8 (1.05 g, 92% yield). LCMS: 410.0, 412.0 [M+H] + .
[0394] Acetic anhydride (780 mg, 7.68 mmol) was added to a solution of compound 43-8 (10.5 g, 2.56 mmol) in DCM (20 mL). The reaction mixture was stirred at 25°C for 1 hour. The solution was poured into ice water, and the aqueous phase was extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-9 (674 mg, 53% yield). LCMS: 494.0, 496.0 [M+H] + .
[0395] Trifluoromethanesulfonic acid (20.5 mg, 0.14 mmol) was added to a solution of compound 43-9 (674 mg, 1.36 mmol) in trifluoroacetic acid (13 mL), and the mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 43-9 (474 mg, 93% yield). LCMS: 374.0 [M+H] + .
[0396] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 43A (3.2 mg), LCMS: 374.0, 376.0 [M+H]. + , 1 H NMR (400 MHz, DMSO- d6) δ 7.85 - 7.80 (m, 1H), 7.69 -7.61 (m, 1H), 5.71 - 5.19 (m, 1H), 4.80 - 4.60 (m, 2H), 4.39 - 4.14 (m, 2H), 4.06 - 3.50 (m, 1H), 3.66 - 3.57 (m, 2H), 3.26 - 3.20 (m, 2H), 1.83 - 1.54 (m, 2H), 1.52 - 1.40 (m, 3H).
[0397] Compound 43B (3.5 mg), LCMS: 374.0, 376.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.85 - 7.80 (m, 1H), 7.69 - 7.62 (m, 1H), 5.74 - 5.19 (m, 1H), 4.84 -4.69 (m, 2H), 4.33 - 4.15 (m, 2H), 4.10 - 4.00 (m, 1H), 3.70 - 3.55 (m, 2H), 3.27 - 2.85 (m, 2H), 2.09 - 1.96 (m, 1H), 1.80 - 1.71 (m, 1H), 1.53 - 1.43(m, 3H).
[0398] Example 1.44
[0399] To 1,2-dichloro-3-methoxybenzene (10 g, 56.5 mmol) and dichloro( p-cymene Ruthenium(II) dimer (519 mg, 0.85 mmol) was added to a solution of bis(trifluoroacetic acid)iodobenzene (48.6 g, 113 mmol) in trifluoroacetic anhydride (150 mL). The reaction mixture was stirred in a sealed tube at 80°C for 10 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 44-2 (2.0 g, 18.3% yield). 1 H NMR (400 MHz, CDCl3) δ 6.86 (d, J = 9.1 Hz, 1H), 6.75 (d, J= 9.1 Hz, 1H), 5.23 (s, 1H).
[0400] The synthetic method was similar to that for compounds 5-9, using the same starting materials to obtain compound 44 (46.4 mg). LCMS: 344.3, 346.3 [M+H] + .
[0401] Compound 44 (46.4 mg) was separated by chiral SFC to give compound 40A (peak 1, 15.6 mg, t). R =1.197 min) and compound 40B (peak 2, 17.6 mg, t) R = 1.987 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 70 / 30; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 70 / 30, room temperature, flow rate: 140.0 mL / min, detection wavelength: 214 nm.
[0402] Compound 44A, LCMS: 344.3, 346.3 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.47- 7.33 (m, 1H), 5.71 - 5.07(m, 1H), 4.79 - 4.70 (m, 1H), 4.31 - 4.10 (m, 2H), 4.07 - 3.83 (m, 4H), 3.55 - 3.40 (m, 1H), 3.07 - 2.75 (m, 2H), 1.58 - 1.37 (m, 3H).
[0403] Compound 44B, LCMS: 344.3, 346.3 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.51- 7.31 (m, 1H), 5.73 - 5.05 (m, 1H), 4.75 (s, 1H), 4.33 - 4.11 (m, 2H), 4.08- 3.85 (m, 4H), 3.52 - 3.39 (m, 1H), 3.08 - 2.73 (m, 2H), 1.59 - 1.37 (m, 3H).
[0404] Example 1.45
[0405] The synthetic method was similar to that of compound 8, using the same starting materials to obtain compound 45 (30.0 mg). LCMS: 358.4 [M+H] + .
[0406] Compound 45 (30.0 mg) was isolated by chiral SFC to give compound 45A (peak 1, 5.5 mg, t). R =1.038 min) and compound 45B (peak 2, 5.3 mg, t) R = 1.794 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 70 / 30; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 70 / 30, room temperature, flow rate: 140.0 mL / min, detection wavelength: 214 / 254 nm.
[0407] Compound 45A, LCMS: 358.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.46 - 7.26(m, 1H), 5.68 - 5.12 (m, 1H), 4.82 - 4.45 (m, 1H), 4.43 - 4.12 (m, 2H), 4.01(s, 3H), 3.27 - 2.97 (m, 1H), 2.95 - 2.81 (m, 1H), 1.77 - 1.49 (m, 3H), 1.39 - 1.17 (m, 4H).
[0408] Compound 45B, LCMS: 358.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.43 - 7.27(m, 1H), 5.74 - 5.08 (m, 1H), 4.82 - 4.45 (m, 1H), 4.43 - 4.12 (m, 2H), 4.01(s, 3H), 3.29 - 2.98 (m, 1H), 2.93 - 2.79 (m, 1H), 1.69 - 1.53 (m, 3H), 1.38 - 1.20 (m, 4H).
[0409] Example 1.46
[0410] Triethylamine (70.8 mg, 0.70 mmol) and 2-methoxyacetyl chloride (57 mg, 0.53 mmol) were added to a solution of compound 28-9 (100 mg, 0.35 mmol) in THF (5 mL) at 25°C. The mixture was stirred at 25°C for 18 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 46 (80 mg, 64% yield). LCMS: 358.0 [M+H] + .
[0411] Compound 46 (80.0 mg) was separated by chiral SFC to give compound 46A (peak 1, 17.2 mg, t). R =1.561 min) and compound 46B (peak 2, 16.8 mg, t) R= 2.685 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 75 / 25; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 50 / 50, temperature: 25°C, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0412] Compound 46A, LCMS: 358.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.36 - 7.30(m, 1H), 5.84 - 5.17 (m, 1H), 4.75 - 4.66, 4.10 - 4.02 (m, 1H), 4.32 - 4.15(m, 2H), 4.01 (s, 3H), 3.59 - 3.44, 3.21 - 3.09 (m, 1H), 3.18 - 3.05 (m, 3H), 3.09 - 2.79 (m, 2H), 1.58 - 1.40 (m, 3H).
[0413] Compound 46B, LCMS: 358.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.37 - 7.28(m, 1H), 5.83 - 5.20 (m, 1H), 4.75 - 4.65, 4.09 - 4.02 (m, 1H), 4.32 - 4.15(m, 2H), 4.01 (s, 3H), 3.57 - 3.45, 3.19 - 3.09 (m, 1H), 3.32 - 3.31 (m, 3H), 3.08 - 2.79 (m, 2H), 1.58 - 1.40 (m, 3H).
[0414] Example 1.47
[0415] Iodomethacin was added to a solution of compound 40 (75 mg, 0.22 mmol) in DMF (2 mL) at room temperature. d3 (157 mg, 1.08 mmol) and Cs₂CO₃ (211 mg, 0.65 mmol). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 72 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 47 (20 mg, 25% yield). LCMS: 364.2 [M+H] + .
[0416] Compound 47 (75.0 mg) was isolated by chiral SFC to give compound 47A (peak 1, 5.2 mg, t). R =1.210 min) and compound 47B (peak 2, 6.8 mg, t) R = 2.547 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 80 / 20; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: methanol (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 75 / 25, room temperature, flow rate: 140.0 mL / min, detection wavelength: 214 nm.
[0417] Compound 47A, LCMS: 364.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.34 - 7.31(m, 1H), 5.82 - 5.20 (m, 1H), 4.75 - 4.63, 4.09 - 4.00 (m, 1H), 4.31 - 4.14(m, 2H), 3.58 - 3.45 (m, 1H), 3.20 - 2.98 (m, 1H), 2.96 - 2.79 (m, 1H), 1.56- 1.42 (m, 3H).
[0418] Compound 47B, LCMS: 364.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.36 - 7.30(m, 1H), 5.81 - 5.20 (m, 1H), 4.74 - 4.64, 4.08 - 3.99 (m, 1H), 4.32 - 4.14(m, 2H), 3.56 - 3.45 (m, 1H), 3.21 - 2.99 (m, 1H), 2.97 - 2.77 (m, 1H), 1.56- 1.42 (m, 3H).
[0419] Example 1.48
[0420] NaBH4 (3.76 g, 92 mmol) was added fractionally to a solution of 5,6-dimethoxynicotinaldehyde (15.3 g, 92 mmol) in MeOH (30 mL) at 0°C. The reaction mixture was then stirred at 25°C for 1 hour. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 48-2 (12.7 g, 82% yield). 1 H NMR (400MHz, CDCl3) δ 7.64 (d, J = 1.8 Hz, 1H), 7.11 (d, J = 1.8 Hz, 1H), 4.61 (s, 2H), 4.00 (s, 3H), 3.87 (s, 3H).
[0421] NBS (16.0 g, 90 mmol) was added to a solution of compound 48-2 (12.7 g, 75 mmol) in acetonitrile (377 mL) and acetic acid (2 mL) at 25°C. The solution was then stirred at 25°C for 1 hour. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 48-3 (13.8 g, 74% yield). 1 H NMR (400MHz, CDCl3) δ 7.22 (s, 1H), 4.66 (d, J = 5.2 Hz, 2H), 4.01 (s, 3H), 3.88 (s,3H), 2.03 (t, J = 5.8 Hz, 1H).
[0422] At 0°C, a solution of compound 48-3 (13.8 g, 55.6 mmol) in DCM (460 mL) was added fractionally with Dys-Martin oxidant (35.4 g, 83 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with an aqueous sodium thiosulfate solution and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 48-4 (10.7 g, 78% yield). 1 H NMR (400 MHz, CDCl3) δ 10.16 (s, 1H), 7.49 (s, 1H), 4.11 (s, 3H), 3.91 (s, 3H).
[0423] The synthetic method was similar to that for compound 19-4, using the same starting materials to give compound 48-5 (5.4 g, 83% yield). LCMS: 196.2 [M+H] + .
[0424] Hydrochloric acid (35 mL, 12 N) was added to a solution (2.9 g, 14.8 mmol) of compound 48-5 at 25°C. The solution was then stirred at 100°C for 18 hours. The reaction mixture was concentrated under reduced pressure to give compound 48-6. (3.0 g, crude product). LCMS: 182.0 [M+H] + .
[0425] A mixture of compound 48-6 (3.0 g, 16.5 mmol) and phosphoryl chloride (30 mL) was stirred at 110°C for 18 hours. The solution was added dropwise to water, and the aqueous phase was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 48-7 (1.4 g, 42% yield). LCMS: 200.0, 202.0 [M+H] + .
[0426] The synthesis method was similar to that of Example 1.8, using the same starting materials to obtain compound 48 (80 mg). LCMS: 327.0 [M+H] + .
[0427] Compound 48 (80 mg) was isolated by chiral SFC to give compound 48A (peak 1, 24.2 mg, t). R =1.561 min) and compound 48B (peak 2, 26.5 mg, t) R = 2.685 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 75 / 25; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 50 / 50, temperature: 25°C, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0428] Compound 48A, LCMS: 327.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.98 - 7.85(m, 1H), 5.88 - 5.17 (m, 1H), 4.83 - 4.75, 3.99 - 3.93 (m, 1H), 4.73 - 4.64,4.33 - 4.26 (m, 1H), 4.26 - 4.11 (m, 2H), 4.01 (s, 3H), 3.57 - 3.46, 3.26 -3.16 (m, 1H), 3.11 - 2.84 (m, 2H), 1.56 - 1.42 (m, 3H).
[0429] Compound 48B, LCMS: 327.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.00 - 7.85(m, 1H), 5.83 - 5.18 (m, 1H), 4.81 - 4.74, 3.98 - 3.93 (m, 1H), 4.74 - 4.63,4.33 - 4.25 (m, 1H), 4.25 - 4.13 (m, 2H), 4.01 (s, 3H), 3.57 - 3.46, 3.26 -3.16 (m, 1H), 3.11 - 2.82 (m, 2H), 1.60 - 1.37 (m, 3H).
[0430] Example 1.49
[0431] The synthesis method is similar to that of compounds 43-13. Using the corresponding starting materials, compound 49 (crude product) was obtained, which was then purified by preparative HPLC (20 mL / min, 25°C, Ultimate C18, 21.2 × 250 mm, 5 µm, ACN-H2O, 0.1% FA) to give compound 49A (peak 1, 7.0 mg, t). R = 5.140 min), LCMS: 372.4 [M+H] + , 1 HNMR (400 MHz, DMSO- d 6) δ 7.34 - 7.32 (m, 1H), 5.78 - 5.23 (m, 1H), 4.53 -4.23 (m, 1H), 4.17 (dd, J= 33.6, 10.0 Hz, 1H), 4.01 (s, 3H), 3.85 - 3.63 (m,1H), 3.33 (d, J = 2.8 Hz, 3H), 3.31 - 3.14 (m, 2H), 1.53 - 1.40 (m, 3H), 1.29 - 1.16 (m, 3H) and compound 49B (peak 1, 3.9 mg, t) R = 5.243 min), LCMS: 372.4 [M+H] + , 1 HNMR (400 MHz, DMSO- d 6) δ 7.33 (s, 1H), 5.86 - 4.61 (m, 1H), 4.35 - 4.16 (m,2H), 4.10 - 3.93 (m, 4H), 3.32 (s, 3H), 3.27 - 2.74 (m, 2H), 1.55 - 1.43 (m,3H), 1.31 (d, J = 6.8 Hz, 3H).
[0432] Example 1.50
[0433] The synthetic method was similar to that for compound 19-9, using the same starting materials to obtain compound 50-2 (330 mg). LCMS: 270.0 [M+H] + .
[0434] Triethylamine (52 µL, 0.37 mmol) and 2-methoxyacetyl chloride (30 mg, 0.28 mmol) were added to a solution of compound 50-2 (50 mg, 0.19 mmol) in DCM (2 mL) at room temperature. The mixture was stirred at room temperature for 2 hours. The reaction was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 50 (13.7 mg, 21.6% yield). LCMS: 342.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.35 (d, J= 6.8 Hz, 1H), 5.81 - 5.18 (m, 1H), 4.76 - 4.63 (m, 1H), 4.31 - 4.15 (m, 2H), 4.07 - 4.00 (m, 1H), 3.99 (s, 3H), 3.55 - 3.45 (m, 1H), 3.31 (s, 3H), 3.19 -2.77 (m, 2H), 1.56 - 1.41 (m, 3H).
[0435] Compound 50 (80.0 mg) was separated by chiral SFC to give compound 50A (peak 1, 22.8 mg, t). R =1.903 min) and compound 46B (peak 2, 25.9 mg, t) R = 3.082 min). Chiral analysis method: Column: DAICELCHIRALPAK® IA, 40 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 75 / 25; temperature: 35°C, flow rate: 130 mL / min, detection wavelength: 210 nm. Chiral preparation method: Column: Daicel ChiralPak IA, 40 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 75 / 25, room temperature, flow rate: 130.0 mL / min, detection wavelength: 210 nm.
[0436] Compound 46A, LCMS: 342.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.35 (d, J =6.8 Hz, 1H), 5.79 - 5.19 (m, 1H), 4.74 - 4.62 (m, 1H), 4.33 - 4.13 (m, 2H), 4.09 - 4.01 (m, 1H), 3.99 (s, 3H), 3.56 - 3.43 (m, 1H), 3.32 (s, 3H), 3.18 -2.96 (m, 1H), 2.96 - 2.79 (m, 1H), 1.56 - 1.41 (m, 3H).
[0437] Compound 46B, LCMS: 342.2 [M+H]+ , 1 H NMR (400 MHz, DMSO- d 6) δ 7.35 (d, J =6.8 Hz, 1H), 5.80 - 5.18 (m, 1H), 4.77 - 4.63 (m, 1H), 4.32 - 4.13 (m, 2H), 4.11 - 4.01 (m, 1H), 3.99 (s, 3H), 3.56 - 3.46 (m, 1H), 3.32 (s, 3H), 3.19 -2.97 (m, 1H), 2.96 - 2.77 (m, 1H), 1.55 - 1.41 (m, 3H).
[0438] Example 1.51
[0439] The synthetic method was similar to that of compound 4, using the same starting materials to obtain compound 51 (32.6 mg). LCMS: 327.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.46 - 7.30 (m, 1H), 5.83 - 5.23 (m,1H), 4.78 - 4.67 (m, 1H), 4.08 - 3.91 (m, 4H), 3.59 - 3.43 (m, 3H), 3.19 -3.10 (m, 1H), 3.07 - 2.96 (m, 1H), 2.96 - 2.75 (m, 2H), 1.54 - 1.41 (m, 3H).
[0440] Example 1.52
[0441] Compound 39-4 (1.0 g, 4.09 mmol) was subjected to treatment at room temperature. N , NCopper (1.04 g, 16.38 mmol) was added to a mixture of dimethylformamide (20 mL). The reaction mixture was stirred at 130 °C for 48 hours. The reaction mixture was cooled to room temperature and quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 52-2 (340 mg, 41% yield). 1 H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 5.6, 0.4 Hz, 1H), 7.25 (dd, J = 5.6, 3.6 Hz, 1H), 7.13 (dd, J = 6.8, 1.6 Hz, 1H), 3.96 (s, 3H).
[0442] A solution of lithium diisopropylamino (0.75 mL, 2.0 M, in THF) was added dropwise to a solution of compound 52-2 (200 mg, 1.00 mmol) in THF (10 mL) at -70°C under a nitrogen atmosphere. The reaction mixture was stirred at -70°C for half an hour, and then added to a solution of compound 52-2 (200 mg, 1.00 mmol) in THF (10 mL) at -70°C. R 4-Methyl-1,2,3-oxathiazolidin-3-carboxylic acid Uncle Ding Ester 2,2-dioxide (356 mg, 1.50 mmol). The mixture was stirred at -70°C for 2 hours and then slowly cooled to room temperature overnight. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 52-3 (330 mg, 92% yield). LCMS: 380.0 [M+Na] + .
[0443] Compound 52-3 (330 mg, 0.92 mmol) was dissolved in dioxane (5 mL) and 4 M HCl / dioxane (5 mL), and the mixture was stirred at room temperature under a nitrogen atmosphere for 12 hours. The reaction mixture was concentrated to give compound 52-4 (270 mg, HCl salt, crude product). LCMS: 258.2 [M+H] + .
[0444] Triethylamine (0.44 mL, 3.15 mmol) and acetic anhydride (161 mg, 1.57 mmol) were added to a solution of compound 52-4 (270 mg, 1.05 mmol) in DCM (5 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was then quenched with ice water. The resulting mixture was extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 52-5 (260 mg, 86% yield). LCMS: 300.2 [M+H] + .
[0445] Phosphoryl chloride (666 mg, 4.34 mmol) was added to a solution of compound 52-5 (260 mg, 0.87 mmol) in acetonitrile (5 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at 100°C for 2 hours. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous sodium bicarbonate solution, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give compound 52-6 (300 mg, crude). LCMS: 282.2 [M+H] + .
[0446] NaBH4 (40.3 mg, 1.07 mmol) was added fractionally to a solution of compound 52-6 (300 mg, 1.07 mmol) in MeOH (5 mL) at room temperature. The reaction mixture was stirred at room temperature for half an hour. The reaction mixture was quenched with ice water and DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 52-7 (200 mg, 66% yield). LCMS: 284.2 [M+H] + .
[0447] To a solution of compound 52-7 (50 mg, 0.18 mmol) and triethylamine (53.6 mg, 0.54 mmol) in DCM (2 mL), 2-chloro-2-oxoethyl acetate (36.1 mg, 0.27 mmol) was added at room temperature. The mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with ice water. The resulting mixture was extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 52-8 (60 mg, 89% yield). LCMS: 384.2 [M+H]+ .
[0448] K₂CO₃ (64.9 mg, 0.47 mmol) was added to a solution of compound 52-8 (60 mg, 0.16 mmol) in MeOH (2 mL) at room temperature, and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with ice water. The resulting mixture was extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 52 (28.8 mg, 53.9% yield). LCMS: 342.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.42 - 7.30 (m, 1H), 5.70- 5.25 (m, 1H), 5.20 - 4.69 (m, 1H), 4.61 - 4.42 (m, 1H), 4.39 - 4.14 (m,2H), 3.99 (s, 3H), 3.23 - 2.98 (m, 1H), 2.89 - 2.79 (m, 1H), 1.65 - 1.55 (m, 3H), 1.35 - 1.25 (m, 3H).
[0449] Example 1.53
[0450] Triethylamine (53.6 mg, 0.53 mmol) and 2-methoxyacetyl chloride (28.7 mg, 0.27 mmol) were added to a solution of compound 52-7 (50 mg, 0.18 mmol) in DCM (2 mL) at room temperature. The mixture was stirred at room temperature for 12 hours. The reaction was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 53 (19.9 mg, 32% yield). LCMS: 356.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d6) δ 7.39 - 7.30(m, 1H), 5.68 - 5.25 (m, 1H), 5.22 - 4.51 (m, 1H), 4.42 - 4.15 (m, 2H), 3.99(s, 3H), 3.34 (s, 3H), 3.19 - 3.00 (m, 1H), 2.91 - 2.80 (m, 1H), 1.67 - 1.54 (m, 3H), 1.36 - 1.23 (m, 3H).
[0451] Example 1.54
[0452] Boron tribromide (23.1 mL, 1 M, in DCM) was added dropwise to a solution of compound 28-4 (1.0 g, 4.62 mmol) in DCM (20 mL) at -70°C under a nitrogen atmosphere. The reaction mixture was slowly cooled to room temperature and stirred under a nitrogen atmosphere for 12 hours. The reaction mixture was quenched by adding methanol (10 mL) dropwise at -70°C. The reaction mixture was then quenched with a saturated aqueous solution of NaHCO3 and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 54-2 (900 mg, 96% yield). LCMS: 225.0 [M+Na] + .
[0453] Iodomethacin was added to a solution of compound 54-2 (900 mg, 4.44 mmol) in DMF (20 mL) at room temperature. d Compound 54-3 (966 mg, 6.66 mmol) and potassium carbonate (1.23 g, 8.88 mmol) were added, and the reaction mixture was stirred at room temperature under a nitrogen atmosphere for 12 hours. The reaction mixture was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 54-3 (900 mg, 92% yield). 1 H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 5.2Hz, 1H), 7.28 - 7.25 (m, 1H), 7.12 (d, J = 1.2 Hz, 1H).
[0454] The synthesis method was similar to that of compound 52, using the same starting materials to obtain compound 54 (29.8 mg). LCMS: 361.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.29 (m, 1H), 5.68 - 5.26 (m,1H), 5.23 - 5.12 (m, 1H), 4.78 - 4.69 (m, 1H), 4.63 - 4.43 (m, 1H), 4.39 -4.14 (m, 2H), 3.23 - 2.99 (m, 1H), 2.92 - 2.81 (m, 1H), 1.66 - 1.56 (m, 3H), 1.35 - 1.25 (m, 3H).
[0455] Example 1.55
[0456] Iodomethyl ether was added to a solution of compound 28A (30 mg, 0.09 mmol) in DMF (2 mL) at room temperature. d Compound 3 (63.2 mg, 0.44 mmol) and cesium carbonate (85 mg, 0.26 mmol) were added, and the reaction mixture was stirred at room temperature under a nitrogen atmosphere for 48 hours. The reaction mixture was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 55 (10.2 mg, 32.4% yield). LCMS: 361.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.36 - 7.30 (m, 1H), 5.82 - 5.21 (m, 1H), 4.79 - 4.64 (m, 1H), 4.30 - 4.14 (m, 2H), 4.07 - 4.02 (m, 1H), 4.01 (s, 3H), 3.57 - 3.45 (m, 1H), 3.19 - 2.98 (m, 1H), 2.97 - 2.79 (m, 1H), 1.56 - 1.39 (m, 3H).
[0457] Example 1.56
[0458] Add ( ) to a solution of compound 28-9 (50.0 mg, 0.18 mmol) in DMF (2 mL) at room temperature. S 2-Hydroxypropionic acid (23.6 mg, 0.26 mmol), EDCI (67.1 mg, 0.35 mmol), HOBt (47.3 mg, 0.35 mmol), and TEA (53.1 mg, 0.53 mmol) were added. The reaction mixture was stirred at 50°C under nitrogen atmosphere for 48 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by preparative HPLC to give compound 56 (27.6 mg, 44.1% yield). LCMS: 358.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.29 (m, 1H), 5.84 - 5.38 (m, 1H), 5.23 - 4.98 (m, 1H), 4.73 - 4.47 (m, 1H), 4.43 - 4.24(m, 1H), 4.01 (s, 3H), 3.57 - 3.44 (m, 1H), 3.23 - 2.78 (m, 2H), 1.58 - 1.41 (m, 3H), 1.29 - 1.11 (m, 3H).
[0459] Example 1.57
[0460] The synthesis method was similar to that of compound 56, using the same starting materials to obtain compound 57 (26.6 mg). LCMS: 358.2 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 7.37 - 7.30 (m, 1H), 5.83 - 5.17 (m,1H), 4.83 - 4.65 (m, 1H), 4.35 - 4.14 (m, 2H), 4.05 - 3.94 (m, 4H), 3.54 -3.45 (m, 1H), 3.23 - 3.00 (m, 1H), 2.97 - 2.81 (m, 1H), 1.49 (dd, J= 30.0, 6.4 Hz, 3H).
[0461] Example 1.58
[0462] To a solution of compound 28-9 (31.0 mg, 0.11 mmol) in DMF (2 mL), 5-(2-hydroxyethoxy)pyrimidine-2-carboxylic acid (20.0 mg, 0.11 mmol), HATU (49.6 mg, 0.13 mmol), and DIPEA (57 µL, 0.33 mmol) were added at 25°C. The reaction mixture was stirred at 25°C for 1 hour. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give a crude residue. The residue was purified by preparative HPLC to give compound 58 (24.7 mg, 50% yield). LCMS: 452.0 [M+H] + .
[0463] Compound 58 (24.7 mg) was separated by chiral SFC to give compound 58A (peak 1, 6.5 mg, t). R =1.434 min) and compound 58B (peak 2, 8.0 mg, t R = 1.887 min). Chiral analysis method: Column: CHIRALPAK IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 70 / 30; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: CHIRALPAK IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 55 / 45, room temperature, flow rate: 160.0 mL / min, detection wavelength: 214 nm.
[0464] Compound 58A, LCMS: 452.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 8.75 - 8.51(m, 2H), 7.51 - 6.98 (m, 1H), 6.02 - 5.88, 4.95 - 4.87 (m, 1H), 5.05 - 4.96(m, 1H), 4.85 - 4.75 (m, 1H), 4.31 - 4.18 (m, 2H), 4.07 - 3.87 (m, 3H), 3.81 - 3.72 (m, 2H), 3.62 - 3.55 (m, 1H), 3.05 - 2.83 (m, 2H), 1.66 - 1.50 (m,3H).
[0465] Compound 58B, LCMS: 452.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.71 - 8.59(m, 2H), 7.46 - 6.98 (m, 1H), 6.00 - 5.87 (m, 1H), 4.95 - 4.87, 5.04 - 4.96(m, 1H), 4.84 - 4.73 (m, 1H), 4.30 - 4.19 (m, 2H), 4.08 - 3.86 (m, 3H), 3.82 - 3.70 (m, 2H), 3.62 - 3.54 (m, 1H), 3.08 - 2.81 (m, 2H), 1.62 - 1.52 (m,3H).
[0466] Example 1.59
[0467] The synthesis method was similar to that of compound 43-8, using the same starting materials to obtain compound 59-4 (252 mg), LCMS: 270.2 [M+H]. + .
[0468] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 59 (82 mg), LCMS: 354.4 [M+H]. + .
[0469] Compound 59 (82 mg) was isolated by chiral SFC to obtain compound 59A (peak 1, 23.6 mg, t). R =2.167 min) and compound 59B (peak 2, 21.8 mg, t) R= 5.263 min). Chiral analysis method: Column: Daicel ChiralPak IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 85 / 15; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 70 / 30, room temperature, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0470] Compound 59A, LCMS: 354.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.06 (s,1H), 7.48 - 7.32 (m, 1H), 5.70 - 5.12 (m, 1H), 5.10 - 4.63 (m, 1H), 4.63 -4.03 (m, 3H), 3.96 (s, 3H), 3.23 - 2.84 (m, 2H), 1.80 - 1.50 (m, 5H), 1.00 -0.87 (m, 3H).
[0471] Compound 59B, LCMS: 354.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.06 (s,1H), 7.48 - 7.34 (m, 1H), 5.70 - 5.10 (m, 1H), 5.10 - 4.64 (m, 1H), 4.60 -4.04 (m, 3H), 3.96 (s, 3H), 3.22 - 2.82 (m, 2H), 1.80 - 1.49 (m, 5H), 0.99 -0.87 (m, 3H).
[0472] Example 1.60
[0473] The synthesis method was similar to that of compound 53, using the same starting materials to obtain compound 60 (80 mg). LCMS: 361.2 [M+H] + .
[0474] Compound 60 (80 mg) was separated by chiral SFC to give compound 60A (peak 1, 29.2 mg, t). R =4.645 min) and compound 60B (peak 2, 28.7 mg, t) R = 5.655 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 4.6 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 0 / 100; temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 254 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 25 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 0 / 100, temperature: 38°C, flow rate: 130 mL / min, detection wavelength: 214 nm.
[0475] Compound 60A, LCMS: 361.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.37 - 7.30(m, 1H), 5.82 - 5.20 (m, 1H), 4.74 - 4.65 (m, 1H), 4.31 - 4.15 (m, 2H), 4.09- 4.00 (m, 1H), 3.56 - 3.45 (m, 1H), 3.32 - 3.31 (m, 3H), 3.19 - 2.98 (m,1H), 2.97 - 2.75 (m, 1H), 1.56 - 1.42 (m, 3H).
[0476] Compound 60B, LCMS: 361.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.36 - 7.26(m, 1H), 5.81 - 5.20 (m, 1H), 4.75 - 4.65 (m, 1H), 4.33 - 4.14 (m, 2H), 4.10- 3.99 (m, 1H), 3.57 - 3.46 (m, 1H), 3.31 (s, 3H), 3.19 - 2.98 (m, 1H), 2.97- 2.75 (m, 1H), 1.56 - 1.42 (m, 3H).
[0477] Example 1.61
[0478] The synthesis method was similar to that of compound 53, using the same starting materials to obtain compound 61 (17.5 mg). LCMS: 375.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.38 - 7.27 (m, 1H), 5.69 - 5.25 (m,1H), 5.24 - 4.49 (m, 1H), 4.43 - 4.18 (m, 2H), 3.34 (s, 3H), 3.22 - 2.99 (m,1H), 2.92 - 2.79 (m, 1H), 1.67 - 1.55 (m, 3H), 1.36 - 1.24 (m, 3H).
[0479] Example 1.62
[0480] The synthesis method was similar to that of compound 55, using the same starting materials to obtain compound 62 (4.7 mg). LCMS: 359.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.30 (m, 1H), 5.67 - 5.25 (m,1H), 5.22 - 4.51 (m, 1H), 4.43 - 4.16 (m, 2H), 3.99 (s, 3H), 3.21 - 2.98 (m,1H), 2.92 - 2.79 (m, 1H), 1.66 - 1.54 (m, 3H), 1.35 - 1.24 (m, 3H).
[0481] Example 1.63
[0482] The synthetic method was similar to that for compounds 54-9, using the same starting materials to obtain compound 63 (25.7 mg). LCMS: 359.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.30 (m, 1H), 5.68 - 5.25 (m,1H), 5.22 - 4.49 (m, 1H), 4.43 - 4.19 (m, 2H), 3.34 (s, 3H), 3.23 - 2.97 (m,1H), 2.92 - 2.79 (m, 1H), 1.67 - 1.54 (m, 3H), 1.35 - 1.23 (m, 3H).
[0483] Example 1.64
[0484] The synthetic method was similar to that for compound 54, using the same starting materials to obtain compound 64 (37.9 mg). LCMS: 345.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.44 - 7.30 (m, 1H), 5.69 - 5.26 (m,1H), 5.20 - 4.69 (m, 1H), 4.63 - 4.43 (m, 1H), 4.40 - 4.14 (m, 2H), 3.22 -2.98 (m, 1H), 2.90 - 2.78 (m, 1H), 1.66 - 1.55 (m, 3H), 1.35 - 1.24 (m, 3H).
[0485] Example 1.65
[0486] The synthesis method was similar to that of compound 55, using the same starting materials to obtain compound 65 (16.8 mg). LCMS: 362.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 7.40 - 7.29 (m, 1H), 5.70 - 5.25 (m,1H), 5.24 - 4.47 (m, 1H), 4.40 - 4.15 (m, 2H), 3.20 - 2.99 (m, 1H), 2.91 -2.78 (m, 1H), 1.67 - 1.54 (m, 3H), 1.36 - 1.23 (m, 3H).
[0487] Example 1.66
[0488] K₂CO₃ (6.07 mg, 43.9 mmol) and iodomethane (5.49 mL, 88.0 mmol) were added to a solution of compound 66-1 (9.9 g, 43.9 mmol) in DMF (90 mL) at room temperature. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 4 hours. The reaction mixture was poured into ice water and extracted with EA. The combined organic phases were washed with water and brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give compound 66-2 (9.50 g, 90% yield, crude product). 1 HNMR (400 MHz, CDCl3) δ 7.38 (dd, J = 9.0, 7.4 Hz, 1H), 6.64 (dd, J = 9.0, 1.6Hz, 1H), 3.90 (s, 3H).
[0489] To a solution of compound 66-2 (9.80 g, 40.9 mmol) in 1,4-dioxane (390 mL), pinacol diboronate (52.0 g, 205 mmol), potassium acetate (32.1 g, 327 mmol), and Pd(dppf)Cl2 (2.99 g, 4.09 mmol) were added. The solution was stirred at 110°C under a nitrogen atmosphere for 12 hours. The reaction mixture was cooled to room temperature and quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 66-3 (35.0 g, 122 mmol).
[0490] Sodium perborate tetrahydrate (318 g, 612 mmol) was added to a solution of compound 66-3 (35.1 g, 122 mmol) in H2O / THF (v / v = 1 / 4, 1250 mL) at 25°C. The reaction mixture was stirred at 55°C for 3 hours. The reaction was then quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 66-4 (3.6 g, 16% yield). 1 H NMR (400 MHz, CDCl3) δ 6.86 (t, J = 9.2 Hz, 1H), 6.62 (dd, J = 9.0, 2.0 Hz, 1H), 5.40 (s, 1H), 3.85 (s, 3H).
[0491] The synthetic method was similar to that for compounds 5-8, using the same starting materials to obtain compound 66-11 (360 mg). LCMS: 284.2 [M+H] + .
[0492] 2-Methoxyacetyl chloride (40 mg, 0.37 mmol) was added to a solution of compound 66-11 (80 mg, 0.28 mmol) and TEA (57.1 mg, 0.56 mmol) in THF (2 mL) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 66 (18 mg, 17% yield). LCMS: 356.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.76 - 7.65(m, 1H), 7.64 - 7.51 (m, 1H), 5.76, 5.29 (q, J = 6.4 Hz, 1H), 4.74, 4.04 (dd, J = 13.0, 5.4 Hz, 1H), 3.56 - 3.48 (m, 1H), 3.47 - 3.40 (m, 2H), 3.15 - 2.77(m, 4H), 1.56 - 1.35 (m, 3H).
[0493] Example 1.67
[0494] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 67 (19.7 mg), LCMS: 342.0 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.33 - 7.13 (m, 1H), 5.58 - 5.37 (m,1H), 5.19 - 5.06, 4.53 - 4.43 (m, 1H), 4.36 - 4.15 (m, 2H), 3.94 (s, 3H), 3.20 - 2.93 (m, 1H), 2.77 - 2.61 (m, 1H), 1.68 - 1.45 (m, 3H), 1.34 - 1.14 (m, 3H).
[0495] Example 1.68
[0496] Compound 28-9 (40 g) was separated by chiral SFC to give compound 68-2A (peak 1, 15.5 g, t). R =1.209 min) and compound 68-2B (peak 2, 15.3 g, t) R = 2.935 min). Chiral analysis method: Column: DAICELCHIRALPAK® AD, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 70 / 30; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 210 nm. Chiral preparation method: Column: DAICELCHIRALPAK® AD, 40 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 50 / 50, room temperature, flow rate: 140 mL / min, detection wavelength: 210 / 254 nm.
[0497] Compound 68-2A, LCMS: 286.0 [M+H] + And compound 68-2B, LCMS: 286.0 [M+H] + .
[0498] The synthesis method was similar to that of compound 1, using the same starting materials to obtain compound 68A (90.9 mg), LCMS: 346.2 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.39 - 7.29 (m, 1H), 5.83 - 5.17 (m,1H), 4.81 - 4.64 (m, 1H), 4.08 - 3.95 (m, 4H), 3.59 - 3.43 (m, 1H), 3.26 -2.98 (m, 1H), 2.97 - 2.77 (m, 1H), 1.56 - 1.41 (m, 3H).
[0499] The synthesis method was similar to that of compound 1, using the same starting materials to obtain compound 68B (81.8 mg), LCMS: 346.0 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.38 - 7.31 (m, 1H), 5.86 - 5.16 (m,1H), 4.84 - 4.63 (m, 1H), 4.05 - 3.94 (m, 4H), 3.59 - 3.43 (m, 1H), 3.23 -2.99 (m, 1H), 2.97 - 2.79 (m, 1H), 1.56 - 1.43 (m, 3H).
[0500] Example 1.69
[0501] The synthetic method was similar to that for compounds 5-8, using the same starting materials to obtain compound 69-8 (70 mg), LCMS: 300.0 [M+H]. + .
[0502] 2-Methoxyacetyl chloride (16.5 mg, 0.15 mmol) was added to a solution of compound 69-8 (35 mg, 0.28 mmol) and TEA (23.6 mg, 0.23 mmol) in THF (2 mL) at 0°C. The mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with ice water. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 69 (25.0 mg, 57.6% yield). LCMS: 372.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ7.46 - 7.28 (m, 1H), 5.58 - 5.34 (m, 1H), 5.20 - 4.53 (m, 1H), 4.42 - 4.13(m, 2H), 3.94 (s, 3H), 3.33 (s, 3H), 3.23 - 2.96 (m, 1H), 2.83 - 2.64 (m, 1H), 1.68 - 1.52 (m, 3H), 1.34 - 1.22 (m, 3H).
[0503] Example 1.70
[0504] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 70 (19.7 mg), LCMS: 358.2 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.45 - 7.31 (m, 1H), 5.58 - 5.37 (m,1H), 5.15 - 4.66 (m, 1H), 4.65 - 4.46 (m, 1H), 4.39 - 4.27 (m, 1H), 4.24 -4.13 (m, 1H), 3.94 (s, 3H), 3.25 - 2.98 (m, 1H), 2.83 - 2.68 (m, 1H), 1.67 -1.52 (m, 3H), 1.34 - 1.22 (m, 3H).
[0505] Example 1.71
[0506] Add 2-hydroxyacetic acid-2,2- to a solution of compound 52-7 (100 mg, 0.35 mmol) in DMF (5 mL). d Compound 2 (41 mg, 0.53 mmol), DIPEA (228 mg, 1.77 mmol), and HATU (268 mg, 0.71 mmol) were reacted. The reaction mixture was stirred at 60°C for 12 hours. The reaction mixture was quenched by adding ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 71 (82 mg, 67% yield). LCMS: 408.0 [M+H] + , 1 H NMR (400 MHz, DMSO-) d 6) δ 7.42 - 7.30 (m, 1H), 5.68 - 5.25 (m, 1H), 5.19 - 4.40(m, 2H), 3.99 (s, 3H), 3.23 - 2.98 (m, 1H), 2.94 - 2.78 (m, 1H), 1.65 - 1.53 (m, 3H), 1.35 - 1.24 (m, 3H).
[0507] Example 1.72
[0508] The synthesis method is similar to that of compound 39-4, using the same starting materials to obtain compound 72-3 (11.8 g). 1 HNMR (400 MHz, DMSO- d 6) δ 13.35 (s, 1H), 8.26 (dd, J = 5.6, 1.2 Hz, 1H), 8.08(d, J = 3.2 Hz, 1H).
[0509] The synthetic method was similar to that for compound 19-9, using the same starting materials to obtain compound 72-9 (450 mg). LCMS: 318.0 [M+H] + .
[0510] Triethylamine (95 mg, 0.94 mmol) and 2-methoxyacetyl chloride (77 mg, 0.71 mmol) were added to a solution of compound 72-9 (150 mg, 0.47 mmol) in DCM (3 mL) at 0°C. The mixture was stirred at room temperature for 2 hours. The reaction was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 72 (40.0 mg, 22% yield). LCMS: 390.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.14 - 8.01 (m,1H), 5.78 - 5.25 (m, 1H), 4.71 - 4.01 (m, 1H), 4.32 - 4.14 (m, 2H), 3.54 -3.13 (m, 1H), 3.31 (s, 3H), 3.12 - 2.78 (m, 2H), 1.46 (dd, J = 32.9, 6.6 Hz, 3H).
[0511] Example 1.73
[0512] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 73 (80 mg), LCMS: 376.0 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.08 (dd, J 1.46 (dd, J = 27.2, 6.8 Hz, 3H).
[0513] Example 1.74
[0514] The synthetic method was similar to that for compounds 5-8, using the same starting materials to obtain compound 74-7 (80 mg), LCMS: 332.2 [M+H]. + .
[0515] Triethylamine (25.7 mg, 0.25 mmol) and 2-methoxyacetyl chloride (20.7 mg, 0.19 mmol) were added to a solution of compound 74-7 (42.0 mg, 0.13 mmol) in DCM (2 mL) at 0°C. The mixture was stirred at room temperature for 2 hours. The reaction was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 74 (15.0 mg, 29% yield). LCMS: 404.0 [M+H] + . 1 H NMR (400 MHz, DMSO- d 6) δ 8.14 - 7.99(m, 1H), 5.68 - 4.49 (m, 2H), 4.38 - 4.15 (m, 2H), 3.34 (s, 3H), 3.23 - 2.81(m, 2H), 1.58 (dd, J = 22.4, 6.8 Hz, 3H), 1.28 (dd, J = 22.8, 6.8 Hz, 3H).
[0516] Example 1.75
[0517] The synthesis method was similar to that of compound 11, using the same starting materials to obtain compound 75 (30 mg), LCMS: 390.0 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.07 (dd, J = 13.6, 4.8 Hz, 1H),5.73 - 4.65 (m, 2H), 4.62 - 4.42 (m, 1H), 4.38 - 4.12 (m, 2H), 3.25 - 2.84(m, 2H), 1.58 (dd, J = 15.2, 6.8 Hz, 3H), 1.28 (dd, J = 15.2, 6.8 Hz, 3H).
[0518] Example 1.76
[0519] The synthesis method was similar to that of compound 52, using the same starting materials to obtain compound 76 (5 mg), LCMS: 384.3 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.61 - 7.25 (m, 1H), 5.83 - 5.11 (m,1H), 4.83 - 4.49 (m, 1H), 4.48 - 4.05 (m, 2H), 4.01 (s, 3H), 3.92 - 3.49 (m,1H), 3.27 - 2.93 (m, 2H), 1.80 - 1.61 (m, 3H), 1.13 (s, 1H), 0.63 - 0.27 (m, 4H).
[0520] Example 1.77
[0521] The synthesis method was similar to that of compound 52, using the same starting materials to obtain compound 77 (5 mg), LCMS: 368.4 [M+H]. + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.44 - 7.31 (m, 1H), 5.78 - 5.12 (m,1H), 4.83 - 4.55 (m, 1H), 4.50 - 4.23 (m, 1H), 4.23 - 4.08 (m, 1H), 4.07 -4.03, 3.65 - 3.55 (m, 1H), 4.00 (s, 3H), 3.24 - 2.94 (m, 2H), 1.79 - 1.60 (m,3H), 1.21 - 1.03 (m, 1H), 0.63 - 0.29 (m, 4H).
[0522] Compound 77 (42 mg) was separated by chiral SFC to give compound 77A (peak 1, 19.4 mg, t). R =3.092 min) and compound 77B (peak 2, 12.5 mg, t R= 7.210 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: n-hexane, mobile phase B: EtOH, A / B: 50 / 50; temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 40 mm ID × 250 mm, 10 µm, mobile phase A: n-hexane, mobile phase B: EtOH, A / B: 60 / 40, temperature: 25°C, flow rate: 45 mL / min, detection wavelength: 214 nm.
[0523] Compound 77A, LCMS: 368.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.44 - 7.33(m, 1H), 5.75 - 5.14 (m, 1H), 4.80 - 4.55 (m, 1H), 4.52 - 4.23 (m, 1H), 4.21- 4.05 (m, 1H), 4.03 - 3.97 (m, 3H), 3.62 - 3.57, 3.23 - 3.16 (m, 1H), 3.03 (s, 1H), 1.80 - 1.62 (m, 3H), 1.18 - 1.05 (m, 1H), 0.65 - 0.31 (m, 4H).
[0524] Compound 77B, LCMS: 368.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.43 - 7.33(m, 1H), 5.45 (dd, J = 202.7, 6.0 Hz, 1H), 4.80 - 4.55 (m, 1H), 4.52 - 4.23(m, 1H), 4.21 - 4.05 (m, 1H), 4.00 (s, 3H), 3.62 - 3.56, 3.23 - 3.15 (m, 1H), 3.03 (s, 1H), 1.79 - 1.61 (m, 3H), 1.18 - 1.06 (m, 1H), 0.61 - 0.32 (m, 4H).
[0525] Example 1.78
[0526] A solution of lithium diisopropylamino (2.7 mL, 2.0 M, in THF) was added dropwise to a solution of compound 28-4 (1.0 g, 4.62 mmol) in THF (10 mL) at -78°C under a nitrogen atmosphere. The reaction mixture was stirred at -78°C for half an hour, and then 4-methyl-1,2,3-oxathiazolidin-3-carboxylic acid in THF (10 mL) was added at -78°C. Uncle Ding Ester 2,2-dioxide (1.64 g, 6.92 mmol). The mixture was stirred at -78°C for 2 hours and then slowly cooled to room temperature overnight. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl. The resulting mixture was extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 78-2 (1.5 g, 88% yield). LCMS: 318.0 [M-56+H] + .
[0527] TFA (10 mL) was added to a solution of compound 78-2 (3.0 g, 8.02 mmol) in DCM (10 mL) at room temperature. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction mixture was concentrated to give compound 78-3 (4.0 g, crude product). LCMS: 274.2 [M+H] + .
[0528] Triethylamine (2.96 g, 29.2 mmol) and acetic anhydride (2.24 g, 21.9 mmol) were added to a solution of compound 78-3 (4.0 g, 14.6 mmol) in DCM (40 mL). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then quenched with ice water. The resulting mixture was extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 78-4 (2.28 g, 49% yield). LCMS: 316.2 [M+H] + .
[0529] Phosphoryl chloride (5.53 g, 36.1 mmol) was added to a solution of compound 78-4 (2.28 g, 7.22 mmol) in acetonitrile (20 mL) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous sodium bicarbonate solution, and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 78-5 (2.07 g, 96% yield). LCMS: 298.2 [M+H] + .
[0530] NaBH4 (340 mg, 8.34 mmol) was added fractionally to a solution of compound 78-5 (2.07 g, 6.95 mmol) in MeOH (20 mL) at room temperature. The reaction mixture was stirred at room temperature for half an hour. The reaction mixture was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 78-6 (2.07 g, 99% yield). LCMS: 300.4 [M+H] + .
[0531] Triethylamine (135 mg, 1.33 mmol) and 2-methoxyacetyl chloride (109 mg, 1.00 mmol) were added to a solution of compound 78-6 (200 mg, 0.67 mmol) in acetonitrile (5 mL) at room temperature. The mixture was stirred at room temperature for 16 hours. The reaction was quenched with ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 78 (120 mg, 48% yield). LCMS: 372.4 [M+H] + .
[0532] Compound 78 (83 mg) was separated by chiral SFC to give compound 78A (peak 1, 30.9 mg, t). R =0.905 min) and compound 78B (peak 2, 34.5 mg, t R= 1.632 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 50 / 50; temperature: 35°C, flow rate: 1.5 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 30 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 50 / 50, 25°C, flow rate: 70.0 mL / min, detection wavelength: 214 nm.
[0533] Compound 78A, LCMS: 372.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.44 - 7.23(m, 1H), 5.77 - 5.27 (m, 1H), 5.24 - 4.49 (m, 1H), 4.44 - 4.15 (m, 2H), 4.00(s, 3H), 3.33 - 2.98 (m, 3H), 2.95 - 2.80 (m, 1H), 1.74 - 1.52 (m, 3H), 1.41 - 1.10 (m, 4H).
[0534] Compound 78B, LCMS: 372.4 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.25(m, 1H), 5.72 - 5.26 (m, 1H), 5.25 - 4.50 (m, 1H), 4.44 - 4.17 (m, 2H), 4.00(s, 3H), 3.33 - 3.00 (m, 3H), 2.95 - 2.79 (m, 1H), 1.72 - 1.50 (m, 3H), 1.45 - 0.75 (m, 4H).
[0535] Example 1.79
[0536] The synthesis method was similar to that of compound 39, using the same starting materials to obtain compound 79 (40.0 mg). LCMS: 390.0 [M+H] + .
[0537] Compound 79 (40.0 mg) was separated by chiral SFC to give compound 79A (peak 1, 9.3 mg, t). R =0.944 min) and compound 79 B (peak 2, 8.4 mg, t) R = 2.558 min). Chiral analysis method: Column: Regis WhelkO1 (R,R), 4.6 mm ID × 150 mm, 5 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 60 / 40; temperature: 35°C, flow rate: 2.0 mL / min, detection wavelength: 210 nm. Chiral preparation method: Column: Regis WhelkO1 (R,R), 40 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH, A / B: 60 / 40, temperature: 35°C, flow rate: 140 mL / min, detection wavelength: 214 / 254 nm.
[0538] Compound 79A, LCMS: 390.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.08 (d, J =5.2 Hz, 1H), 5.78 - 5.25 (m, 1H), 4.71 - 4.01 (m, 1H), 4.32 - 4.12 (m, 2H), 3.60 - 3.09 (m, 1H), 3.31 (s, 3H), 3.06 - 2.79 (m, 2H), 1.51 - 1.41 (m, 3H).
[0539] Compound 79B, LCMS: 390.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.08 (d, J=5.2 Hz, 1H), 5.78 - 5.25 (m, 1H), 4.71 - 4.01 (m, 1H), 4.31 - 4.13 (m, 2H), 3.58 - 3.08 (m, 1H), 3.31 (s, 3H), 3.07 - 2.77 (m, 2H), 1.51 - 1.41 (m, 3H).
[0540] Example 1.80
[0541] The synthesis method was similar to that of compound 52, using the same starting materials to obtain compound 80 (100 mg). LCMS: 376.0 [M+H] + .
[0542] Compound 80 (100 mg) was separated by chiral SFC to give compound 80A (peak 1, 43.0 mg, t). R =1.027 min) and compound 80 B (peak 2, 41.8 mg, t) R = 2.046 min). Chiral analysis method: Column: DAICELCHIRALPAK® AD, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% DEA in MeOH), A / B: 60 / 40; temperature: 35°C, flow rate: 2.0 mL / min, detection wavelength: 210 nm. Chiral preparation method: Column: DAICELCHIRALPAK® AD, 40 mm ID × 250 mm, 10 µm, mobile phase A: supercritical CO2, mobile phase B: MeOH (0.1% 7.0 mol / L ammonia in MeOH solution), A / B: 60 / 40, temperature: 35°C, flow rate: 130 mL / min, detection wavelength: 210 / 254 nm.
[0543] Compound 80A, LCMS: 376.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 8.08 (s,1H), 5.79 - 5.23 (m, 1H), 4.92 - 3.97 (m, 2H), 4.33 - 4.15 (m, 2H), 3.53 -3.14 (m, 1H), 3.11 - 2.79 (m, 2H), 1.51 - 1.41 (m, 3H).
[0544] Compound 80B, LCMS: 376.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.08 (t, J =5.2 Hz, 1H), 5.79 - 5.22 (m, 1H), 4.79 - 3.97 (m, 1H), 4.30 - 4.16 (m, 2H), 3.55 - 3.14 (m, 1H), 3.12 - 2.81 (m, 2H), 1.51 - 1.41 (m, 3H).
[0545] Example 1.81
[0546] The synthesis method was similar to that of compound 53, using the same starting materials to obtain compound 81 (42 mg), LCMS: 382.2 [M+H]. + .
[0547] Compound 81 (42 mg) was separated by chiral SFC to obtain compound 81A (peak 1, 6.2 mg, t). R = 2.571 min) and compound 81B (peak 2, 5.1 mg, t R = 5.354 min). Chiral analysis method: Column: DAICELCHIRALPAK® IH, 3.0 mm ID × 100 mm, 3 µm, mobile phase A: n-hexane, mobile phase B: EtOH, A / B: 50 / 50; temperature: 35°C, flow rate: 1.0 mL / min, detection wavelength: 214 nm. Chiral preparation method: Column: DAICELCHIRALPAK® IH, 40 mm ID × 250 mm, 10 µm, mobile phase A: n-hexane, mobile phase B: EtOH, A / B: 50 / 50, 25°C, flow rate: 45 mL / min, detection wavelength: 214 nm.
[0548] Compound 81A, LCMS: 368.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.32(m, 1H), 5.81 - 5.10 (m, 1H), 4.52 - 4.22 (m, 1H), 4.19 - 4.05 (m, 1H), 4.00(s, 3H), 3.34 (s, 1H), 3.32 (s, 3H), 3.65 - 3.60, 3.22 - 3.14 (m, 1H), 3.04 -2.99 (m, 1H), 2.07 - 1.49 (m, 3H), 1.17 - 1.06 (m, 1H), 0.91 - 0.30 (m, 4H).
[0549] Compound 81B, LCMS: 368.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 7.41 - 7.33(m, 1H), 5.81 - 5.11 (m, 1H), 4.52 - 4.22 (m, 1H), 4.19 - 4.05 (m, 1H), 4.00(s, 3H), 3.34 (s, 1H), 3.30 (s, 3H), 3.65 - 3.59, 3.21 - 3.15 (m, 1H), 3.03 -2.99 (m, 1H), 2.06 - 1.60 (m, 3H), 1.13 (s, 1H), 0.80 - 0.21 (m, 4H).
[0550] Example 1.82
[0551] To a solution of compound 52-7 (100 mg, 0.35 mmol) in DMF (5 mL), 5-(2-hydroxyethoxy)pyrimidine-2-carboxylic acid (104 mg, 0.57 mmol), DIPEA (91 mg, 0.71 mmol), and HATU (215 mg, 0.57 mmol) were added. The reaction mixture was stirred at 60°C for 12 hours. The reaction mixture was quenched by adding ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography and preparative HPLC to give compound 82 (19.8 mg, 12% yield). LCMS: 450.0 [M+H] + , 1 H NMR (400 MHz, DMSO- d 6) δ 8.69 - 8.60 (m, 2H), 7.51 - 7.02 (m,1H), 5.89 - 5.30 (m, 1H), 5.04 - 4.97 (m, 1H), 4.96 - 4.90, 4.13 - 4.04 (m,1H), 4.32 - 4.22 (m, 2H), 4.03 - 3.85 (m, 3H), 3.77 (q, J = 2.5 Hz, 2H), 3.24- 3.01 (m, 1H), 3.00 - 2.72 (m, 1H), 1.83 - 1.50 (m, 3H), 1.44 - 1.24 (m, 3H).
[0552] Example 1.83
[0553] Sodium hydride (14.7 mg, 0.37 mmol) was added to a solution of compound 82 (110 mg, 0.25 mmol) in THF (7 mL) at 0°C under a nitrogen atmosphere. The reaction mixture was stirred for 30 minutes, followed by dropwise addition of iodomethane (521 mg, 6.66 mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched by adding ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography and preparative HPLC to give compound 83 (33.6 mg, 12% yield). LCMS: 464.2 [M+H] + , 1H NMR (400 MHz, DMSO- d 6) δ 8.71 - 8.63 (m, 2H), 7.48- 6.99 (m, 1H), 5.87 - 5.33 (m, 1H), 4.98 - 4.87, 4.13 - 4.04 (m, 1H), 4.40 -4.32 (m, 2H), 4.03 - 3.85 (m, 3H), 3.76 - 3.66 (m, 2H), 3.33 - 3.31 (m, 3H), 3.23 - 3.00 (m, 1H), 3.00 - 2.75 (m, 1H), 1.81 - 1.53 (m, 3H), 1.41 - 1.23(m, 3H).
[0554] Example 1.84
[0555] Add to a solution of compound 52-7 (100 mg, 0.35 mmol) in DMF (2 mL) N -( Uncle Ding (oxycarbonyl)- N -Ethylglycine (68 mg, 0.39 mmol), DIPEA (91 mg, 0.71 mmol), and HATU (161 mg, 0.42 mmol). The reaction mixture was stirred at 50°C for 2 hours. The reaction mixture was quenched by adding ice water and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 84-2 (120 mg, 73% yield). LCMS: 491.0 [M+Na] + .
[0556] TFA (1 mL) was added to a solution of compound 84-2 (120 g, 0.26 mmol) in DCM (2 mL) at room temperature. The reaction mixture was then stirred at room temperature under a nitrogen atmosphere for 1 hour. The reaction mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by preparative HPLC to give compound 84 (69.6 mg, 74% yield). LCMS: 369.2 [M+H] + , 1 H NMR (400 MHz, DMSO- d6) δ 8.78 (s, 1H), 7.44 - 7.30 (m,1H), 5.72 - 5.28 (m, 1H), 5.26 - 4.40 (m, 1H), 4.40 - 4.04 (m, 2H), 4.00 (s,3H), 3.28 - 3.05 (m, 1H), 3.05 - 2.89 (m, 3H), 1.72 - 1.59 (m, 3H), 1.40 -1.28 (m, 3H), 1.24 (t, J = 7.2 Hz, 3H).
[0557] Example 1.85
[0558] A solution of lithium diisopropylamino (128 mL, 2.0 M, in THF) was added dropwise to a solution of 1,2-dichloro-3-fluorobenzene (23.4 g, 142 mmol) in THF (450 mL) at -78°C. The reaction mixture was then stirred at -78°C for 1 hour. DMF (54.9 mL) was then added dropwise to the mixture. The reaction was heated to 0°C and stirred under nitrogen atmosphere for 2 hours. The reaction mixture was poured into a saturated ammonium chloride solution and extracted with EA. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 85-2 (23.2 g, 85% yield). 1 H NMR (400 MHz, CDCl3) δ 10.31 (s, 1H), 7.74 (t, J =7.6 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H).
[0559] Trifluoromethanesulfonic acid (12.6 mL, 141 mmol) was added dropwise to a solution of compound 85-2 (18.2 g, 94.0 mmol) and 1,3-dibromo-5,5-dimethylhydantoin (40.4 g, 141 mmol) in DCM (400 mL) at 0°C. The mixture was then heated to 25°C and stirred under nitrogen atmosphere for 48 hours. The mixture was quenched with ice water and extracted with DCM. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 85-3 (24.1 g, 94% yield). 1H NMR (400 MHz, CDCl3)δ 10.27 (s, 1H), 8.05 (d, J = 6.8 Hz, 1H).
[0560] K₂CO₃ (8.79 g, 63.6 mmol) was added to a solution of compound 85-3 (24.1 g, 89.0 mmol) and methyl 2-mercaptoacetate (9.9 g, 93.0 mmol) in DMF (500 mL) at room temperature. The reaction mixture was stirred at 50°C under a nitrogen atmosphere for 12 hours. The reaction mixture was then poured into ice water (200 mL) and stirred for 5 minutes. The reaction mixture was filtered, and the filter cake was dried to give compound 85-4 (23.2 g, 77% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 8.51 (s, 1H), 8.23 (s, 1H), 3.92 (s, 3H).
[0561] Sodium hydroxide (5.46 g, 136 mmol) was added to a mixture of compound 85-4 (23.2 g, 68.2 mmol) in MeOH / H₂O (volume / volume = 1 / 1, 500 mL) at room temperature. The reaction mixture was stirred at 50°C for 12 hours. The reaction mixture was poured into ice water and acidified to pH 2 using an aqueous HCl solution (2N). The reaction mixture was filtered, and the filter cake was dried to give compound 85-5 (19.5 g, 88% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 13.93 (s, 1H), 8.48 (s, 1H), 8.12 (s, 1H).
[0562] A solution of boranetetrahydrofuran complex (61.4 mL, 1 M) was added to a solution of compound 85-5 (10.0 g, 30.7 mmol) in THF (100 mL), and the mixture was stirred at 50°C for 12 hours. The mixture was concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel chromatography to give compound 85-6 (4.5 g, 47% yield). 1 H NMR (400 MHz, DMSO- d 6) δ 8.25 (s, 1H), 7.34 (s, 1H), 5.88 (t, J = 5.6 Hz, 1H), 4.78 (dd, J= 5.6, 0.8 Hz, 2H).
[0563] The synthesis method is similar to that of compounds 15-10, using the corresponding raw materials to obtain compound 85.
[0564] Example 2: Biological assay
[0565] Example 2.1: hcGAS luminescence determination
[0566] Experimental steps:
[0567] First, serially diluted compounds were aliquoted into 384-well microplates using an Echo system (BECKMAN, 655 system) with duplicate wells. cGAS (ICE, E2304T-H58HU) enzyme solution was then added. After centrifugation at 1000 rpm for 1 minute and incubation at 25°C for 10 minutes, ATP (Promega, V915B), GTP (Sigma, G8877-25MG), and dsDNA (Genscript, P41901-01) were added to the plate. The final concentrations of cGAS, dsDNA, ATP, and GTP in the reaction system were 200 nM, 60 nM, 100 μM, and 100 μM, respectively. The plate was then centrifuged at 1000 rpm for 1 minute and incubated at 25°C for 180 minutes. ATP was then measured using a Kinase Glo Max (Promega, V6073). The ATP luminescence signal was read using a microplate reader (BMG PHERAstar FSX). cGAS activity was assessed by detecting ATP consumption. The IC50 of the compounds was then calculated using nonlinear regression in XLfit 5.5.0 or GraphPadPrism 8. 50 .
[0568] Example 2.1: hcGAS TR-FRET determination
[0569] Experimental steps:
[0570] hcGAS TR-FRET assay. Serially diluted compounds were dispensed into 384-well microplates (Greiner, 784075) using an Echo system (Labcyte, 550) with duplicate wells. The plates were sealed and centrifuged at 1000 g for 1 min. 2X cGAS (Bellbrook, 2228) was prepared in 1X assay buffer, and 5 μl of the 2X cGAS / DNA mixture (Bellbrook, 3025-10K) was added to the 384-well plate. The plate was centrifuged at 1000 g for 1 min and incubated at room temperature for 60 min. Simultaneously, a 2X GTP / ATP mixture (Bellbrook, 3025-10K) was prepared in 1X assay buffer and added to initiate the reaction by adding 5 μl of the 2X GTP / ATP mixture. The plate was then centrifuged at 1000 g for 1 min, sealed, and incubated at room temperature for 120 min. Subsequently, 1X assay reagent (Bellbrook, 3025-10K) was prepared in HTRF nuclease-free water, and 10 μl of the reagent was added to each well of the assay plate. The plate was then centrifuged at 1000g for 30 seconds and incubated at room temperature for 1 hour. Finally, fluorescence signals were read at 615 nm and 665 nm using a microplate reader (Perkin Elmer, Envision 2104). cGAS activity was assessed by detecting cGAMP production. The IC50 of the compounds was then calculated using nonlinear regression in XLfit 5.5.0 or GraphPad Prism 8. 50 .
[0571] result:
[0572] Data for exemplary compounds are shown in Tables 3 and 4.
[0573] Table 3: IC50 values of exemplary compounds for inhibiting hcGAS 50 (hcGAS luminescence assay)
[0574] Table 4: IC50 of the exemplary compounds on the inhibitory effect of hcGAS 50 (hcGAS TR-FRET assay)
[0575] Other compounds disclosed in this paper also showed cGAS inhibitory activity.
[0576] Example 3: In vivo pharmacokinetic study
[0577] Experimental steps:
[0578] To assess pharmacokinetics, the test compound was administered orally to male C57BL / 6J mice or male SD mice (n=3 at each time point) at given doses and formulation carriers. Plasma (EDTA-K2) and brain tissue were collected simultaneously at given time points (e.g., 0.5 h, 2 h, 4 h, and 8 h after drug administration). Prior to brain tissue collection, the brain tissue was perfused with saline via the heart. Bioanalysis of the brain tissue and plasma extracts was performed using liquid chromatography-tandem mass spectrometry.
[0579] AUC in brain and plasma was measured 0-last The ratio of C in the brain and plasma max The ratio and free partition coefficient (K) p,uu The compounds disclosed in this paper exhibit good blood-brain barrier (BBB) permeability.
[0580] In some embodiments, such as those measured in C57BL / 6J mice, the AUC of the compounds disclosed herein in brain and plasma 0-last The ratio is greater than about 1.0, greater than about 2.0, greater than about 3.0, greater than about 4.0, or greater than about 5.0. In some embodiments, such as those measured in SD rats, the AUC of the compounds disclosed herein in the brain and plasma... 0-last The ratio is higher than about 1.0, higher than about 2.0, higher than about 3.0, higher than about 4.0, or higher than about 5.0.
[0581] In some embodiments, such as those measured in C57BL / 6J mice, the compounds disclosed herein have C in the brain and plasma. max The ratio is greater than about 0.5, greater than about 1.0, greater than about 2.0, greater than about 3.0, greater than about 4.0, or greater than about 5.0. In some embodiments, such as those measured in SD rats, the compounds disclosed herein have C in the brain and plasma. max The ratio is higher than about 0.5, higher than about 1.0, higher than about 2.0, higher than about 3.0, higher than about 4.0, or higher than about 5.0.
[0582] In some embodiments, such as those measured in C57BL / 6J mice, the K of the compounds disclosed herein p,uu Greater than about 0.3, greater than about 0.5, greater than about 1.0, greater than about 1.2, greater than about 1.3, or greater than about 1.5. In some embodiments, such as those measured in SD rats, the K of the compounds disclosed herein... p,uu Above approximately 0.3, above approximately 0.5, above approximately 1.0, above approximately 1.2, above approximately 1.3, or above approximately 1.5.
[0583] Example 4: Cytochrome P450 (CYP450) Inhibition
[0584] Experimental steps:
[0585] The aim of this study was to evaluate the activity of compounds against seven cytochrome P450 (CYP) isoenzymes in human liver microsomes. CYP450 isoenzyme-specific probe substrates were co-incubated with human liver microsomes and different concentrations of the test compounds (0, 0.0300, 0.100, 0.300, 1.00, 3.00, 10.0, 30.0, and 100 μM). The reaction was initiated by adding reduced nicotinamide adenine dinucleotide phosphate (NADPH). After the reaction, the samples were processed and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS / MS) to quantify the metabolites of the probe substrates. Under the test conditions, the test compounds showed inhibitory activity against CYP1A2 (using α-naphthylflavonoid as a substrate).
[0586] Table 5: IC50 of CYP1A2 inhibition 50
[0587] In some embodiments, the compounds disclosed herein inhibit IC50 by CYP1A2. 50 Above approximately 1.0 µM, above approximately 2.0 µM, above approximately 4.0 µM, above approximately 6.0 µM, above approximately 8.0 µM, above approximately 10 µM, above approximately 12 µM, above approximately 14 µM, above approximately 16 µM, above approximately 18 µM, or above approximately 20 µM.
[0588] Other compounds disclosed in this paper have a lower risk of DDI.
[0589] Example 5: Cisplatin-induced AKI mouse study
[0590] Experimental steps:
[0591] The compound was evaluated in a cisplatin-induced AKI model in male C57BL / 6 mice. Animals were intraperitoneally injected with cisplatin (25 mg / kg, 2 mg / mL) dissolved in 0.9% saline at 8–10 weeks of age. The compound was orally administered to mice at the given dose via QD or BID 1 hour before and after cisplatin administration. Mice were sacrificed 16 hours after cisplatin administration, and blood and tissues were collected for processing.
[0592] The disclosed compounds demonstrated dose-dependent cytokine inhibition and therapeutic effects in AKI mouse studies.
Claims
1. Compounds of formula (I): Equation (I), Or its pharmaceutically acceptable salts or stereoisomers. in: Is it a single bond or a double bond? Ring A is a heterocyclic, aryl, or heteroaryl group; Ring B is a cycloalkyl, heterocyclic, aryl, or heteroaryl group; Ring C is a heterocyclic group; X 1 It is O, S, Se, N, NR 1a CR 1a or CR 1a R 1b ; X 2 It is C, CR 2 Or N; X 3 It is C, CR 3 Or N; X 4 It is CR 4 Or N; X 5 It is CR 5 Or N; X 6 It is CR 6 Or N; X 7 It is CR 7 Or N; X 8 It is C or N; X 9 It is C or N; X 10 It is NR 10a or CR 10a R 10b ; R 10a and R 10b Each is independently hydrogen or R X ; or R 4 With R 10a Together they form a linking group L that connects ring A and ring C; or R 4 With an R X Together they form a linking group L that connects ring A and ring C; L is each a key or optionally a key of one or more R. y Replacement of linear C 1-20 A divalent hydrocarbon chain, wherein one or more methylene units of the chain are optionally and independently converted by cycloalkyl, heterocyclic, or -C(R) groups. L )=C(R L )-、 -O-, -S-, -N(R) L )-, -C(=O)-, -OC(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2-, -N(R L )C(=O)-、-C(=O)N(R L )-、-N(R L )S(=O)2- or -S(=O)2N(R L - Substitution; R L Each is independently hydrogen, alkyl, or cycloalkyl; R y Each is independently a halogen, oxo, cyano, nitro, or -OR group. y1 -OC(=O)R y1 -OC(=O)OR y1 -OC(=O)N(R) y2 )2、-SR y1 -S(=O)R y1 -S(=O)2R y1 -S(=O)2N(R) y2 )2、-S(=O)(=NR y2 )R y1 -N(R) y2 )2、-NR y2 C(=O)N(R y2 )2、-NR y2 C(=O)R y1 -NR y2 C(=O)OR y1 -NR y2 S(=O)2R y1 -N=S(=O)(R y1 )2、-C(=O)R y1 -C(=O)OR y2 -C(=O)N(R) y2 2. Alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, or heterocyclic group, wherein the alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, or heterocyclic group is optionally surrounded by one or more R groups. y3 replace; R y1 Each is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocyclic, each optionally being radically influenced by one or more R groups. y3 replace; R y2 Each of the following is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, or -alkyl-heterocyclic, optionally influenced by one or more R y3 replace; Or two R atoms on the same atom y2 Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. y3 Substituted heterocyclic groups; and R y3 Each of these can be independently a halogen, cyano, hydroxyl, oxo, -SF5, -SH, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)2NH2, -S(=O)2NH-alkyl, -S(=O)2N(alkyl)2, -S(=O)(=N-alkyl)(alkyl), -NH2, -NH-alkyl, -N(alkyl)2, -N=S(=O)(alkyl)2, -C(=O)-alkyl, -C(=O)OH, -C(=O)O-alkyl, -C(=O)NH2, -C(=O)NH-alkyl, -C(=O)N(alkyl)2, -P(=O)(alkyl)2, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, heteroalkyl, or cycloalkyl; L 1 For bonds, -C(=O)-, -S(=O)-, -S(=O)2- or -S(=NH)(=O)-; L 2 The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl groups. L 3 It is hydrogen, cyano, -OR a -N(R) b 2. Cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by one or more groups independently selected from the group consisting of: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl. R X Each of these groups is independently a halogen, hydroxyl, cyano, alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocyclic, -alkyl-aryl, or -alkyl-heteroaryl, wherein the alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocyclic, -alkyl-aryl, and -alkyl-heteroaryl groups are optionally substituted by one or more groups independently selected from: -OR a -SR a Halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; Or two Rs X Together with the atoms in between, they form cycloalkyl, heterocyclic, aryl, or heteroaryl groups, wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from: -OR a -SR a Halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl or hydroxyalkyl; Or two Rs X Together with the same atom they are attached to, they form C (=O); Or two Rs X Together with the same atoms they are attached to, they form C=C(R) a R b ); R 1a R 1b R 2 and R 3 Each of the groups is independently hydrogen, halogen, hydroxyl, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. or R 1a and R 1b Together with the same atom they are attached to, they form C (=O); or R 1a and R 1b Together with the same atom to which they are attached, they form cycloalkyl or heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one or more groups independently selected from the following groups: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl; R 4 R 5 R 6 and R 7 Each is independently hydrogen, -OR a -SR a -SF5, -N(R) b )2、-N(R b )C(=O)R c -OC(=O)R c Halogen, hydroxyl, cyano, oxo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by one or more groups independently selected from the group consisting of: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl; R a R b and R c Each of the groups is independently hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl. n1, n2, and n3 are each independently 0 or 1; m is any integer from 0 to 8; and The condition is (1) When X 1 When it is O or S, then X 10 Is it optional to be R X The NH that is replaced or is replaced by one or two R X Replaced CH2; (2) When X 1 When it is N or NH, then X 2 Is it C or CH, X 4 It is CH, X 10 It is -C(CH3)-, and -L 2 -L 3 It is -CH2NH2, -CH2OH, or -CH2OCH3; and (3) The compound is not , , , , , .
2. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 It is O, S, or Se, and X 2 It's C.
3. The compound of claim 2 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 10 It is CR 10a R 10b And R 10a and R 10b At least one of them is R X .
4. The compound of claim 3 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has the formula (I-1): Equation (I-1), in: X 1 Is it O, S, or Se? R 11a R 11b R 12a R 12b R 13a R 13b R 14a and R 14b Each is independently hydrogen or R X ;and The condition is when X 1 It is O or S and R 10a When it is hydrogen, then R 10b It is R X .
5. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 It is CR 1a R 1b And X 2 It is N.
6. The compound of claim 5 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has formula (I-2): Equation (I-2), in: R 11a R 11b R 12a R 12b R 13a R 13b R 14a and R 14b Each is independently hydrogen or R X .
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein... (1) n1 is 0, n2 is 0, and n3 is 0; (2) n1 is 1, n2 is 0, and n3 is 0; (3) n1 is 0, n2 is 1, and n3 is 0; (4) n1 is 1, n2 is 1, and n3 is 0; (5) n1 is 0, n2 is 1, and n3 is 1; or (6) n1 is 1, n2 is 1, and n3 is 1.
8. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 With R 10a Together they form a linking group L that connects ring A and ring C.
9. The compound of claim 1 or 8, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein n1 is 0, and X 10 It is CR 10a R 10b .
10. The compound of any one of claims 1, 8, and 9, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has formula (IA): Equation (IA).
11. The compound of claims 1, 8-10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has formula (IA-1) or (IA-2): Equation (IA-1); Formula (IA-2).
12. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 With an R X Together they form a linking group L that connects ring A and ring C.
13. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein n1 is 1.
14. The compound of claims 1, 12-13, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has the formula (IB): Formula (IB).
15. The compound of claims 1, 12-14, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound has formula (IB-1) or (IB-2): Equation (IB-1), Formula (IB-2).
16. The compound of any one of claims 1, 8-15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L is L 11 L 12 L 13 L 14 and L 15 Each is independently selected from bond, S, -C(=O)-, O, NH, -S(=O)2-, -S(=O)-, alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, heteroynyl, cycloalkyl, or heterocyclic, wherein the alkyl, alkenyl, ynyl, heteroalkyl, heteroalkenyl, cycloalkyl, or heterocyclic group is optionally separated by one or more R y replace.
17. The compound of any one of claims 1, 8-16, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L 11 L 12 L 13 L 14 and L 15 Each is independently selected from the following: bond, S, -C(=O)-, O, NH, -S(=O)2-, -S(=O)-, -CH2-, -CH2CH2-, -CH=CH-. or Among them, NH, -CH2-, -CH2CH2-, -CH=CH- or Optionally by one or more R y replace.
18. The compound of any one of claims 1, 8-15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L is a bond or optionally bound by one or more R bonds. y Replacement of linear C 1-20 A divalent hydrocarbon chain, wherein one or more methylene units of the chain are optionally and independently C 3-6 cycloalkyl, 3- to 6-membered heterocyclic, -C(R) L )=C(R L )-、 -O-, -S-, -N(R) L )-, -C(=O)-, -OC(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2-, -N(R L )C(=O)-、-C(=O)N(R L )-、-N(R L )S(=O)2- or -S(=O)2N(R L - Replacement. In some implementations, R L Each is independently hydrogen, C 1-6 Alkyl or C 3-6 Cycloalkyl.
19. The compound of any one of claims 1, 8-15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L is -CH2CH2-#, -CH2CH2CH2-#, -CH2CH2CH2CH2-#, -CH2CH2O-#, -OCH2CH2-#, -CH2OCH2CH2-#, -NHCH2CH2-#, -CH2CH2NH-#, -NHCH2CH2CH2-#, -CH2CH2CH2O-#, -OCH2CH2CH2-#, -CH2CH2CH2CH2O-#, -OCH2CH2CH2CH2-#, -OCH2CH2O-#, -OCH2CH2CH2O-#, -OCH2CH2CH2O-#, -CH=CHCH2O-#, -OCH2CH=CH-#, -CH2CH2CH2NH-#, or -NHCH2CH2CH2-#, wherein the # end of L is connected to ring A or ring C.
20. The compound of any one of claims 1-19 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein one or more R X Independently, it is halogen, cyano, C 1-6 Alkyl, C 3-6 cycloalkyl, 5- to 6-membered heteroaryl or -C 1-6 Alkyl-C 6-8 aryl, wherein the alkyl, cycloalkyl, heteroaryl, and -alkyl-aryl groups are optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
21. The compound of claim 20 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein one or more R X Independently, it can be cyano, -F, -Cl, -Br, -CH3, -CH2CH3, -CH(CH3)2, -CH2F, -CH2OH, -CH2CH2OH, -CH2C(CH3)2OH, -CH2CN, -CHF2, -CH2OCH3, -CH2SCH3, -CH2CH2OH, -CH2C(CH3)2OH, -CH2CN, , , or .
22. The compound of claim 4 or 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10a and R 10b Together with the same atom to which they are attached, they form cycloalkyl or heterocyclic groups, wherein the cycloalkyl and heterocyclic groups are optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
23. The compound of claim 4 or 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11a and R 11b 、or R 12a and R 12b 、or R 13a and R 13b 、or R 14a and R 14b Together with the same atom to which they are attached, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl; or R 11a and R 11b 、or R 12a and R 12b 、or R 13a and R 13b 、or R 14a and R 14b Together with the same atom they are attached to, they form C(=O) or C=C(R) a R b ).
24. The compound of claim 4 or 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11a and R 12a 、or R 12a and R 14a 、or R 10a and R 13a Together with the atoms they are attached to, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
25. The compound of claim 4 or 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10a and R 11a 、or R 10a and R 12a 、or R 10a and R 14a 、or R 13a and R 14a 、or R 13a and R 12a 、or R 13a and R 11a 、or R 11a and R 14a Together with the atoms in between, they form cycloalkyl or heterocyclic groups, each optionally substituted by one or more groups independently selected from: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, ynyl, haloalkyl, -OR a -SR a Or hydroxyalkyl.
26. The compound of any one of claims 1-7, 20-25, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10a It is hydrogen, and R 10b It is -CH3 or -CH2CH3.
27. The compound of any one of claims 1, 9-11, R 10b It is hydrogen or alkyl.
28. The compound of any one of claims 1-7, 20-26, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the ring C is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ,in Indicates with L 1 The connection point.
29. The compound of any one of claims 1, 8-27, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the ring C is , , , , , , , , , , , , , , , , , , , , or ,in Indicates with L 1 The connection point is indicated by #, which represents the connection point with L.
30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 R 5 R 6 and R 7 Each is independently hydrogen, -OR a -SR a -N(R) b )2、-N(R b )C(=O)R c , cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 The alkynyl, halogen, or 5- to 6-membered heteroaryl group is optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl.
31. The compound of claim 30 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R a R b and R c Each is independently hydrogen or alkyl, and is optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl.
32. The compound of claim 30 or 31 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 4 R 5 R 6 and R 7 Each of these can be independently represented by hydrogen, cyano, -F, -Cl, -Br, -CH2CH3, -CH3, -OH, -OCH3, -SCH3, -OCH2CN, -OCH2CH3, -OCHF2, -OCH2F, -SCHF2, -CH2CH2CN, -CH2CN, -CHF2, or -CH=CH2. , , , or .
33. The compound of any one of claims 1, 6, 11, and 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1a It is hydrogen, and R 1b It is hydrogen or alkyl; or R 1a and R 1b Together with the same atom they are attached to, they form C (=O).
34. The compound of any one of claims 1, 10, and 14, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 and R 3 Each is hydrogen.
35. The compound of any one of claims 1-34, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L 1 For key or -C(=O)-.
36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L 2 For key, C 1-6 Alkyl or 5- to 6-membered heteroaryl, wherein the alkyl and heteroaryl groups are optionally substituted by one or more groups independently selected from the group consisting of halogen, hydroxyl, amino, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or hydroxyalkyl.
37. The compound of any one of claims 1-36, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein L 3 It is hydrogen, cyano, -OR a -N(R) b )2 or 5 to 6-membered heterocyclic group, which is optionally substituted by one or more groups independently selected from the following: halogen, hydroxyl, amino, cyano, oxo, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy or hydroxyalkyl.
38. The compound of claim 37 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R a and R b Each is either hydrogen or alkyl.
39. The compound of any one of claims 1-38 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein -L 1 -L 2 -L 3 It is hydrogen. , , , , , , , , , , , , , , or .
40. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is selected from any of the compounds listed in Table 1 or Table 2.
41. A pharmaceutical composition comprising a compound of any one of claims 1-40 or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient.
42. A method for inhibiting cyclic GMP-AMP synthase (cGAS) in an individual in need, the method comprising administering to the individual an effective amount of a compound of any one of claims 1-40 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutical composition of claim 41.
43. A method for treating a disease or disorder in an individual in need, the method comprising administering to the individual an effective amount of a compound of any one of claims 1-40 or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutical composition of claim 41.
44. The method of claim 43, wherein the disease or disorder is a cGAS-related disease or disorder.
45. The method of claim 40, wherein the disease or disorder is inflammation, autoimmune disease, cancer, infection, central nervous system disease or disorder, metabolic disease, cardiovascular disease, respiratory disease, kidney disease, liver disease, eye disease, skin disease, lymphatic disease, rheumatic disease, mental illness, graft-versus-host disease, abnormal pain, or cGAS-related disease in an individual who has been identified as carrying a cGAS germline or somatic non-silent mutation.
46. The method of claim 45, wherein the disease or disorder is a central nervous system disease or disorder (e.g., Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, or multiple sclerosis); a kidney disease (e.g., acute kidney disease, chronic kidney disease, or rare kidney disease); a skin disease (e.g., psoriasis, hidradenitis suppurativa (HS), or atopic dermatitis); a rheumatic disease (e.g., dermatomyositis, Still's disease, or juvenile idiopathic arthritis); or a cold pyridine-associated autoinflammatory syndrome (e.g., familial cold autoinflammatory syndrome, Mue-Weir syndrome, or neonatal multisystem inflammatory disease).
Citation Information
Patent Citations
Enhancement of the efficacy of nifedipine by deuteration
US5846514A
Method of using deuterated calcium channel blockers
US6334997B1
